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Macrophages are part of the immune system and these cells are present in 
virtually every tissue of the body. Macrophages are sometimes referred to as 
‘guardians of the tissue’ since they are vital for keeping the tissue healthy by 
clearing dead and dying cells. When infection or injury occurs, the 
macrophages recruit other immune cells to help clear the infectious agent. In 
addition, macrophages also carry out unique functions depending on the tissue 
which they inhabit. Using new technologies, we are trying to understand 
exactly how a macrophage is ‘trained’ to carry out these functions. Incomplete 
macrophage ‘training’ could allow disease to occur which would have been 
prevented by fully ‘trained’ macrophages.  
 
I aimed to understand how this macrophage ‘training’ is occurring in the space 
between the abdominal organs. This space is called the peritoneal cavity, and 
the unique population of tissue macrophages that inhabit this cavity are 
referred to as peritoneal macrophages. When the peritoneal cavity is infected, 
cells are recruited from the blood into the cavity. These blood cells give rise to 
a new set of recruited macrophages that are needed to clear the infection. I 
found that these recruited macrophages persist long after the infection has 
been resolved and that they did not become true peritoneal macrophages. An 
important reason why these cells stayed different was because the original 
population of peritoneal macrophages prevented them from ‘training’. 
Consequently, the recruited macrophages did not receive training and they 
remained untrained recruited macrophages. Importantly, these untrained 
recruited macrophages are not as good at clearing bacteria, and are not 
carrying out the specific functions of peritoneal macrophages.   
 
Hence, my work indicates that after a mild peritoneal infection the cavity is 
colonized by these recruited macrophages that don’t carry out macrophage 
functions as efficiently as true peritoneal macrophages.  Consequently, the 
presence of these recruited cells likely alters the response of the cavity to 
subsequent infections. 
 14 
List of abbreviations 
 
ANOVA  Analysis of variance 
ATRA   All trans retinoic acid 
BHLHE40  Basic Helix-Loop-Helix Family Member E40 
BHLHE41  Basic Helix-Loop-Helix Family Member E41 
BM   Bone marrow 
BSA   Bovine serum Albumin 
C1q   Complement component 1q 
CCL24  C-C Motif Chemokine Ligand 24 
CCL5   C-C Motif Chemokine Ligand 5 
CCR2   C-C Motif Chemokine Receptor 2 
CCR5   C-C Motif Chemokine Receptor 5 
CD   Cluster of differentiation (usually with number i.e. CD45) 
CD206  Cluster of differentiation 206 (mannose receptor) 
CD45.1  Cluster of differentiation 45a 
CD45.2  Cluster of differentiation 45b 
CEBP/β  CCAAT/enhancer binding protein 
CREB   cyclic AMP-response element binding protein 
CSF2r   Colony stimulating factor 2 receptor. 
CSFr1   Colony stimulating factor 1 receptor (CD115) 
Ctrl   Control 
CX3CR1  fractalkine receptor 
CXCL13  C-X-C Motif Chemokine Ligand 13 
DNA   Deoxyribonucleic acid 
dPBS   Dulbecco's Phosphate-Buffered Saline 
EMP   Erythro-myeloid precursors 
F4/80   EGF-like module-containing mucin-like hormone 
receptor-like 1 
FCGR1  Fc Fragment Of IgG Receptor Ia 
FCGR3  Fc Fragment Of IgG Receptor IIIa 
FCS   Fetal calf serum 
 15 
FIRE   Fms-intronic regulatory element 
FOXP3  Forkhead box P3 
FSC   Forward scatter 
GATA6   GATA binding protein 6 
GFP   Green Fluorescent protein 
GM-CSF  Granulocyte-macrophage colony-stimulating factor 
GO term  Gene ontology term 
GSEA   Gene set enrichment analysis 
ID3   Inhibitor Of DNA Binding 3, HLH Protein  
DTR   Diphteria toxin 
IFN   Interferon 
Il   Interleukin 
IMacZ10  Inflammatory macrophage elicited using 10µg zymosan 
IMacZ1000  Inflammatory macrophage elicited using 1000µg 
zymosan 
IP    Intraperitoneal 
IRF4   Interferon Regulatory Factor 4 
IV   Intravenous 
KO    Knock out 
LoxP   Locus of X-over P1 
LPM   Large peritoneal macrophage 
LPS   Lipopolysaccharides 
LXRα   Liver X receptor a 
Ly6b   Lymphocyte antigen 6b 
Ly6c   Lymphocyte antigen 6c 
Lysm    Lysin motif 
MertK   c-mer proto-oncogene tyrosine kinase 
MFI   Mean fluorescence intensity 
MHCII   Major histocompatibility complex 2 
Mo-LPM  Monocyte-derived LPM 
MoZ10-LPM  Monocyte-derived LPM, elicited using 10µ zymosan 
mRNA  Messenger ribonucleic acid 
 16 
Ms4a3  Membrane Spanning 4-Domains A3  
NK cells  Natural Killer cells 
Om factors  Omentum Factors 
PGSE2  Prostaglandin E2 
PKH26-PCL  Paul Karl Horan 26 cell linker kit 
PPARγ  Peroxisome proliferator-activated receptor γ 
RAG   recombination activating gene 1 
Relma   Resistin like molecule a 
Rfp   Red fluorescent protein 
RFP   Red fluorescent protein 
RM-LPM  Resident macrophage-derived LPM 
RMac   Resident peritoneal macrophages 
RMacZ10  Resident peritoneal macrophages elicited using 10µg 
zymosan 
RMZ10-LPM  Resident macrophage-derived LPM, elicited using 10µg 
zymosan 
Runx1   Runt-related transcription factor 1 
RXRa   Retinoic X receptor a 
RXRb   Retinoic X receptor b 
S.Aureus   Streptococcus Aureus 
S.Pneumomoniae Streptococcus pneumoniae 
S100A4  S100 calcium-binding protein A 
Flt3   Fms Related Receptor Tyrosine Kinase 3 
SerpinB2  Serpin Family B Member 2 
SPM   Small peritoneal macrophage 
SSC   Side scatter 
Tim4   T Cell Immunoglobulin And Mucin Domain Containing 4 
TLR4   Toll Like Receptor 4 
TNFa   Tumor Necrosis Factor a 
CXCL1  C-X-C Motif Chemokine Ligand 1 
CXCL10  C-X-C Motif Chemokine Ligand 10 
CCL2   C-C Motif Chemokine Ligand 2 
 17 
VSIG4  V-Set And Immunoglobulin Domain Containing 4 
WT   Wild type 
YFP   Yellow Fluorescent protein 
Zeb2   Zinc finger E-box-binding homebox 2 
FACS   Fluorescence-activated cell sorting 
FMO   Fluorescence minus one 
FRb   Folate receptor b 
  
 18 
List of publications 
 
Bain, C. C., D. A. Gibson, N. J. Steers, K. Boufea, P. A. Louwe, C. Doherty, 
V. Gonzalez-Huici, R. Gentek, M. Magalhaes-Pinto, T. Shaw, M. Bajénoff, C. 
Bénézech, S. R. Walmsley, D. H. Dockrell, P. T. K. Saunders, N. N. Batada 
and S. J. Jenkins (2020). "Rate of replenishment and microenvironment 
contribute to the sexually dimorphic phenotype and function of peritoneal 
macrophages." Sci Immunol 5. 
 
Hawley, C. A., R. Rojo, A. Raper, K. A. Sauter, Z. M. Lisowski, K. Grabert, C. 
C. Bain, G. M. Davis, P. A. Louwe, M. C. Ostrowski, D. A. Hume, C. Pridans 
and S. J. Jenkins (2018). "Csf1r-mApple Transgene Expression and Ligand 
Binding In Vivo Reveal Dynamics of CSF1R Expression within the 
Mononuclear Phagocyte System." J Immunol 200(6): 2209-2223. 
 
Li, Z., E. G. Solomonidis, M. Meloni, R. S. Taylor, R. Duffin, R. Dobie, M. S. 
Magalhaes, B. E. P. Henderson, P. A. Louwe, G. D'Amico, K. M. Hodivala-
Dilke, A. M. Shah, N. L. Mills, B. D. Simons, G. A. Gray, N. C. Henderson, A. 
H. Baker and M. Brittan (2019). "Single-cell transcriptome analyses reveal 
novel targets modulating cardiac neovascularization by resident endothelial 





Inflammation is known to lead to long-term changes in the responsiveness to 
subsequent inflammatory challenges but the mechanism driving this alteration 
is poorly understood. In the peritoneal cavity a similar phenomenon has been 
described and historic peritoneal inflammation is thought to lead to dampened 
neutrophil recruitment in response to a subsequent insult. Acute peritoneal 
inflammation is characterized by the transient loss of embryonically-seeded 
resident macrophages and infiltration by large numbers of monocyte-derived 
inflammatory macrophages. The long-term fate of inflammatory macrophages 
post-inflammation has remained controversial. Hence, I hypothesized that 
inflammatory macrophages persist long-term but could remain functionally 
distinct. In addition, I aimed to explore what regulates the survival and identity 
of these cells by examining how severity of the initial inflammatory insult 
changes the post inflammation micro-environment. Furthermore, a 
combination of cell-intrinsic regulation and environmental signals limits 
inflammatory macrophages from converting into resident macrophages.   
 
To investigate these questions, I developed a flow-cytometric method based 
on dye-labelling of resident macrophages in conjunction with conventional 
antibody staining to unequivocally delineate resident from inflammatory 
macrophages during resolution of a well characterised model of sterile 
peritoneal inflammation induced by injection of zymosan A. Following a low 
dose of zymosan, both resident and inflammatory macrophages persisted in 
the peritoneal cavity by day 3 whereas severe inflammation resulting from 
injection of a high dose of zymosan led to complete loss of resident 
macrophages. I then used adoptive transfer of purified resident or 
inflammatory macrophages present during resolution of mild peritonitis into 
congenic recipient mice that harboured an equivalent inflammatory response 
to investigate their long-term survival and identity. To investigate if the post 
resolution environment dictates these features, cells were transferred into 
naïve recipient mice. To ascertain if competition with incumbent resident 
macrophages for niche signals alters this fate and phenotype, donor cells were 
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transferred into recipient mice transiently-depleted of endogenous resident 
macrophages. Combined these data allowed me to ascertain to what degree 
survival and identity of inflammatory macrophages is dictated by 
environmental niche cues, competition with incumbent resident macrophages 
and to what degree these features are pre-determined. 
 
These adoptive transfer experiments revealed that following mild peritonitis 
both resident and inflammatory macrophages persist through inflammation 
resolution, when the macrophage compartment contracts to pre-inflammation 
size. Long-term fate mapping indicated that transferred cells survived to an 
equivalent degree up to 8 weeks. This suggests that cells that persisted shortly 
after resolution become long-lived. However, Nanostring mRNA analysis at 8 
weeks demonstrated that inflammatory macrophages acquired some resident 
features such as CD102 expression but remained transcriptionally distinct. 
Importantly, inflammatory macrophages failed to acquire equivalent levels of 
the peritoneal identity transcription factor GATA6 whilst maintaining high 
expression of inflammatory macrophage markers, most notably MHCII and 
Sema4a. Critically, inflammatory macrophages transferred into macrophage-
deplete recipients adopted a more complete resident macrophage identity, 
including equivalent expression of GATA6 and MHCII to their resident 
counterparts, whilst retaining differential expression of few genes, including 
the embryonic macrophage marker Tim4. Combined these data indicate that 
the failure of inflammatory macrophages to adopt a resident identity is largely 
environment and competition dictated. However, over time more complete 
conversion occurs, as fate mapping until 5 months after mild peritonitis 
indicated that inflammatory macrophages gradually reprogram both 
environment dependent and independent features.   
 
In contrast, after severe peritoneal inflammation resident macrophages were 
completely and irrevocably lost, which was confirmed using tissue-protected 
bone marrow chimeric mice. Inflammatory macrophages recruited during 
severe inflammation adopted a somewhat ‘resident like’ identity including high 
 21 
levels of GATA6, equivalent to resident macrophages. However, after severe 
peritonitis, and complete loss of resident macrophages, inflammatory 
macrophages retained high levels of MHCII. As MHCII was rapidly 
downregulated by low dose inflammatory macrophages after transfer into 
macrophage-deplete recipients but not after transfer into naïve or equivalently 
inflamed recipients these data indicate that signals unique to the severely 
inflamed cavity drive expression of MHCII. Consistently, naïve resident 
macrophages expressing low levels of MHCII transferred into high dose 
zymosan treated recipients rapidly upregulated MHCII.  
 
Finally, I showed that inflammatory macrophages that persisted 8 weeks after 
mild peritonitis were more proliferative, less phagocytic and produced less 
TNFa in response to LPS stimulation both in vitro and in vivo. One feature of 
inflammatory macrophages, irrespective of the severity of peritonitis was an 
inability to produce the B1 cell chemokine CXCL13 and as a likely 
consequence peritoneal B1 cells failed to accumulate post inflammation. 
 
Hence, these data support a model where inflammation drives the integration 
of functionally divergent monocyte-derived inflammatory macrophages into the 
peritoneal cavity. Moreover, during mild inflammation competitive pressure 
from incumbent resident macrophages for environmental signals largely 
dictates the extent to which inflammatory macrophages adopt a more resident-
like identity. Conversely, after severe peritonitis no competing resident 
macrophages persist but environmental signals are altered and consequently 
inflammatory macrophages adopt a unique identity. 
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1.1 From frog to tissue-resident macrophage 
The first in-depth characterization of phagocytes was carried out by Elie 
Metchnikoff in starfish and frogs1-3. He described a population of ‘eating cells’ 
involved in host defence as well as removal of the dying cells during 
development from tadpole into mature frog1,2. He named these cells 
‘phagocytes’ and described distinct roles for circulating ‘microphages’ and 
tissue-resident ‘macrophages’ in the control of invading pathogens1. His work 
was expanded upon by numerous research groups which, in 1972, culminated 
in the definition of the mononuclear phagocyte system by van Furth et al to 
classify highly phagocytic cells and their precursors on the basis of 
morphology, function and origin4.  
Metchnikoff’s initial description of tissue-resident macrophages as key players 
in immunological processes, including bactericidal control, as well as 
maintenance of tissue homeostasis and development, through phagocytosis 
of debris and dying cells, has been the cornerstone of contemporary 
macrophage research. With the advent of high-throughput sequencing 
technologies it has become clear that vast populations of transcriptionally 
distinct tissue-resident macrophages, uniquely adapted to the tissue they 
inhabit, are present in virtually every organ5,6 across species, including 
humans. Reflecting this common functionality, tissue-resident macrophages 
share a core panel of genes and functions upon which a tissue-specific 
transcriptional and functional identity is over-laid7-9. Tissue-resident 
macrophages have proved vital in maintaining health through clearance of 
debris and immunological protection through phagocytosis of infectious agents 
regulation of initiation and resolution of inflammatory response 5,10. 
1.2 The shared immunological function of tissue-resident macrophages 
Tissue-resident macrophages have long been postulated to act as sentinels 
that survey the tissue. With advances in live imaging technologies this process 
has been visualized in great detail and tissue-resident macrophages have 
been shown to continuously survey the surrounding tissue using filopodia-like 
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protrusion in, for example, the brain11 , the liver12 and the lung13. Through a 
variety of pattern recognition receptors expressed on their surface, most 
notably: toll-like receptors, scavenger receptors and C-type lectins, tissue-
resident macrophages detect a variety of pathogenic motifs and proceed to 
phagocytose invading microorganisms10. Phagocytosed particulates are 
encapsulated in phagosomes which subsequently acidify and fuse with 
lysosomes, forming highly acidic phagolysosomes that ultimately degrade 
engulfed particulates14. In response to encountering and engulfing pathogens 
tissue-resident macrophages produce a cocktail of inflammatory mediators 
dictated by the nature and severity of the encountered stimuli. In addition, 
tissue-resident macrophages influence adaptive immune response either via 
secreted mediators or through antigen presentation via class II MHC10. 
A key function of tissue-resident macrophages is the clearance of debris and 
dying cells via phagocytosis. Under homeostatic conditions, cell-death occurs 
predominantly through a regulated series of processes known as 
phagocytosis. As part of this apoptotic process, dying cells express various 
cellular components on their surface, including phosphatidylserine and 
calreticulin, that are normally sequestered inside the cell15,16. Exposed 
phosphatidylserine serves as ligands for soluble factors that are secreted by 
macrophages and dendritic cells. These soluble factors include milk-fat 
globule epidermal growth factor (MFG-E8), growth arrest-specific gene 6 and 
complement component 1q (C1q). Once bound, these mediators serve as 
bridging molecules and allow binding and engulfment by phagocytes via 
vitronectin receptor, c-mer proto-oncogene tyrosine kinase (MerTk) and C1q-
receptors respectively. In addition, macrophages express numerous receptors 
that directly recognize phosphatidylserine including, T-cell immunoglobulin 
and mucin domain containing 1 and 4 (Tim1/4) and Stabilin-115-17. Some of 
these surface receptors, such as MertK, are highly expressed by macrophages 
across tissues whereas others, such as Tim4, are more unique to tissue-
macrophage subsets18. Pan-macrophage deletion of some of these receptors 
or soluble factors involved in apoptotic cell clearance, such as the bridging 
molecule MFGE8, leads to impaired apoptotic cell clearance across tissues18. 
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In contrast, pan-macrophage deletion of Tim4, highly expressed by 
macrophages in the liver and the peritoneal cavity, does not affect apoptotic 
cell clearance in most tissues but does affect efferocytosis by Kupffer cells19 
and greatly affects homeostasis of the peritoneal cavity and clearance of 
apoptotic cells by peritoneal macrophages19-21. Hence, some mediators of 
apoptotic cell clearance are shared by macrophages across tissues18 whereas 
others are specific to macrophages inhabiting distinct sites19-21 suggesting 
tissue-specific types of apoptotic cell clearance.  
1.3 Origin of tissue-resident macrophages 
In 1972 van Furth et al proposed the mononuclear phagocyte system to group 
phagocytes4,22 (recently review in23) in the body. He established a number of 
criteria for cells to be included in the mononuclear phagocyte system. Cells 
had to have high phagocytic capacity, a criterion which excluded less 
phagocytic endothelial cells. Moreover, van Furth et al argued that in order for 
a group of cells to constitute a system these cells had to have a shared origin. 
A number of studies indicated that following lethal irradiation macrophages, 
including those in the liver and the lung,  were derived from circulating 
monocytes that in turn originated from the bone marrow4,22. To generate 
chimeric mice, animals where lethally irradiated to destroy bone marrow 
hematopoietic stem cells and reconstituted using congenic donor bone 
marrow, usually sourced from congenic CD45.1 mice, thus allowing long-term 
tracking of donor CD45.1+ bone marrow-derived cells to CD45.2+ immune cell 
populations. However, lethal irradiation also depletes various tissue-resident 
macrophage populations thus confounding these observations. Largely on the 
basis of these irradiation experiments van Furth suggested that the most 
immature cell of the mononuclear phagocyte system was the promonocyte, 
present in the bone marrow. Promonocytes gave rise to a more mature 
monocytes that circulated in the blood and infiltrated tissues where they gave 
rise to highly phagocytic macrophages. Interestingly, van Furth et al remarked 
on the existence of ‘fixed’ tissue macrophages of which the monocytic origin 
was yet to be established but that these cells should be included in 
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mononuclear phagocyte system based on their morphology and phagocytic 
capacity. Despite the inclusion of these fixed cells, of which the origin was 
ambiguous, the mononuclear phagocyte system and the bone marrow origin 
of tissue macrophages became established dogma until recently. 
A major break from this idea that macrophages originated from monocytes 
came from studies using a model of murine parabiosis, a methodology that 
does not rely on irradiation. Using this methodology, it was found that 
circulating monocytes did not contribute over a 5 month period to Microglia24 
,the resident macrophages in the brain, or over a period of 12 months to 
Langerhans cells25, the resident macrophages in the skin. Hence, it was 
suggested that these cells were likely self-maintaining throughout life. Merad 
and colleagues observed that Langerhans cells self-maintenance was 
established directly following birth. Hence, they postulated that hematopoietic 
precursors infiltrated the skin during embryonic life and gave rise to 
Langerhans cells that self-maintained for at least 12 months and likely 
throughout life25. 
With the development of new fate-mapping tools the questions concerning the 
origin of tissue-resident macrophages have been investigated in more detail. 
The most important of these tool is the inducible gene-specific fate-mapping 
tools utilizing the Cre-loxP methodology. Briefly, this two-part system consists 
of a Cre recombinase that recognizes specific DNA sequences, known as 
LoxP sites, and mediates depletion of the DNA sequence between the two 
LoxP sites. Commonly, a transgenic Cre-driver mouse line is generated by 
placing expression of the Cre recombinase under control the promoter of a 
gene of interest. Usually, this gene is selected to be specific to a tissue or cell 
type of interest. Secondly, a transgenic mouse is generated where LoxP sites 
flank a gene of interest to generate a conditional knockout. Alternatively, LoxP 
sites can be placed around a stop codon placed prior to the DNA sequence 
encoding for a fluorescent protein. The Cre-recombinase will remove the stop 
codon and the fluorescent protein will be expressed allowing tracking of cells 
of interest. This methodology has been expanded upon with the generation of 
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an inducible system, referred to as CreERT or later generation versions as 
CreERT2, generated by fusing the Cre-recombinase with an estrogen 
receptor. This CreERT protein is normally sequestered in the cytoplasm but 
after administration of tamoxifen   translocate to the nucleus and mediates 
depletion of the DNA sequence in-between LoxP sites similar to the original 
Cre-recombinase (reviewed in26,27). 
Yona and colleagues placed cre-recombinase under the promoter of CX3CR1 
gene, widely expressed in the mononuclear phagocyte system28. Utilizing 
CX3Cr1gfp, CX3Cr1cre-R26yfp and CX3Cr1CreER- R26yfp transgenic mouse lines 
allowed them to investigate historic and temporal expression of CX3CR1 by 
circulating monocytes and different tissue-resident macrophages. They found 
that, for example, Kupffer cells, alveolar macrophage and peritoneal 
macrophages did not express CX3Cr1gfp after they had adopted the resident 
identity. However, using CX3Cr1cre-R26yfp tracking studies indicated that 
Kupffer cells, alveolar macrophage and peritoneal macrophages originated 
from precursor cells that had expressed CX3CR1. Finally, using the inducible 
CX3Cr1CreER- R26yfp it became clear that Kupffer cells, alveolar macrophage 
and peritoneal macrophages did not originate from CX3CR1-expressing 
monocytes. Consequently, they concluded that these populations of resident 
macrophages are self-maintaining and do not rely on circulating monocytes for 
replenishment28 but do originate from a CXC3CR1-expressing progenitor. 
These findings were mirrored by work of Schultz et al29, using a similar 
CX3CR1 based fate-mapping methodology. Utilizing S100a4Cre- R26Tomato   
and Flt3Cre-R26Tomato/GFP transgenic monocyte-tracking mice, Hashimoto and 
colleagues concluded that resident macrophages in, for example, the brain, 
lung and peritoneal cavity did not rely on circulating monocytes for 
replenishment30. Parabiosis experiments carried out in the same study further 
supported this conclusion30 . Combined, these data supported the hypothesis 
that precursors seeded tissue during embryonic life and subsequent gave rise 
to self-maintaining tissue-resident macrophage subsets. However, the identity 
of this precursor and the dynamics of embryonic seeding remained unclear. 
 28 
The developmental origin of tissue-resident macrophages has been 
investigated by numerous groups. I will briefly touch on some of the key 
findings in this topic and highlight how embryonic precursors give rise to 
distinct tissue-resident macrophages population persisting throughout life.  
A better understanding of the embryonic origin of tissue-resident macrophages 
came from studies that utilized Runt-related transcription factor 1 (Runx1- mer-
cre-mer) transgenic mice. Runx1 is required for the development of erythro-
myeloid precursors (EMPs) and primitive hematopoietic stem cells (HSCs)31. 
It should be noted that the terminology for macrophage precursors is not well 
established yet and early-EMPs have been referred to as yolk sac 
precursors32. For this introduction I will using the EMP-nomenclature as 
recently reviewed by Ginhoux and colleagues33  
Importantly, expression of Runx1 is temporarily restricted to discrete stages of 
development. Consequently, tamoxifen treatment of inducible 
Runx1MercreMer/EYFP reporter mice at gestational day E7.0-E7.5 labelled Runx1-
expressing early EMPs in the yolk sac that seed various tissues as embryonic 
macrophages but ultimately only persist as microglia in the brain following 
birth31,34. In contrast, later tamoxifen labelling at E8.5, marks a discrete 
population of Runx1-expressing late EMPs that infiltrate the fetal-liver and give 
rise to fetal-liver monocytes which seed various tissue sites as embryonic 
macrophages and persist as resident macrophages post birth34,35. Similar 
dynamics were observed using inducible CSF1R transgenic mice 
(CSF1RMercreMer/EYFP). Early EMPs express high levels of CSF1R whereas late 
EMPs express low levels. Consequently, tamoxifen induction at E8.5 of 
inducible CSF1RMercreMer/EYFP mice, labels early EMPs but not late EMPs and 
similarly shows that early EMP-derived cells seed various sites but only persist 
as microglia in the brain29,34,36. These findings have been elaborated upon by 
utilizing inducible S100 calcium-binding protein A4 (S100a4Cre-RosaEYFP) 
transgenic mice. S100a4 is largely absent in early and late EMPs but highly 
expressed by fetal-liver monocytes. Consistent with findings utilizing other 
fate-mapping methodologies, S100a4-expressing fetal liver monocytes were 
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found to give rise to various issue resident macrophage populations but not 
microglia34.  
It remained unclear to what degree fetal hematopoietic stem cells (HSCs) 
contributed to adult tissue-resident macrophage populations. Fetal-HSCs were 
initially thought to contribute based on studies utilizing inducible m-cell- factor 
receptor c-Kit (KitMercreMerR26eYFP) transgenic mice. In these mice tamoxifen 
administration at E8.5 labelled all hematopoietic cells and resulted in labelling 
of most adult tissue-resident macrophage populations37, leading the 
hypothesis that fetal c-Kit-expressing HSCs may be the source of tissue-
resident macrophages. Utilizing HSCs-specific FLT3Cre-ROSA26YFP reporter 
mice it was found that HSCs only marginally contributed to tissue-resident 
macrophages in the liver and the brain, whereas macrophages in the dermis 
and the gut had much higher contribution of HSCs. These findings were 
elaborated upon by utilizing inducible Tek-Mer-cre-Mer transgenic mice 
(Tie2MeriCreMerRosa26YFP) which label both populations of EMPs and by fetal-
HSCs36. Importantly, following tamoxifen administration, adult leukocytes (T-
cells, B-cells and granulocytes) in the spleen were equivalently labelled as 
bone marrow-HSCs, indicative of their HSC origin. Labelling of Tie2-
expressing cells at different stages of embryonic development indicated that 
labelling at E7.5 resulted in higher labelling of post birth of tissue-resident 
macrophages than leukocytes, labelling at E8.5 in comparable labelling 
between these populations whereas labelling at E.9.5 results in more frequent 
labelling of leukocytes than tissue-resident macrophages36.  Hence, they 
concluded that tissue-resident macrophages originated largely independent of 
the HSC lineage and originated from yolk sac EMPs that express Tie2 at E7.5 
but not at E9.536.  
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Figure 1.1 Origin of tissue-resident macrophages. 
Developmental relationship between macrophage precursor populations, 
present at distinct times during embryonic development and tissue-resident 
macrophage populations present post-birth. At E7.0 yolk sac CSF1rHi Runx1+ 
early EMPs infiltrate various tissues, giving rise to macrophages. With the 
exception of Microglia in the brain and a small subset of Langerhans cells in 
the skin the majority of early EMP-derived macrophages are replaced by  
CSF1rLo S100a4+ Tie2 fetal-liver monocytes macrophages between E9.5 and 
E10. These fetal-liver monocytes are derived from yolk sac Runx1+ CSF1rLo 
Tie2+ late EMPs around E7.5. During embryogenesis fetal monocytes give rise 
to self-maintaining tissue-resident populations including Kupffer cells in the 
liver and alveolar macrophages in the lungs. Around E10.5 Flt3+ Tie2+ fetal 
HSCs from the Aorta-gonad-mesonephros (AGM) give rise to fetal liver 
monocytes that in turn give rise to bone-marrow HSCs which seed other tissue 
resident populations including those in the dermis and the gut during, a 
process which occurs continuously throughout life. This is a graphical 
summary of paragraph 1.3 which contains a more detailed description and the 
relevant references.  
Since, it has become apparent that the origin of macrophages inhabiting 
different tissues is highly variable. Some tissue-resident macrophage 
populations, such as Kupffer cells38, Langerhans Cells25 and microglia24,39 are 
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embryonically-seeded and completely self-maintaining. Others, such as the 
majority of tissue-resident macrophages in the gut wall40, rely on continuous 
replenishment from circulating monocytes. Finally, some tissues, such as the 
heart41, the peritoneal cavity42 ,the lung43  and intestine44 are inhabited by 
phenotypically and functionally distinct subsets of embryonically-seeded and 
monocyte-derived macrophages. To what degree these dynamics take place 
in human macrophage populations has remained unclear. However, 
investigation of skin macrophages in sex-mismatched bone marrow transplant 
patients suggested that even 1 year after transplantation approximately a 
quarter of skin macrophages were not replaced45,suggesting these cells are 
self-maintaining. 
Although a full understanding of these dynamics is still lacking, taken together 
these data support a model whereby tissue-resident macrophages are seeded 
during embryogenesis. Depending on the tissue and potentially their 
anatomical location within the tissue, tissue-resident macrophages are reliant 
on infiltrating monocytes for replenishment throughout life in varying degrees. 
1.4 Tissue-specific identity and functionality of tissue-resident 
macrophages  
With the advent of next-generation sequencing technologies it has become 
apparent that different tissue-resident macrophage subsets share a core panel 
of genes, reflective of their shared functionality, but also contain a gene 
signature uniquely adapting them to carry out tissue-specific functions required 
to maintain homeostasis7-9,46. Some of these tissue-specific functions have 
been characterized and linked to human pathologies. A good example of this 
is the clearance of surfactant by alveolar macrophages and consequently the 
development of proteinosis in lungs devoid of alveolar macrophages. 
Proteinosis develops in the lungs of transgenic CSF2Rb-/- 47 mice and patients 
with mutations in the CSF2R48,49, both of whom lack alveolar macrophages. 
Other tissue-resident macrophages that have been functionally characterized 
are Kupffer cells in the liver that are required for effective erythrocyte-derived 
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iron recycling50 and microglia in the brain, implicated in synaptic 
pruning51,52(reviewed in10). This raises the question of how this unique tissue-
resident identity and functionality is imprinted and develops. As mentioned, 
different tissue-resident macrophages across tissues share a core program of 
genes related to shared functions. This core program is driven by a group of 
lineage-determining transcription factors6. The most well characterized of 
these lineage-determining transcription factors are Pu153,54, MafB55 and the 
more recently discovered, Zeb256. These core-program transcription factors 
drive expression of various pattern recognition receptors, Fc-receptors and 
phagocytic receptors required for core macrophage functionality described in 
section 1.2. Critically, Pu1 drives expression of CSF1R the receptor for CSF1 
and Il34 which is vital for the survival and proliferation of most tissue-resident 
macrophage populations54. 
Upon this shared signature a tissue-specific gene identity is overlaid by tissue-
identity imprinting transcription factors. A number of these tissue-identity 
imprinting transcription factors have been identified6,57. Recent findings have 
indicated that identity-imprinting transcription factors are not necessarily 
tissue-specific but can even be specific to one region within a tissue. For 
example, splenic red pulp macrophages rely on the transcription factor Spi-C58 
whereas splenic marginal zone macrophages rely on LXRα59. In addition, 
some tissue-identity driving transcription factors are seemingly shared 
between tissue-resident macrophages in different sites. A striking example of 
this overlay is the shared dependency of peritoneal and alveolar macrophages 
on C/EBPβ60 and BHLHE4061,62. This overlap may indicate some degree of 
functional similarity. However, peritoneal macrophages are also uniquely 
dependent on the transcription factor GATA663-65 whereas alveolar 
macrophages are uniquely dependent on the nuclear receptor PPARγ66 and 
the transcription factor BHLHE4161. Hence, the unique identity of tissue-
resident macrophages is not necessarily dictated by unique tissue-identity 
imprinting transcription factors but rather a distinctive combination of 
transcription factors.   
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1.5 Plasticity of the tissue-resident macrophage identity.  
 
It remained unclear how the tissue-resident identity is imparted on 
macrophages.  Work by Lavin et al7 and Gosselin et al found9 an important 
role for the microenvironment in shaping tissue-resident identity via chromatin 
accessibility. Tissue-specific signals shape the chromatin landscape of 
resident macrophages thus impacting genome accessibility. Specifically, 
tissue signals were found to alter the chromatin landscape to allow binding of 
the core macrophage transcription factor Pu1 to common genomic locations, 
shared across tissue-resident macrophage subsets, but also to unique tissue-
resident specific genomic locations9. Moreover, tissue signals altered the 
chromatin landscape to allow binding of tissue-resident specific transcription 
factors such as LXRα and GATA69. After lethal irradiation tissue-resident 
macrophages in the liver, lung, spleen and liver were replaced by bone 
marrow-derived cells that adopted a complete resident-like epigenetic 
enhancer landscape7. Moreover, mature peritoneal macrophages transferred 
into the lung adopted an alveolar-like transcriptional identity, suggesting a high 
degree of plasticity7. Hence, monocytes and macrophages are highly plastic 
cells, reliant on environmental cues to imprint the resident identity and likely 
functionality. 
 
Since, a number of these of environmental signals have been identified. For 
example, PPARγ, driving the alveolar macrophage signature, is regulated by 
GM-CSF abundant in the alveoli66. Conversely, expression of GATA6, the 
transcription factor that dictates the peritoneal macrophage identity, is driven 
by retinoic-acid, abundant in the peritoneal cavity micro-environment63. At 
present, little is known about the factors that drive CEBP/β, the transcription 
factor required for both peritoneal and alveolar macrophages60, but it possible 
that expression of this transcription factor is driven by environmental cues 
shared between the alveolar space and the peritoneal cavity.  
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Based on these findings a number of studies set out to ascertain whether 
monocytes could give rise to bona-fide resident macrophages that are 
normally of embryonic origin, such as alveolar macrophages in the lung and 
Kupffer cells in the liver.  
Utilizing Csf2Rb-/- mice devoid of alveolar macrophages it was found that 
transferred yolk-sac macrophages, fetal-liver monocytes and bone marrow-
derived monocytes give rise to alveolar macrophages that are transcriptionally 
equivalent to embryonically seeded alveolar macrophages and clear 
surfactant. Importantly, all three transferred precursor populations expanded 
and fully reconstituted the alveolar macrophage niche. In contrast, transferred 
mature tissue-resident macrophage populations, including Kupffer cells and 
colonic macrophages did not persist. Unlike the study by Lavin et al, this study 
found that while transferred peritoneal macrophages persisted, these cells did 
not expand and only partially adopted an alveolar phenotype67. 
Subsequent studies in the liver found that following artificial depletion of 
embryonically-seeded Kupffer cells the liver macrophage compartment is 
reconstituted monocyte-derived Kupffer cells38. However, to what degree 
these cells were equivalent to bona-fide Kupffer cells varied depending on 
study. One study utilized a Clec4f-DTR mice to deplete embryonically-seeded 
Kupffer cells. Monocytes infiltrated the liver following Kupffer cell depletion and 
by day 15 had partially adopted a Kupffer cell transcriptome and by 30 almost 
completely adopted a Kupffer cell transcriptome. Moreover, these monocyte-
derived Kupffer cells had similar self-renewal capacity and similar capacity to 
phagocytose Escherichia coli particles ex vivo38. In contrast, Beatie et al. found 
monocyte-derived Kupffer cell remained more transcriptionally distinct from 
their embryonically seeded counterparts than suggested by Scott et al. and 
had enhanced capacity to phagocytose Neisseria meningitidis and Listeria 
monocytogenes in vivo but responded similarly to Leishmania donovani 
infection68. One further study by David et al. indicated that monocyte derived 
Kupffer cells have impaired capacity to phagocytose E coli in vivo until 17 days 
after repopulating the depleted liver69. Furthermore, chemical injury of liver 
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was worse for at least 1 month in after Kupffer cell-depletion but had returned 
to normal by 2 months following depletion. Importantly, these studies utilized 
different tools to deplete Kupffer cells. Whereas Scott et al. and David et al. 
specifically depleted embryonically-seeded Kupffer cells using transgenic 
Clec4f-DTR mice38 or clodronate liposomes69, Beattie et al. lethally irradiated 
mice to deplete Kupffer cells68. Consistent with less targeted methodology 
Beattie et al found evidence of transient inflammation in the liver shortly after 
depletion68 whereas the other studies did not. Similar studies depleting 
microglia using transgenic CX3CR1CreER R26DTA 70 mice or using lethal-
irradiation71 found that infiltrating monocytes give rise to monocyte-derived 
microglia that remain transcriptionally and phenotypically distinct from their 
embryonically seeded counterparts. Combined these studies suggest that 
monocyte derived cells can give rise to bona-fide tissue-resident macrophages 
but that the context under which they infiltrate the tissue may be altering their 
capacity do so.  
1.6 The niche hypothesis as a model of tissue-resident identity 
The observation that monocytes are capable of reconstituting an artificially 
depleted macrophage compartment and adopt a tissue-resident identity led to 
the formulation of the niche hypothesis by Guilliams et al. in 201772. In short, 
they postulated that all macrophage precursors have the capacity to 
reconstitute a macrophage compartment but cells compete for a limited 
number of ‘niches’. If the niche is available, a precursor-cells can take up 
residence in the niche which provides signals to adopt the unique tissue-
resident identity. In some tissues, such as the liver, resident macrophages 
repopulate the niche when it becomes available as low numbers of resident 
macrophages die under homeostatic or mildly inflamed conditions. Under 
these conditions resident macrophages have a repopulation advantage and 
prevent monocytes from repopulating the available niche space. If more 
catastrophic loss of resident macrophages occurs resident monocyte 
repopulation does occur in these tissues.  
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This model was largely based on liver studies and indeed the first detailed 
description of the cellular composition of the macrophage niche was found in 
the liver. Using a combination of live imaging techniques and transgenic 
mouse lines Bonnardael et al73 observed that monocyte that infiltrate the liver 
after depletion of Kupffer cells migrated to distinct areas in the perisinusoidal 
space and interacted with endothelial cells and stellate cells to acquire the 
Kupffer cell-identity determining transcription factor LXRα, and with 
hepatocytes to acquire expression of the ID3, another Kupffer cell-identity 
determining transcription factor. Work by Sakai et al published around the 
same time corroborated these findings and indicated that Notch signaling 
activated enhancers to drive LXRα and establish the Kupffer cell-identity74. 
Moreover, the niche concepts includes a role for niche cells in providing factors 
required for macrophage survival as well as imprinting. It has long been known 
that most tissue-resident macrophages rely on CSF1 for survival and 
proliferation and hence production of is likely to form a core part of any niche75. 
It has been postulated that for tissue-resident macrophages to acquire 
sufficient levels of CSF1 to undergo the proliferation required to self-maintain, 
a local source of CSF1 is required76,77. In various tissues where tissue-resident 
macrophages rely on CSF178, CSF1 producing stromal cells have been 
identified including the spleen79, the liver73 and the peritoneal cavity80. This 
exchange of growth factors between macrophages and stromal cells is similar 
to the two-cell systems proposed by Zhou et and colleagues which was based 
on their studies were macrophages and fibroblasts that were co-cultured and 
found to provide one another with survival factors. Macrophages provided 
PDGFB to fibroblasts whilst fibroblasts provide CSF1 indicating a symbiotic 
relationship81. 
Hence the tissue niche provides both identity and survival factors to the 
macrophages that inhabit the nice. 
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1.7 The effect of inflammation on the origin of resident macrophages.  
It is poorly understood how the niche may be altered following an inflammatory 
insult, and how monocytes are programmed into resident macrophages after 
taking up residence in the niche under steady state conditions or following 
inflammation or artificially-driven depletion of resident macrophages. This 
question concerning the niche hypothesis in the context of inflammation is 
highly relevant as the biological process where a high degree of tissue-resident 
replacement is likely to occur is following inflammation. Indeed, inflammation 
induced loss of tissue-resident macrophages and a concurrent influx of 
monocytes has been observed in numerous tissues including the liver69,82,83 
the brain84,85 and the peritoneal cavity86,87. Some studies indicated that 
monocytes only transiently inhabited the tissue in mouse models of 
acetaminophen induced liver injury83 and encephalitis85. In contrast, it has 
been found that monocytes integrate into the resident macrophage 
compartment following autoimmune hepatitis-induced loss of Kupffer cells in 
the liver although it is unclear whether these cells persist long-term88.   
During the last year of my PhD there has been a number of studies that have 
shown that tissue inflammation can drive monocyte integration into the 
macrophage compartment in various tissues. In the skin, monocytes were 
found to give rise to Langerhans cells that transcriptionally resembled their 
embryonically seeded counterparts in a model of graft versus host disease 89. 
Meningeal infection with lymphocytic choriomeningitis virus induced loss of 
resident macrophages and long-term integration of monocyte-derived 
macrophages but these cells remained transcriptionally and functionally 
discrete 90. Monocytes were shown to give rise to long-lived Kupffer cells in 
the liver following loss of embryonically seeded pro-inflammatory Kupffer cells 
in a model of non-alcoholic steatohepatitis 91. Similar integration occurs in 
metabolic-associated fatty liver disease92 after which monocyte-derived 
Kupffer cells were found to inhabit discrete anatomical zones in the liver, 
compared to embryonically-seeded Kupffer cells. In the lungs, following 
bleomycin treatment, monocytes integrate into the alveolar macrophage 
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compartment and have a pro-fibrotic effect but also retain significant 
transcriptional differences, even by 10 months post injury93. Influenza drives 
integration of monocytes into the alveolar macrophage compartment that 
confer protection to subsequent Streptococcus pneumonia infection94 but this 
effect was found not to last beyond 1-month post-viral infection.  
These data emphasize that the degree and type of inflammation and also 
potentially the tissue site are likely determinants of monocyte fate following 
resolution of an inflammatory event. Moreover, these studies highlight the 
importance of understanding to what degree monocyte integration into the 
resident-macrophage compartment occurs, the potential impact of this 
phenomenon and the factors that dictate this integration following 
inflammation. 
1.8 The peritoneal macrophage niche  
Peritoneal cavity macrophages are arguably one of the most studied 
populations of tissue-resident macrophages. As the peritoneal cavity is a fluidic 
environment and peritoneal macrophages are easily collected by lavage as a 
single cell suspension, this site has often been used to model inflammation 
and these cells used to model and investigate macrophage functions. The 
peritoneal macrophage compartment is thought to consist of two subsets of 
peritoneal macrophages95 By far the most predominant population of these 
cells have historically been characterized by high levels of the macrophage 
marker F4/80 and variable levels of MHCII and are often referred to as large 
peritoneal macrophages (LPM)42,96 on the count of having a mean diameter of 
approximately 11µm. On the basis of surface markers, a second rarer 
population of peritoneal macrophages characterized by low levels of F4/80 and 
high levels of MHCII has been identified, referred to as small peritoneal 
macrophages as these cells have are smaller than their LPM counterparts with 
a mean diameter of approximately 8µm 42,95,96.  
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The origin of these macrophage subsets remained unclear until relatively 
recent. In CCR2-/- mice, in which monocytes are unable to egress from the 
bone marrow, it was found that the number of LPM was unaltered whereas 
numbers of SPM were strongly reduced suggesting that LPM self-maintain 
independent of circulating monocytes42. Moreover, LPM did not label in studies 
by Yona et al utilizing inducible CX3Cr1creER-R26yfp reporter mice, again 
indicating these cells do not rely on circulating monocytes for replenishment28. 
The most detailed description on the origin of peritoneal LPM and SPM came 
from Bain et al42. Utilizing a partial bone marrow chimera methodology, they 
irradiated the hindlegs of mice whilst protecting the peritoneal cavity resident 
macrophage pool. Hence, tissue-protected bone marrow chimeric mice, 
allowed them to ascertain contribution of bone marrow-derived cells to the 
peritoneal macrophage compartment without the confounding effects of full 
body irradiation. These studies indicated a low degree of chimerism 8-12 
weeks following reconstitution but increasing chimerism 36 weeks after 
reconstitution. Hence, these data supported the notion that LPM were long-
lived cells but that with time these cells were replaced by monocyte-derived 
macrophages. Moreover, monocyte integration into the LPM compartment 
occurred much more rapidly in males than in females, a phenomenon which 
was later found to be mediated by the local microenvironment following sexual 
maturation97. Moreover, found a high degree of chimerism of the SPM 
population indicating that these cells rely on continuous replenishment by 
circulating monocytes for their maintenance and are likely short-lived42. 
Because of their longer lifespan and their abundance, LPM are generally 
considered the resident macrophages of the peritoneal cavity.  
The finding that circulating monocytes contribute to both the LPM and SPM in 
the peritoneal cavity suggests that the cavity microenvironment may contain 
factors that imprint the LPM or SPM identity on infiltrating monocytes.  The 
identity of resident-LPM appears to be driven predominantly by environmental 
signals via tissue-resident identity imparting transcription factors. In the 
peritoneal cavity the CCAAT/enhancer binding protein (CEBP/b)60 and GATA 
binding protein 6 (GATA6)63-65 have been identified as tissue-resident identity 
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driving transcription factors. Loss of either one of these transcription factors 
leads to almost complete loss of peritoneal resident-LPM. Moreover, the small 
population of GATA6-deficient LPM lacks expression of a large set of genes 
expressed specifically by peritoneal LPM63-65. The number of SPM are 
unaffected in these mice, indicating that LPM and SPM, whilst inhabiting the 
same cavity, are regulated independently of one another.  
Recent work has indicated that smaller subsets of tissue-resident identity 
genes are lost in peritoneal resident-macrophages deficient in the 
transcriptional factor BHLHE4062 and the ligand-dependent transcription 
factors Retinoid X receptor alpha (RXRa) and beta (RXRb)98. Both GATA663 
and RXR signalling98 are responsive to the active metabolite of vitamin A, 
retinoic-acid. In the peritoneal cavity the predominant source of retinoic-acid is 
thought to be mesothelial and fibroblastic stromal cells in the omentum63,99. At 
present little is known about how GATA6, RXRs or CEBP/b affect the lifespan 
of LPM. 
In addition to serving as a source of retinoic-acid the omentum, a sheet of intra-
abdominal adipose tissue directly adjacent to the peritoneal cavity100, is 
thought to be important for the identity of resident-LPM in the peritoneal 
cavity101. It has been postulated that monocytes traverse through the 
neighbouring omentum and require GATA6 to exit the omentum and take up 
residence in the peritoneal cavity. However, this hypothesis is largely based 
on the accumulation of macrophages in the omentum of macrophage-specific 
GATA6-deficient mice, but no direct evidence of migration from omentum into 
the cavity has been shown63. The omentum is also thought to produce a variety 
of other, poorly defined, factors that drive expression of a set of peritoneal 
tissue-resident identity genes63,99. In addition, the omentum102 and peritoneal 
mesothelium80 are thought to be the predominant source of CSF1 in the cavity, 
vital for peritoneal macrophage survival. As the peritoneal cavity is a fluidic 
environment in which peritoneal cavity macrophages ‘float’103, most 
environmental cues are thought to be secreted factors. However, it has been 
postulated that peritoneal macrophages intermittently interact with cells that 
 41 
line the peritoneal cavity. Indeed, peritoneal mesothelium has been shown to 
produce secreted and membrane bound CSF1 both of which can drive 
peritoneal macrophage proliferation in vitro80 but that membrane bound CSF1 
signalling requires direct interaction with peritoneal macrophages to do so. 
Similarly, omentum factors are thought to be secreted into the cavity and drive 
peritoneal macrophage identity99. However, a small subset of peritoneal 
identity genes are only induced by direct interaction between omentum cells 
and peritoneal macrophages in vitro99, suggesting that interaction, likely 
intermittent, between peritoneal macrophages and omentum cells is required 
for peritoneal macrophages to completely adopt a resident identity.  
At noted before, in contrast to their resident counterparts, the SPM in the 
peritoneal cavity do not rely on GATA6 for their development. Instead, SPM 
development relies on the transcription factor IRF4 and signals arising from 
the microbiota104. Interestingly, studies in macrophages deficient in GATA6 or 
CEBP/b observed a striking reduction in the overall numbers of peritoneal 
macrophages suggesting there was no compensatory increase in the number 
of SPM60,63 to replace lost LPM. Loss of RXRab signalling in macrophages 
similarly depleted LPM but did lead to a concurrent increase in F4/80LoMHCIIHi 
cells which transcriptionally resembled SPM, and expressed high levels of 
IRF4. Hence, these data suggest that RXRab signalling limits the SPM niche98. 
Indeed, SPM express both RXRa and RXRb but less than their resident 
counterparts98. Finally, both resident-macrophages and SPM express 
CSF1R105 and rely on CSF1 for their survival106 and would appear to share a 
survival niche, as they are likely competing for secreted and membrane bound 
CSF1. Taken together, these data suggest that, except for CSF1, the 
environmental cues that dictate the number and identity of resident-LPM are 
largely discrete from those that drive the number and identity of SPM. This 
difference is surprising as both cells seemingly inhabit the same micro-
environment unlike in, for example, the spleen and gut, where tissue-resident 
identity is imprinted by distinct anatomical regions58,59,107.  
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Figure 1.2 The peritoneal niche. 
Overview macrophage subsets present in the steady-state peritoneal cavity 
with known identity-determining transcription factors and environmental 
signals. Interactions definitively shown to occur in vivo are depicted using solid 
lines. Interactions that are postulated to occur, or have been shown in vitro are 
in depicted using dashed lines. Resident-LPM account for the majority of 
macrophages in the peritoneal cavity and rely on a number of transcription 
factors (listed below the cell) to drive their peritoneal macrophage identity. The 
main transcription factor GATA6 is driven by retinoic acid, thought to 
predominantly originate from the omentum. The omentum also produces 
omentum factors that drive part of the resident LPM identity although the extent 
to which this occurs in vivo is unclear. Resident LPM are replaced by 
monocyte-derived cells over time but it is unknown whether infiltrating 
monocytes can give rise resident-LPM directly have to develop into SPM 
before giving rise to resident-LPM. Moreover, it is unclear if monocytes 
infiltrate the cavity directly or traverse the omentum before entering the 
peritoneal cavity. The smaller population of SPM in the cavity are derived from 
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circulating monocytes and rely on IRF4/microbial signals to establish their 
identity. Both peritoneal macrophage populations rely on CSF1 for survival and 
proliferation. The predominant source of CSF1 in the cavity are the omentum 
and the surrounding mesothelium both of which secrete CSF1 into the 
peritoneal cavity microenvironment but also produce membrane bound CSF1. 
The importance of the latter for peritoneal macrophage survival and 
proliferation is unclear. This is a graphical summary of paragraph 1.8 which 
contains a more detailed description and the relevant references. 
Recently our lab has utilized single cell sequencing and found that the cells 
initially considered LPM actually comprise 3 transcriptionally distinct 
populations of cells. The predominant population of these cells consists of 
long-lived LPM whereas two smaller subsets of LPM are monocyte-derived97 
as determined by analysis of their replenishment by monocytes using tissue-
protected bone marrow chimeras. Similar LPM heterogeneity was found using 
single cell sequencing by Wang et al108 but contrasted by Lantz et al109 who 
identified a cluster of Il1b producing LPM, not observed in our studies or by 
Wang et al. The developmental relationship between these resident-LPM 
clusters and if these cells share the same niche is unclear.  
1.9 The function of resident peritoneal macrophages  
Our overall understanding of the function of peritoneal macrophage is 
incomplete. It has been found that the phosphatidylserine receptor Tim4110, a 
marker for the embryonically seeded subset of peritoneal resident-
macrophages42 is vital for peritoneal cavity homeostasis20 and is required for 
the immunologically silent clearing of apoptotic cells21. As Tim4 expression is 
limited to the embryonically seeded cluster of resident-macrophages these 
cells may be uniquely adapted for apoptotic cell clearance. In addition to 
clearing apoptotic cells peritoneal macrophages have been found to carry out 
immunological functions, including the clearance of Streptococcus 
pneumoniae(S.Pneumoniae)97,111 and Escherichia coli (E.coli)103,112 and 
limiting dissemination of  bacteria from the peritoneal cavity to the blood103. In 
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addition, a surprising function of peritoneal cavity macrophages is their ability 
to infiltrate the liver following a burn injury12. More recently, resident 
macrophages that reside in the pericardium, a physiologically-related serous 
cavity that surrounds the heart, that also depend on GATA6 expression have 
been shown to migrate into the heart following ischemic injury. This gives 
confidence that this migratory capacity of GATA6-expressing serous 
macrophages, including peritoneal LPM, might extend into many organs113. 
Moreover, peritoneal macrophages have been implicated in a number of 
peritoneal pathologies including endometriosis 114,115and development of post-
surgical adhesions116,117 although their role in these diseases is not clear. 
Finally, peritoneal resident-macrophages are one of the main sources of 
peritoneal CXCL13, a chemokine required for the maintenance of peritoneal 
B1 cells in the cavity118.  
1.10 Dynamics of acute peritoneal inflammation 
 
Various irritants have been utilized to induce acute peritoneal inflammation. 
Some infectious models including the cecal ligation and puncture model or 
direct injection of cecal contents into the cavity have been used to model 
polymicrobial sepsis119. A drawback of infectious models is that the 
pathogenicity and growth rate of pathogens and the dynamics of peritoneal 
inflammation vary greatly. Injection pure bacteria or fungi including 
Staphylococcus Pneumoniae120 or Candida Albicans121 suffers less from the 
drawbacks of polymicrobial models119,122. In recent years, sterile models of 
peritoneal inflammation have been used extensively. The main strength of 
these models is their convenience and reproducibility in comparison to 
infectious peritonitis models. To induce sterile peritonitis various substances 
have been used most notably injection of thioglycolate broth86, zymosan122 or 
LPS123. For this introduction I will discuss acute phases of the zymosan model 
of peritonitis in more depth and highlight similarities and differences with other 
commonly used models of sterile peritonitis. I am focussing on the zymosan 
model of peritonitis as it has been used in a number of recent studies that my 
project is based on and it is the model that I have used in this thesis. 
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Zymosan is a preparation of yeast cell wall and is commonly used as a model 
of sterile peritonitis. Zymosan is rich in β-glucan, the most abundant fungal cell 
wall polysaccharide121, which is recognized by predominantly by the pattern 
recognition receptor Dectin1124 but also by heterodimeric complexes of toll-like 
receptor 2 and 6125. Dectin1 is highly expressed by peritoneal macrophages126. 
Loss of Dectin1 abrogates zymosan recognition and phagocytosis by 
macrophages127 and inhibits production of pro-inflammatory cytokines such as 
CCL2 and Il6 in response to zymosan treatment in vitro124. Critically, loss of 
Dectin1 results in impaired recruitment of monocytes and neutrophils into the 
cavity following zymosan treatment124, emphasizing the importance of this 
receptor as a mediator of fungal responsiveness. During zymosan-induced 
peritonitis the peritoneal cavity is infiltrated by high numbers of monocytes and 
neutrophils122. Infiltrating monocytes rely on a CCR2-dependent precursor and 
are thought to originate from Ly6cHi circulating monocytes111. During the early 
stages of peritoneal inflammation monocytes are characterized by high 
expression of the monocyte marker Ly6c, reaffirming their likely origin from 
Ly6cHi circulating monocytes111. Monocyte recruitment into the cavity relies on 
CCL2128,129 and can be inhibited using anti CCL2 blocking antibody or induced 
by injection of recombinant CCL2130. Following zymosan treatment, levels of 
peritoneal fluid CCL2 increase and peak approximately 4 hours later before 
reducing in the succeeding days128,129. Both LPM and SPM produce high levels 
of CCL2, 4 hours following zymosan treatment and then produce progressively 
less in the succeeding 72 hours131, suggesting these cells are an important 
source of CCL2 in the cavity.  
 
Depletion of peritoneal macrophages or mast-cells suggests that neutrophil 
recruitment into the cavity, following zymosan treatment, is mediated by mast-
cells132. Indeed, mast cells have been shown to express Dectin1133 which may 
explain the altered neutrophil recruitment followings zymosan treatment in 
Dectin1-/- mice124. Although peritoneal macrophages appear to be dispensable 
for the recruitment of neutrophils, depletion leads to heightened neutrophil 
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recruitment following zymosan treatment132. It has been proposed that 
peritoneal macrophages serve as a source of anti-inflammatory Il10 which 
inhibits the release of inflammatory cytokines and neutrophil recruitment132. As 
inflammation resolves the number of neutrophils in the cavity rapidly declines, 
through neutrophil apoptosis134,135 and potentially migration of neutrophils into 
the omentum136 
 
A key feature of most models of peritoneal inflammation, including zymosan-
induced peritonitis is the loss of resident macrophages5,137,138. This 
phenomenon has been referred to as the macrophage disappearance 
reaction138 and until recently was poorly understood. It has become clear that 
the macrophage disappearance reaction, at least following zymosan 
treatment, is due to LPM forming clots that serve to entrap microorganisms103. 
This clotting reaction would appear to occur independently of Dectin1 as 
macrophage disappearance occurs in mice deficient in Dectin1124. In addition, 
macrophages exhibit elevated levels of apoptosis, 6 hours following zymosan 
treatment134, suggesting macrophage apoptosis likely contributes to the 
macrophage disappearance reaction. 
 
As described monocytes infiltrate the cavity and their influx coincides with the 
loss of resident macrophages. Infiltrating monocytes differentiate into a subset 
of phagocytes referred to as inflammatory macrophages. Inflammatory 
macrophages are characterized by intermediate levels of the macrophage 
marker F4/80 and high levels of MHCII87,139. In various models of peritoneal 
inflammation resident-LPM and monocyte-derived inflammatory macrophages 
have been shown to inhabit the cavity over the course of inflammation86,87,95.  
 
All these inflammatory phenomena are highly dependent on the degree of 
peritoneal inflammation. Zymosan treatment seemingly induces a dose-
dependent degree of peritoneal inflammation with, as indicated by neutrophil 
recruitment. Low dose zymosan treatment (10µg ~2*106 particles) is used to 
model localized mild peritonitis ,higher doses (100/1000µg ~2*107/8 particles) 
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are used to induce more severe localized peritonitis87,122,139 and very high dose 
of zymosan is used to induce chronic systemic inflammation120 
(10,000µg~2*109 particles). Few studies have directly contrasted changes to 
the peritoneal cavity following different doses of zymosan. However, zymosan 
treatment leads to a dose-dependent influx of monocytes and neutrophils. High 
dose zymosan treatment is also characterized by high levels of CLL5 in the 
cavity, which is largely absent following low dose zymosan treatment122, 
indicating that the peritoneal micro-environment is distinctly different following 
high dose zymosan compared to lower doses. 
 
Thioglycolate injection, another commonly used model of peritoneal 
inflammation, induces more severe localized peritonitis and is characterized 
by almost complete loss of resident macrophages and influx of high numbers 
of monocytes86,87. These monocytes seemingly give rise to distinct subsets of 
inflammatory macrophages characterized by variable levels of MHCII86. 
Nguyen et al140 suggested that these subsets may be programmed by cavity 
levels of Il10, transiently increased during the acute phases of peritoneal 
inflammation. Monocytes that infiltrate during this acute phase adopt an 
MHCIILo phenotype whereas monocytes that infiltrate later, when Il10 levels 
have decreased, adopt an MHCIIHi phenotype. Critically, Nguyen et al injected 
cecal contents to induce peritoneal inflammation and it is not clear whether 
similar Il10 programming may occur following thioglycolate or zymosan-
induced peritonitis. In the thioglycolate model, both subsets of inflammatory 
macrophages have been shown to undergo high levels of apoptosis during 
resolution of inflammation86 whilst a small number migrate into draining lymph 
nodes141,142 although the latter has been contested86. Similarly, high levels of 
apoptosis have been observed following resolution of zymosan-induced 
peritonitis134. At the same time resident macrophages exhibit high levels of 
proliferation whereas only a minor subset of inflammatory macrophages 
exhibits comparable levels of proliferation87,143,144. Combined, these studies 
have supported the notion that inflammatory macrophages present during 
resolution are largely lost due to apoptosis whilst resident macrophages 
 48 
undergo elevated levels of proliferation to reconstitute the macrophage 
compartment.  
 
Figure 1.3 Dynamics of zymosan induced peritonitis 
Overview myeloid dynamics at different stages of mild zymosan-induced 
peritonitis. Background colour denotes the degree of inflammation ranging 
from acute (red background on the left) to resolved (white on the right). 
Resident-LPM and SPM recognize zymosan particulates via Dectin1 and 
TLR2/6 heterodimers. In response to zymosan exposure both macrophage 
subsets produce high amounts of CCL2 and Il6. Consequently, Ly6cHi 
monocytes infiltrate the cavity from the blood and give rise to phenotypically 
distinct inflammatory macrophages over the course of the inflammatory event. 
Shortly following onset of inflammation resident-LPM are lost through the 
formation of clots and apoptosis. During resolution of inflammation (right) the 
remaining resident-LPM exhibit heightened proliferation whilst inflammatory 
macrophages seemingly undergo apoptosis and exhibit limited proliferation. 
This is a graphical summary of paragraph 1.10 which contains a more detailed 
description and the relevant references. 
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1.11 Monocyte-derived cells may persist after peritoneal inflammation 
Because it has been assumed that resident macrophages reconstituted the 
macrophage compartment following peritoneal inflammation only few studies 
have attempted to investigate the long-term fate of monocytes. Studies utilizing 
CX3CR1CreErt2 transgenic mice to track infiltrating monocytes found evidence 
for some integration of monocyte-derived macrophages into the resident 
macrophage compartment following thioglycolate induced peritonitis28,145. 
However, interpretation of these studies is challenging as labelling efficiency 
of CX3Cr1creER-R26yfp in circulating and cavity-infiltrating monocytes was very 
inefficient28. Consequently, the number of labelled cells was quantitively minor 
in both studies and no definitive conclusions can be drawn regarding the 
survival of resident or monocyte-derived inflammatory macrophages. In later 
studies Gundra et al utilized CX3CR1CreERT2-IRES-EYFP transgenic mice to 
investigate monocyte integration following thioglycolate induced peritonitis. 
However, as the labelling efficiency of infiltrating monocytes was poor they 
opted to expand the entire macrophage compartment using Il4-treatment146,147 
to source sufficient labelled monocyte-derived cells for further transcriptional 
analysis145. Consequently, no definitive conclusions can be drawn about the 
degree to which monocytes persist following thioglycolate treatment. In 
addition, by pre-treating with Il4 they imprinted an Il4 gene-signature 
monocyte-derived macrophages making it challenging to asses to what degree 
these cells transcriptionally resemble bona-fide resident macrophages. Near 
the end of my PhD two new transgenic mouse models were developed: the 
Ms4a3Cre -RosaTdT to track constitutive monocyte infiltration and the 
Ms4a3CreERT2 -RosaTdT to track temporal monocyte infiltration123. Importantly, 
following tamoxifen administration to Ms4a3CreERT2 -RosaTdT mice both 
circulating and cavity-infiltrating monocytes are efficiently labelled123 unlike 
following tamoxifen administration to CX3Cr1creER-R26yfp transgenic 
mouse28,145, utilized in previous studies. Using the Ms4a3CreERT2 -RosaTdT 
model, Liu and colleagues found that following thioglycolate-induced peritonitis 
monocyte-derived cells infiltrated the cavity that persisted up to 20 weeks 
following the inflammatory event123. However, they did not carry out in depth 
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analysis to the identity and functionality of these cells. The Ms4a3CreERT2 -
RosaTdT could have been a very powerful tool for my PhD but became available 
too late for me to utilize. 
Using a dye-labelling methodology Newson et al111 labelled resident and 
inflammatory using discrete PKH-labelling reagents to track both populations 
long-term following zymosan-induced (100µg) peritonitis. They presented 
evidence that approximately half of inflammatory macrophages present 3 days 
after zymosan treatment persisted up until 17 days. In later experiments, 
survival of inflammatory macrophages up until 60 days following the 
inflammatory event was suggested, but the degree of integration was not 
quantified. As PKH-dyes are not degraded upon internalization, cells 
undergoing apoptosis transfer PKH-dye to engulfing phagocytes, thus 
confounding results when exclusively relying on dye-labelling as lineage-
tracing tool. Hence, these data should be interpreted with caution. Intriguingly, 
60 days following the zymosan-induced peritonitis insult neutrophil recruitment 
in response to s.pneumoniae infection was inhibited, compared to control mice 
that had not undergone a historic inflammatory event111.  Although this effect 
could not be attributed to the integration of inflammatory macrophages it 
provides the evidence that the responsiveness of the peritoneal cavity on the 
whole is altered following a historic inflammatory event. Hence, it remains 
unclear to what degree monocytes integrate into peritoneal macrophage 
compartment following inflammation, to what degree they adopt the identity 
and functionality of the original tissue-resident macrophages, and what factors 
may regulate their integration. 
It should be noted that the presence monocyte-derived cells in the resident 
macrophage compartment and the presence of SPM in the peritoneal 
cavity42,104 provides proof-of-concept that the cavity is amenable to monocyte 
integration under steady-state conditions. Intriguingly, studies using the 
thioglycolate model of peritonitis found that following thioglycolate induced 
peritonitis there was small population of infiltrating macrophages that was 
transcriptionally distinct from inflammatory macrophages and identical to SPM 
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86. Similarly, following zymosan treatment it was found that although SPM were 
lost shortly after injection, a small fraction of infiltrating monocytes adopted an 
SPM identity whilst the majority adopted an inflammatory macrophage 
phenotype139. Hence, the inflamed peritoneal cavity is temporarily inhabited by 
three distinct subsets of macrophages. A relatively small population of resident 
LPM macrophages, a large population of inflammatory macrophages and a 
small population of SPM. Interestingly, these cells remain transcriptionally 
distinct despite seemingly being exposed to the same fluidic micro-
environment86. 
These findings indicate that during peritoneal inflammation both the resident 
and the much smaller SPM niche are depleted and raises the question whether 
inflammatory macrophages are capable of colonizing either of these niches. 
As monocytes are known to contribute to the SPM population, differentiation 
of monocyte-derived inflammatory macrophages into SPM would not be 
surprising. If indeed this occurs, inflammatory macrophages that differentiate 
into SPM would likely persist relatively briefly as SPM are thought to be short-
lived42. In contrast, if inflammatory macrophages take up residence in the 
resident niche, they will likely become long-lived self-maintaining cells42.  
It is challenging to extrapolate between datasets from different tissues, but 
there appears to be some indication that competition between infiltrating 
monocytes and resident-macrophages dictates the survival of the former. 
Following hepatic injury with acetaminophen, resident Kupffer cells are largely 
lost but a small persistent population undergoes high levels of proliferation to 
reconstitute the liver despite presence of large numbers of monocytes83. 
Similarly, following zymosan induced peritonitis resident-macrophages 
undergo high levels of proliferation despite the presence of high numbers of 
monocyte-derived inflammatory macrophages87,143,144. However, in the liver 
complete loss of Kupffer cells following viral infection88 or bacterial infection148 
does result in monocyte integration. Although the data is incomplete, it would 
appear that resident-macrophages in the peritoneal cavity are lost following 
thioglycolate treatment and that monocytes, at least partially, reconstitute the 
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macrophage compartment long-term28,123. Hence, these data would support a 
key role for resident macrophage proliferation as a mechanism to inhibit 
integration of monocytes into the macrophage compartment.  
1.12 Are monocyte-derived cells capable of reconstituting the 
macrophage niche.  
These findings raise the question whether inflammatory macrophages have 
the capacity to persist and give rise to resident macrophages, irrespective of 
whether they are doing so following an inflammatory event. Similarly, 
monocyte-derived cells are capable of giving rise to Kupffer cells in the liver 
and alveolar macrophages in the lung but only do so in the absence of a 
competing population of resident macrophages. To investigate this question in 
the peritoneal cavity adoptive transfer of resident of monocyte-derived 
inflammatory macrophages into recipient mice that are deplete of peritoneal 
resident macrophages is the most viable option. Pan macrophage GATA6KO63-
65 and CEBPbKO60 transgenic mice are largely devoid of resident peritoneal 
macrophages and hence could be amenable for such adoptive transfer studies 
without competition by incumbent resident macrophages. However, in the 
cavity of GATA6KO 63-65 and CEBPbKO 60 mice, a compensatory population of 
resident-like peritoneal macrophages has been found which are likely to 
compete with transferred cells. In addition, the CEBPbKO60 mice suffer from 
peritoneal eosinophilia, suggesting profound changes to the peritoneal cavity 
immune compartment. Another possibility is the use of clodronate liposomes 
to temporarily deplete peritoneal macrophages132. The major advantage of this 
methodology is that clodronate liposomes are readily available and do not 
require the breeding of transgenic mouse lines. However, intraperitoneal 
delivery of clodronate liposomes depletes various other tissue resident 
macrophage populations, potentially inducing off target effects149. Moreover, 
clodronate-liposome depletion result in high numbers of apoptotic cells in the 
cavity49 without the phagocytes required for immunologically silent clearing of 
these cells21. Hence, a major drawback of clodronate liposomes, and other 
temporary depletion methods, is the high numbers of death cells and 
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consequent inflammation that is induced following the depletion. Moreover, 
following clodronate depletion monocytes are likely to infiltrate the depleted 
tissue and thus only provide a limited window of time during which cells could 
be adoptively transferred. Finally, it is essential to validate that clodronate 
liposomes are effectively cleared at the time of transfer to prevent depletion of 
transferred phagocyte populations.  
Recently a novel transgenic mouse model has been developed that is deficient 
in the fms-intronic regulatory element region of the CSF1r (FIRE-/-) and 
consequently lacks various tissue-resident macrophage populations including 
peritoneal macrophages106.Unlike GATA6KO 63-65 and CEBPbKO 60 mice FIRE-/- 
mice do not have a compensatory population of resident-like macrophages in 
the peritoneal cavity106. Hence, this model would be a very powerful tool to use 
as it allows investigation of the fate potential of inflammatory macrophages 
without the confounding effects of resident-like macrophages or infiltrating 
monocytes. Although these mice are seemingly healthy it is important to note 
that the lack of peritoneal macrophages is potentially altering cavity 
homeostasis, which in turn may alter the fate of transferred cells. Moreover, it 
is unknown whether peritoneal macrophage produce factors required for the 
survival of other (immune) cells that are in, or adjacent to, the peritoneal 
cavity150 and that consequently these cells could also be altered in FIRE-/- 
mice. This could in turn alter the cavity microenvironment and affect the fate 
of transferred cell populations. These phenomena have not been 
characterized in depth and could greatly affect the findings from adoptive 
transfer studies utilizing FIRE-/- recipient mice.  
Hence, no perfect model exists to investigate the capacity of monocyte-derived 
inflammatory macrophages to persist in the cavity in the absence of 
competition. Instead, adoptive transfer of purified macrophage populations into 
clodronate-depleted or FIRE-/- recipient mice would be preferable as these 
methodologies complement one another. 
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1.13 Immune memory could affect resident or monocyte-derived 
macrophages following inflammation 
An increasing number of studies have indicated that exposure of innate 
immune cells to inflammatory stimuli can ‘train’ these cells so upon re-
exposure to inflammatory stimuli their response is altered. Epigenetic changes 
were found to underlie this innate immune memory151,152. Critically, exposure 
of monocytes to Candida Albicans or b-Glucan has been found to induce 
Dectin1-mediated epigenetic changes and leads to enhanced cytokine 
production in vitro and in vivo153. Little is known about epigenetic memory that 
may be acquired by monocytes that infiltrate the peritoneal cavity during 
peritonitis. However, In vitro studies have found heightened TNFa production 
by thioglycolate-elicited inflammatory macrophages in response to LPS 
treatment after pre-treatment with b-Glucan154. Hence, monocytes infiltrating 
the cavity during an inflammatory event could be imprinted to give rise to 
macrophages that are phenotypically and functionally distinct from resident-
LPM but also differ from monocyte-derived macrophages that have 
differentiated under steady-state conditions.  
 
1.14 Project aims   
It is clear that monocyte integration into the resident-macrophage 
compartment occurs following inflammation in a number of tissues and that 
these cells can impact on tissue health and ability to respond to subsequent 
inflammatory insults. What underlies the divergent functions of such cells 
remains unclear but may be related to monocytic origin or related to the 
conditions under which these cells have differentiated or inhabit the cavity 
following resolution of inflammation.  
It has remained unclear recruited monocytes integrate into the resident 
population following peritoneal inflammation. Due to the use of different 
models of peritoneal inflammation in combination with imperfect lineage-
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tracing methodologies incomplete and contrasting datasets have been 
generated. Although the transcriptional identity of peritoneal macrophages has 
been shown to largely depend on environmental cues such as retinoic acid, it 
has remained unclear whether the niche hypothesis, based on phenomena 
observed in solid tissues, is applicable to tissue-resident macrophages in 
fluidic environments such as the peritoneal cavity. Moreover, it is unclear how 
inflammation alters the peritoneal micro-environment which may impact on the 
identity and functionality of both resident and inflammatory macrophages that 
inhabit the cavity.  
Hence, I hypothesized that monocyte-derived inflammatory macrophages 
have the capacity to survive long-term and integrate into the peritoneal 
macrophage compartment. Following mild peritoneal inflammation, monocyte-
derived inflammatory may not persist as resident LPM undergo proliferation to 
prevent integration of these cells into the macrophage compartment. However, 
following more complete loss of resident macrophages that may accompany 
severe peritonitis, monocyte-derived inflammatory macrophages will persist 
more readily. Moreover, I hypothesized that monocyte-derived inflammatory 
macrophages may be relying on environmental niche signals present in the 
peritoneal microenvironment to undergo conversion into resident peritoneal 
macrophages. Consequently, failure of monocyte-derived inflammatory 
macrophages to obtain these signals may prevent them from adopting a 
resident phenotype and functionality.  
 
To investigate these hypotheses, I aimed to: 
• Develop an adoptive transfer methodology to investigate long-term fate of 
inflammatory macrophages following resolution of peritonitis. 
• Determine if inflammatory macrophages persist following resolution of mild 
peritonitis, and adopt a resident phenotype.  
• Examine whether inflammatory macrophages persist long-term following 
mild peritonitis and adopt a transcriptional and phenotypic resident identity. 
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• Ascertain whether the post-inflammatory micro-environment, and 
particularly competition with resident macrophages, regulates inflammatory 
macrophages survival to and phenotypic conversion. 
• Determine whether inflammatory macrophages that persist following 
peritoneal inflammation are functionally equivalent to resident 
macrophages. 
• Investigate whether severe peritoneal inflammation leads to greater 
disappearance of resident macrophages and if this is associated with 
greater integration of inflammatory macrophages. 
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Chapter 2  
 





Mice were bred and maintained in specific pathogen-free facilities at the 
University of Edinburgh. Unless indicated, all mice used were female and age-
matched at 6-10 weeks of age at onset of the experiment. Work was carried 
out in various University of Edinburgh animal facilities. Early experiments, 
presented in chapter 3, were largely carried out at the Ann Walker facility and 
the March animal facility at King’s Buildings campus. Later work was carried 
out at the Scottish Centre for Regenerative Medicine animal facility and Little 
France Phase 2 both at Little France campus. All experiments were permitted 
under project license (PP0860257) granted by the UK Home Office and 
approved by the University of Edinburgh Animal Welfare and Ethical Review 
Body.  
 
C57BL/6-CD45.2+ mice used during early studies were originally purchased 
from Charles River and bred in-house at the Ann Walker facility. To generate 
congenic C57BL/6 CD45.1+CD45.2+ mice, C57BL/6 CD45.2+ were crossed 
with C57BL/6 CD45.1+ mice in-house. During later studies C57BL/6 CD45.2+ 
mice were obtained from the in-house colony of the Scottish Centre for 
Regenerative Medicine animal facility. To generate C57BL/6 CD45.1+CD45.2+ 
mice, C57BL/6 CD45.2+ were crossed with C57BL/6 CD45.1+ mice. FIRE-/-
mice were a gift from Dr.Clare Pridans. FIRE-/- mice were generated on a  
B6CBAF1/J background106 and crossed to C57BL/6. Offspring were interbred 
to establish the transgenic line. Mice used for experimental work were on a 
mixed background as the phenotype had proved to be lethal on a pure C57bl/6 
background (personal communication C. Pridans and D. Hume). FIRE-/- mice 
were bred by in the Little France phase 1 animal facility. Mice were culled using 






2.2 Tissue-protected bone marrow chimeras 
 
Eight week-old female C57BL/6 CD45.1+CD45.2+  or CD45.2+ C57BL/6 mice 
received subcutaneous injection of 8μl/g anaesthetic reagent, detailed below. 
 
Reagent  Dose  Manufacturer 
Medetomidin 500µl Sold as Domitor by 
Vetoquinol 
Ketamine 380µl Boehringer Ingelheim 
Sterile PBS +4.12ml Gibco 
 
The hind-legs were exposed to a single dose of 9.5 Gy g-irradiation for 19 
minutes and 30 seconds. The rest of the body was protected by a 2-inch lead 
shield. Following irradiation mice were kept at 37°C to aid recovery. By 24 
hours later animals were given 2-5×106 Bone marrow cells IV. Bone marrow 
cells were sourced from sex-matched congenic CD45.2+ C57BL/6J or 
C57BL/6J CD45.1+CD45.2+. This protocol to generate tissue-protected bone 
marrow chimaeras is similar to the published protocol from the Jenkins 
laboratory42. Following reconstitution mice were kept for 8 weeks or 26 weeks 
due to COVID19 restrictions prior to zymosan treatment. 
 
2.2.1 Preparation of donor bone marrow cells 
To collect bone-marrow cells CD45.2+ C57BL/6J or C57BL/6J 
CD45.1+CD45.2+   mice were culled as described. The tibia and femurs were 
collected and placed in ice-cold 70% ethanol. The bones were briefly washed 
using PBS and, using sterilized scissors and forceps, both ends of each bone 
were removed. Using a 23-gauge needle (BD) and a 10ml syringe, bone 
marrow was flushed from each bone with approximately 10ml of RPMI 1640 
(Gibco). By repeatedly aspirating the cell mixture with a syringe, the bone 
marrow was broken up and a single cell suspension was prepared. The 
solution was filtered through a 40µm filter (VWR) into a 50ml falcon tube. 
Samples were centrifuged (300g at 4°C for 5 minutes) followed by red blood 
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cell lysis for 5 minutes using 5ml of red blood cell lysis buffer (Sigma). Cells 
were washed and resuspended in RPMI 1640 and counted using a 
haemocytometer. Cells were resuspended at 2.5x107 cells/ml in dPBS (Gibco). 
For reconstitution mice received 200μl of bone-marrow mixture via intravenous 
tail vein injection.  
 
2.3 Peritoneal inflammation models  
 
All reagents that have been used in this thesis are detailed in Table 1. 
 
2.3.1 Zymosan model of sterile peritonitis 
A stock of zymosan was prepared by diluting 0.01g of Zymosan A (Sigma-
Aldrich) in 1ml of sterile Dulbecco’s PBS (dPBS; Invitrogen). The mixture was 
incubated at 95°C for 10 minutes and intermittently vortexed. The mixture was 
further broken up aspirating the mixture repeatedly using a 1ml syringe with a 
23g needle (BD) followed by repeated aspiration using a 27g needle (BD). The 
resulting mixture was checked under a light microscope to verify no clear 
‘clumps’ of zymosan were present. Stock was stored at 4°C for up to 2 weeks 
prior to use. On the day of injection stock solution was briefly vortexed and a 
working solution was prepared in sterile dPBS (Invitrogen). The working 
solution equilibrated to room temperature prior to use. To elicit sterile 
peritoneal inflammation, mice were injected IP with 10µg,100µg or 1000µg of 
zymosan A (Sigma-Aldrich) suspended in 200µl dPBS (Invitrogen). All steps, 
except zymosan weighing, were carried out in a laminar flow hood.  
 
2.3.2 LPS model of peritonitis. 
A stock solution of 1mg/ml of LPS (O111:B4; Sigma-Aldrich) in sterile dPBS 
(Invitrogen) was prepared and stored at -80°C in 50µL aliquots. On the day of 
injection, a working solution was prepared by diluting stock LPS in sterile dPBS 
(Invitrogen). To elicit inflammation, mice were injected IP with 5µg of LPS 
suspended in 200µl dPBS (Invitrogen). The injection solution was equilibrated 
to room temperature prior to injection. All steps were carried out in a laminar 
flow hood.  
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2.4 Other substances administered  
All substances were equilibrated to room temperature prior to injection and 
administered IP using insulin syringes (BD) 
 
2.4.1 Clodronate liposomes 
Clodronate liposome stock (Liposoma) was stored at 4°C according to the 
manufacturer’s instructions. On the day of injection, the appropriate amount of 
clodronate liposomes stock (5mg/ml) was diluted in sterile dPBS (Invitrogen). 
For earlier titration studies the indicated dose of clodronate liposomes was 
diluted in a total volume of 250ul sterile dPBS (Invitrogen) and administered 
IP.  For subsequent studies 0.0625mg clodronate liposomes (Liposoma) 
diluted in a total volume of 250ul dPBS (Invitrogen) was administered IP to 
deplete peritoneal phagocytes. The injection solution was equilibrated to room 
temperature prior to injection. All steps were carried out in a laminar flow hood.  
 
2.4.2 PKH26-PCL red fluorescent cell linker 
Components were stored at 4°C according to the manufacturer’s instructions. 
On the day of injection, a working solution of 700nm was prepared by diluting 
stock PKH26 cell linker (1000µM) in Diluent B (Sigma-Aldrich) to a working 
solution of 700nM. Mice were injected IP with 250µl of working solution 
equivalent to the dose used by Newson et al120. The injection solution was 
equilibrated to room temperature prior to injection. All steps were carried out 
in a laminar flow hood. 
 
2.4.3 All trans retinoic-acid  
A stock solution of all-trans-retinoic acid (ATRA) was prepared by dissolving 
ATRA in Dimethyl Sulfoxide (both Sigma-Aldrich) to a final concentration of 
40mg/ml which was stored in aliquots at -80°C. On the day of injection stock 
ATRA was diluted 5 times in corn oil (Sigma-Aldrich) to a working solution of 
8.33µg/µl ATRA. Mice received IP injections with 30µl working solution at the 
indicated times, equating to 250µg ATRA per IP injection as described145. All 
steps were carried out in a laminar flow hood and in the dark.  
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2.5 Cell isolation protocols 
 
When collecting multiple tissues from one mouse, tissue collection was carried 
out in the order isolation protocols are described in this section. Unless stated 
otherwise centrifugation steps were carried out at 300g at 4°C for 5 minutes 
and all steps were carried out on ice using pre-cooled reagents.  
 
2.5.1 Isolation of peritoneal exudate cells 
The abdominal skin was carefully removed leaving the peritoneal wall intact. 
Using a 5ml syringes with 23g (BD) needle, 3ml of wash solution (dPBS 
containing 2mM EDTA (Invitrogen),1mM HEPES (Fisher Scientific)) or culture 
solution (RPMI 1640 containing 1mM HEPES (Fisher Scientific)) with 
approximately 1ml of air was injected into the peritoneal cavity. The needle 
was withdrawn and the body was shaken gently. The lavage fluid was 
withdrawn using the same needle and, when possible, the same entry-point in 
order to limit damage to the peritoneal wall. The collected fluid was 
immediately placed on ice in a 15ml falcon tube. This lavage procedure was 
repeated two more times without air. Cells were centrifuged and resuspended 
in 1ml of FACS-buffer (2mM EDTA(Invitrogen), 0.5%BSA (Sigma-Aldrich) in 
PBS) for quantification using CASY counter (Roche).  
 
2.5.2 Isolation of omental leukocytes. 
After collection of peritoneal cells, the peritoneal wall was cut open and the 
intestine were gently pushed to the left, exposing the omentum. The omentum 
was identified based its comparatively white colour relative to the surrounding 
fat136. The omentum was excised and immediately placed on ice in 0.5ml of 
RPMI in a 1.5ml Eppendorf tube. The omentum was then removed from the 
RPMI 1640 (Gibco) and finely cut using scissors and digested in 0.5ml pre-
warmed enzyme mix. Enzyme mix was prepared fresh on the day and 
contained RPMI 1640 with 1% FCS (both Gibco) and 1mg/ml Collagenase D 
(Roche). The mixture was incubated for 15 minutes in an orbital shaker (37°C, 
4Hz), briefly agitated using a P1000 Gilson pipette and incubated for an 
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additional 20 minutes (37°C, 4Hz). After incubation, samples were immediately 
placed on ice and 2.5µl of 0.5M EDTA (Invitrogen) was added followed by 
0.5ml ice cold FACS buffer. The resulting mixture was strained though a 
100µm strainer (VWR) and centrifuged (400g for 10 minutes at 4°C). The 
supernatant was discarded and the pellet resuspended in 0.5ml FACS-buffer 
for quantification using CASY counter (Roche).  
 
2.5.2 Isolation of liver leukocytes.  
The liver was perfused with approximately 10ml ice-cold dPBS (Gibco) via the 
inferior vena cava. The complete liver was collected and weighed. The left lobe 
was separated and 0.5g of the lobe was placed into RPMI 1640 (Gibco) and 
placed on ice. If required additional tissue from the right lobe was collected to 
achieve a final weight of 0.5g. The liver was finely cut, using a razor blade, and 
digested in 5ml of pre-warmed enzyme mix. Enzyme mix was prepared fresh 
on the day and contained RPMI 1640 (Gibco) with 0.625mg/ml collagenase D 
(Sigma-Aldrich), 30µg/ml DNase (Roche), 0.8mg/ml collagenase-V (Sigma), 
and 1mg/ml dispase (Invitrogen). The mixture was incubated for 22 minutes in 
an orbital shaker (37°C, 240rpm) and shaken vigorously every 5 minutes by 
hand. The mixture was strained through a 100µm filter (VWR) and washed 
using 50ml RPMI 1640 followed by a second 30ml RPMI 1640 wash. Red 
blood cells were lysed using 3ml of RBC lysis buffer (Sigma) for 3 minutes at 
room temperature after which the mixture was placed back on ice, and 3 ml of 
ice cold FACS-buffer was added. Cells were washed and strained through a 
40µm strainer (VWR) and resuspended in 2ml of FACS buffer for quantification 
using CASY counter (Roche).  
 
2.6 Sample preparation for Flow cytometry   
All antibodies used in this thesis are detailed in Table 2. 
 
Following preparation cells were resuspended using a CASY TT cell-counter 
(Roche) according to the manufacturer’s instructions. Based on established 
protocols in the laboratory, events within 5.0µm and 15.30µm were considered 
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as cells and quantified. Following quantification, 1*106 peritoneal lavage cells 
were stained in a total staining volume of 50µl. For omentum cells, absolute 
counts were low and variable. Hence, all omentum cells were stained and 
considered as 0.5*105 cells for purposes of antibody staining and were stained 
in a staining volume of 50µl. For the liver, 2*106 cells were stained in a total 
staining volume of 50µl 
 
For adoptive transfer studies, all peritoneal cells were prepared and the 
staining volume was adapted accordingly. 
 
2.6.1 Surface antibody staining 
For samples that were used for analysis only viability staining was performed 
using Zombie Aqua (Biolegend). For samples that were used to sort cell 
populations viability was assessed by using DAPI, added prior to cell-sorting.  
 
For zombie aqua staining 10µl of zombie aqua working solution (1:100 in 
PBS) was added to cells followed by a 10 minute incubation at room 
temperature in the dark. Cells were then placed on ice and incubated for 10 
minutes with 10ul of blocking solution containing CD16/CD32 (1:200 
Biolegend) with 10% mouse serum (Life Technologies). Cells were then 
incubated for 30 minutes on ice using a combination of the antibodies 
detailed in Table 2. 
 
Following staining, cells were washed using FACS buffer. If needed cells were 
incubated on ice with fluorescently-labelled streptavidin (Biolegend) for 20-30 
minutes and washed using FACS buffer. Cells were analyzed on the day of 
collection or fixed for analysis of intracellular proteins and later analysis  
 
2.6.2 Intracellular staining 
For intracellular protein staining, cells were fixed immediately after surface 
staining using 50µl of fixation reagent, prepared according to the 
manufacturer’s instructions (eBioscience). Samples were stored at 4°C 
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overnight or 30 minutes at room temperature and washed with 
permeabilization buffer, prepared according to the manufacturer’s instructions 
(eBioscience). Intracellular antibody staining was carried out using indicated 
antibodies in a total volume of 50µl of permeabilization buffer. After staining 
cells were washed once using permeabilization buffer and resuspended in 
FACS buffer for analysis. For GATA6 staining an additional staining step was 
carried out for 20 minutes on ice, using Zenon anti-rabbit reagent 
(ThermoFisher) in volume of 50µ permeabilization buffer. Next, cells were 
washed once using FACS buffer and resuspended in FACS buffer for analysis 
 
For intracellular cytokine staining 1*106 cells/sample were incubated for 4.5 
hours at 37oC in 200µl RPMI 1640, supplemented with Brefeldin A and 
Monensin (Both Biolegend; 1:1000) in cell-repellent 96 well plates (Greiner 
Bio-One). After, cells were washed once with RPMI1640 and stained on ice 
for extracellular antigens as described in the previous section and intracellular 
antigens following fixation as described above with one additional Fc blocking 
step directly after fixation (10 minutes on ice). 
 
2.6.3 Acquisition and analysis  
Samples were acquired using an LSR Fortessa (BD). Cells used for adoptive 
transfer experiments were sorted using a FACS Fusion (BD). Cells purified for 
in vitro LPS stimulation were sorted using a FACS Fusion (BD) or FACSAriaII 
(BD) depending on equipment availability. Flow cytometry acquisition and 
purification was carried out at the QMRI flow cytometry facility. Due to 
COVID19 restrictions one later experiment was acquired using an LSR 
Fortessa (BD) at the SCRM flow cytometry facility. For each experiment a 
compensation matrix was calculated using the FACS Diva software using 
compensation beads (eBioscience) diluted 1:10 in FACS-buffer and stained 
with relevant antibodies. Flow cytometry data was analysed using FlowJo 
10.4.1software (Tree Star)  
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2.7 Adoptive transfer of macrophage subsets 
 
For adoptive transfer peritoneal cells were collected and stained as described 
in the previous section. All steps were carried out on ice, using sterile reagents 
and in a laminar flow hood. Due to unavailability of a laminar flow hood the 
necropsy for early experiments carried out at the Ann Walker animal facility 
was carried out on the bench.  
 
Cells were sorted using a 100µm nozzle into sterile 1.5ml Eppendorf tubes that 
contained 100µl of buffer (10% FCS in sterile dPBS (both Gibco)) kept at 4°C 
during the sort and placed on ice immediately after. After the sort cells were 
pelleted by centrifugation (300g, 5 min at 4°C) and resuspended in 200ul of 
dPBS (Gibco). The sample was gently pipetted to bring cells into solution and 
counted using CASY Counter (Roche). The number of cells required were 
collected and transferred into new 1.5ml Eppendorf tube and supplemented 
with dPBS (Gibco) to a total volume of 200µl for IP injection. 1x105 and 2x105 
cells of the indicated populations were transferred for short and long-term 
lineage tracing studies respectively. For high-dose zymosan rescue, 4x105 of 
RMac were transferred. For LPS responsiveness studies in vivo, 2.5x105 of 
the indicated cell populations was transferred. Purified populations were 
injected IP using BD insulin syringe (BD). 
 
2.8 In vitro studies  
 
For all in vitro studies peritoneal cells were collected in a laminar flow hood 
using sterile reagents.  
 
2.8.1 Production of omentum factors 
 
Omentum factor cocktail was generated using the protocol described by 
Okabe et al63. The authors kindly provided additional details required to repeat 
the procedure. The omentum was collected, as described in the previous 
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section, from naive mice and cultured in 1ml of macrophage serum free media 
(Gibco) at 37°C for 5 days. After 5 days the medium was collected and 
centrifuged (300g, 5 min at 4°C) and collected 1:2 in serum free media (Gibco) 
for use. 
 
2.8.2 In vitro culture of peritoneal macrophages post-zymosan. 
 
11 Days following low dose zymosan treatment(10µg/mouse), peritoneal 
exudate cells were collected as described in the previous section. Cells were 
counted and 5x105 peritoneal cells were plated at 37°C for 2 hours in culture 
medium (RPMI 1640, 10%FCS, 1% L-Glutamine and 1% Pen/strep (all Gibco) 
supplemented with 20ng/ml CSF1(Peprotech). After 2 hours the media was 
aspirated and cells were incubated for 24 hours in 250µl culture medium 
supplemented with 250µl Omentum factors or an equivalent volume of 
macrophage-serum free media (Gibco) with or without ATRA (Sigma-Aldrich, 
1µm) hours. After 24 hours the medium was aspirated and adherent cells were 
incubated with ice-cold 5mM EDTA (Invitrogen) in dPBS (Gibco) for 10 minutes 
on ice to release cells. Using a microscope wells were inspected confirm only 
few adherent cells remained. Cells were counted and prepared for analysis 
using flow-cytometry as described.  
 
2.8.3 In vitro LPS stimulation of purified macrophage populations  
 
Using sterile reagent peritoneal exudate cells were collected in a laminar flow 
hood using the protocol described in the previous sections. For each of the 
indicated populations of interest 1x103 cells were sorted into a sterile 1.5ml 
Eppendorf tube containing 75µl sort medium (Folic acid deficient RPMI 
containing 20% FCS (confirmed low endotoxin, Ge-Healthcare), 2% L-
Glutamine and 2% Pen/strep (both Gibco). Sorted cells were centrifuged 
(100g, 5 min at 4°C) to make sure all cells were in the fluid. The cell-mixture 
was transferred into a 96-well plate and incubated for 2 hours at 37°C. Media 
was gently aspirated and cells were resuspended in 75µl cell culture medium 
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(Folic acid deficient RPMI supplemented with 1µg/ml Folic Acid (Sigma-
Aldrich), 10% FCS (Ge-Healthcare), 1% L-glutamine and 1% Pen/Strep (both 
Gibco). In later studies ready-made complete RPMI 1640 (containing 1µg/ml 
Folic Acid) was used as base medium. As indicated, culture medium was 
supplemented with LPS of 1ng/ml (O11:B4, Sigma-Aldrich) or equivalent 
amount of dPBS (Gibco). After incubation for 14 hours, medium was collected 
and analysed for cytokine release using Legendplex Mouse Anti-Virus or 
Mouse-Inflammation panels (Biolegend) according to the manufacturer’s 
instructions. All samples were measured in duplicate and samples with high 
degree of variability between duplicates were excluded. Data was acquired on 
an Attune flow cytometer and analysis was carried out using the Legendplex 
analysis software (Biolegend).  
 
2.8.4 Phrodo-labelled E.coli phagocytosis assay 
 
Peritoneal exudate cells were collected and prepared as described. For each 
sample 2x106 cells were washed twice using ice-cold RPMI 1640. Cells were 
split equally between two polypropylene FACS tubes and incubated on ice 
for 10 minutes. To each tube 10µl of Phrodo E.Coli reagent (ThermoFisher) 
was added and for each sample one tube was incubated at 37°C and one at 
4°C for 1 hour. Immediately following incubation cells were placed on ice, 
washed using 300µl Buffer C (ThermoFisher) and resuspended in 300µl 
Buffer C. Cells were analysed using an LSR Fortessa (BD) immediately after.  
 
2.9 Transcriptional analysis  
 
All transcriptional analysis was carried out by me utilizing datasets generated 
by me or that have been made publicly available. When using public datasets, 





2.9.1 Nanostring mRNA analysis 
For indicated populations 5000 cells were sorted into sterile 1.5ml Eppendorf 
tubes containing 2µl of RLT (Qiagen) using a FACSFusion with a 70µm nozzle 
(BD). Immediately after collection the cell-RLT mixture was centrifuged at 
maximum speed for 15 seconds followed by 10 seconds of vertexing. This step 
was repeated once and cells were stored at -80°C until analysis using the 
nCounter Myeloid innate immunity panel  or a mouse Immunology panel 
(Nanostring) according to the manufacturer’s instructions. The Nanostring 
assay was carried out by Alison Munro at the the MRC Institute of Genetics 
and Molecular Medicine in Edinburgh. Quality control and data analysis was 
carried out using the nSolver advanced analysis software package 
(Nanostring). To calculate differential gene expression pairwise comparison 
was carried out between IMacZ10 and RMac Z10 to RMac for the first set of 
experiments. Following LPS stimulation pairwise comparison was carried out 
between RMZ10-LPM and MoZ1-LPM. Nominal P-values were adjusted using 
Benjamini Hochberg method and genes with adjusted p-value <0.05 were 
considered differentially expressed. Figures were generated using R with the 
following packages: Pheatmap, EnhancedVolcano, GGplot2 and GOplot. 
Similar Nanostring analysis was carried out on dataset deposited NCBI’s Gene 
Expression Omnibus under accession number GSE102735 to identify LPS-
driven genes (P<0.05). 
 
2.9.1 Gene expression ranking and scoring 
Following mRNA analysis using Nanostring advanced analysis package 
normalized mRNA values were obtained. For all detected genes normalized 
mRNA transcripts were ordered based on expression level and each gene was 
assigned a percentile score based on the rank in the gene list. For each gene 
a delta gene rank percentile was calculated (Percentile rank in native 
environment – Percentile rank in depleted environment). This analysis 
methodology was adapted from work by Galatro et al155. 
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2.9.2 Gene set enrichment analysis (GSEA) 
 
A list of GATA6-regulated genes was generated by analysis of published 
datasets deposited on NCBI’s Gene Expression Omnibus under accession 
numbers: GSE56711, GSE37448 and GSE47049. All of these datasets 
assessed the transcriptome of GATA6KO LPM. Datasets were analyzed using 
the GEO2R web tool. Genes that were differentially expressed in 2 out of the 
3  published datasets (adjusted p<0.05) were considered GATA6-regulated, 
similar to earlier analysis by Shroder et al156. Genes were then split into those 
upregulated in GATA6KO LPM and downregulated in GATA6KO LPM. GSEA 
analysis was performed using GSEA software package version 4.1 (Broad 
institute) using default settings and 10.000 gene-set permutations. For RXRab 
analysis, the dataset GSE129095 was analyzed using the GEO2R web tool 
and differentially expressed genes (adjusted p value <0.05) were split into 
genes upregulated in RXRab KO LPM and downregulated in RXRab KO LPM. 
GSEA analysis was performed using GSEA software package version 4.1 
(Broad institute) using default settings and 10.000 gene-set permutations. 
Figures were generated using the GSEA software package version 4.1 and 
simplified using affinity designer for inclusion in the thesis. 
 
2.10 Assessment of peritoneal and serum levels of LPS-driven 
cytokines. 
 
To collect concentrated peritoneal lavage, the peritoneal-cell collection 
protocol was altered. The first wash was carried out using 1ml of altered lavage 
buffer (RPMI 1640 (Gibco) 1:100 HEPES (Fisher Scientific)). The remainder 
of the lavage washed was carried out according to the normal protocol, but 
were kept separate. Following collection, the first wash was centrifuged and 
the lavage fluid was collected and stored at -80°C. To collect serum, the carotid 
artery was cut using a scalpel and blood was collected into BD Microtainer 
SST tubes (BD). If insufficient amount of blood was obtained using this 
methodology more blood was collected from the inferior vena cava after 
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peritoneal wash. Serum was collected by centrifugation according to the 
manufactures instructions and stored at -80°C. 
 
Measurement of serum and lavage cytokines was carried out by Ms. Holly 
Webster and Dr. Georgia Perona-Wright. As I was not directly involved in this 
analysis, the methods for this assay are not included here. 
 
2.11 Assessment of serum levels of natural antibodies.  
Serum collected as described in the previous section and stored at -80°C. 
Measurement of natural antibodies was carried out by Ms. Lucia Badiola 
Gomez and Dr. Steve Jenkins. As I was not directly involved in this analysis, 
the methods for this assay are not included here. 
 
2.12 Statistical analysis 
Data were analysed and visualized using Prism version 7 (GraphPad). For 





Table 1 List of reagents used in this thesis   
Reagent Manufacturer Catalogue NO
Brefeldin A Biolegend 420601
BSA Sigma-Aldrich A7906-100g
Casein VWR 22544.292
Clodronate Liposomes Liposoma n/a
dPBS Gibco/ThermoFisher 14190-094
EDTA 0.5M Invitrogen 15574020
FCS Gibco/ThermoFisher 10500-064
Folic Acid Sigma-Aldrich F8758-5G
FoxP3 Transcription factor staining set ThermoFisher 00-5523-00
FSC (LE confirmed in house) GE-Healthcare n/a
HEPES 1M Fisher Scientific 10041703
Intracellular Fixation and ThermoFisher 889-8824-00
L-Glutamine 200mM Gibco/ThermoFisher 25030024
LEGENDplex mouse anti-virus Biolegend 740622
LEGENDplex mouse inflammation Biolegend 740446
LPS (O111:B4) Sigma-Aldrich L2630-10MG
Macrophage SFM Gibco/ThermoFisher 12065074
Monensin Biolegend 420701
PC-BSA 2B Scientific PC-1011-10
Pen/Strep Gibco/ThermoFisher 15140122
Phrodo E.coli phagocytosis kit Invitrogen/ThermoFisher A10025 
PKH26-PCL Cell Linker kit Sigma-Aldrich PKH26PCL-1KT
Recombinant murine CSF1 Peprotech 315-02
Red blood cell lysis buffer Sigma-Aldrich R7757
Retinoic Acid Sigma-Aldrich R2625-50MG
RPMI 1640 Gibco/ThermoFisher 21870076
RPMI 1640 no folic acid Gibco/ThermoFisher 27016021
Zombie Aqua Biolegend 423102
Zymosan A Sigma-Aldrich  01-1111-42
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Table 2 list of antibodies used in this thesis 
  
Target Manufacturer Clone Fluorochrome Catalogue NO
CD3 Biolegend 17A2 Biotin 100244
PB 100214
CD11b Biolegend M1/70 PE-Dazzle 101256
CD11c Biolegend N418 APC-Cy7 117324
CD16/32 Biolegend 2.4G2 Purified 101320
CD19 Biolegend 6D5 Biotin 115504
PB 115523
CD45.1 Biolegend A20 FITC 110706
AF700 110724
CD45.2 Biolegend 104 AF700 109822
CD102 Biolegend 3C4 FITC 105606
AF647 105612
Biotin 105604
CD209b eBioscience/ThermoFisher 22D1 APC 17-2093-82
GATA6 Cell Signalling Technologies D61E4 Purified 5851S
F4/80 Biolegend BM8 PE-Cy7 123114
APC-Cy7 123118
FRb Biolegend 10/FR2 APC 153306
PE 153303
Sema4a Biolegend 5E3/SEMA4a APC 148406
PE 148404
CCR5 Biolegend HM-CCR5 AF488 107008
CD62L Invitrogen MEL-14 SuperBright 702 67-0621-82
FITC 11-0621-82
MHC II (IA-IE) Biolegend M5/114.15.2 AF700 107622
PB 107620
APC-Cy7 107628
Ly6C Biolegend HK1.4 BV711 128037
SiglecF Miltenyi Biotec ES22-10D8 Biotin 130-101-861
VSIG4 eBioscience/ThermoFisher NLA14 PE-Cy7 25-5752-82
Ly6G Biolegend 1A8 Biotin 127604
PB 127612
Tim4 Biolegend RMT4-54 PE 130006
PE-Cy7 130010
AF647 130008
Streptavidin Biolegend BV650 405232
Zenon anti-rabbit reagent Molecular Probes AF647 Z25308
Siglec F BD E50-2440 BV421 562681
Ki67 Miltenyi REA183 FITC 130-117-803
CXCL13 Invitrogen M1/70 APC 17-7981-82
CD11c Biolegend N418 APC-Cy7 117324
TNFa Biolegend MP6-XT22 BV421 506328




Developing a ‘toolbox’ to investigate inflammatory 





As discussed in the general introduction, numerous studies have investigated 
monocyte fate and phenotype at various stages of peritoneal inflammation. 
However, due to the use of different peritonitis models in conjunction with 
various lineage tracing tools a comprehensive understanding of monocyte fate 
post peritonitis is lacking with some datasets contrasting one another. In the 
two most commonly used models of peritonitis, thioglycolate or zymosan  
injection, it has been suggested that monocyte derived macrophages do not 
persist and the majority undergo apoptosis86  or emigrate into draining 
lymphatics141. However, these conclusions were drawn on the basis of surface 
markers86 or short-term monitoring in partial BM chimeras87 or following in vivo 
dye labelling methodology111,120. Conversely, experiments using transgenic 
Cx3cr1creERR26-rfp28 and more recently Ms4a3Cre-RosaTdT123 mice to track 
infiltrating monocytes or using dye labelling to distinguish resident and 
inflammation-elicited macrophages over a longer time frame suggested that 
monocyte-derived macrophages do persist after thioglycolate or zymosan 
induced peritonitis28,111,145. Moreover, the irritant used to induce peritoneal 
inflammation appears to affect the progression of inflammation and 
consequently the fate of inflammation-elicited macrophages. Whereas 
thioglycolate induced peritonitis is characterized by the complete loss of 
resident macrophages during early inflammation and prolonged monocyte 
infiltration86,123, in zymosan-induced peritonitis the extend of these phenomena 
varies greatly depending on the dose87,122,139. Is it likely that these differences 
account for some of the contrasting results between work by Newson et al111,120 
using a relatively high dose of zymosan and Davies et al87,144 using a lower 
dose of zymosan . Hence, the extent of resident macrophage disappearance 
and the concurrent monocyte influx would appear to be the two processes that 
determine the constitution of the peritoneal macrophage compartment during 
resolution and consequently are likely to shape the fate and relative 
contribution of monocyte derived macrophages thereafter.  
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To definitively ascertain the fate of monocyte-derived macrophages post-
resolution requires a robust lineage tracing method. Studies, carried out by the 
Jenkins laboratory prior to my PhD used partial bone marrow chimeras to 
investigate the contribution of monocyte derived cells to the resident 
macrophage pool42. Although this is a very powerful tool that I could have used 
to investigate integration of monocyte-derived cells post resolution it lacks the 
capacity to differentiate monocytes infiltrating during inflammation from those 
that infiltrate the cavity in preceding and succeeding weeks. Studies at the time 
when I started my PhD had used a transgenic Cx3cr1creER driver line to show 
contribution of monocyte derived cells to the macrophage compartment after 
thioglycolate induced peritonitis28. However, no recombination was detectable 
in classical blood monocytes and as a likely consequence the authors found 
that only 0.3% of peritoneal macrophages were of monocyte origin28. This 
contrasts with earlier work, using CCR2-/- mice indicated that the majority of 
the macrophage compartment are monocyte derived following thioglycolate 
treatment157. Near the end of my studies, a transgenic Ms4a3CreERT2 mouse 
line with more effective recombination (over 90%) in circulating blood 
monocytes was generated123 which could have been a powerful lineage tracing 
tool. Indeed, using this transgenic line it was confirmed that following 
thioglycolate treatment large numbers of monocytes infiltrate the cavity and 
persist long-term123. 
 
Critically, all these tools lack the capacity to investigate the role of the 
resolution environment, and competition with incumbent resident 
macrophages and their effect on inflammatory macrophage fate and 
conversion potential. Hence, I took advantage of the fluidic nature and easy 
access to the peritoneal cavity to develop an adoptive transfer system whereby 
purified resident and monocyte-derived macrophages present during 
resolution could be transferred into congenic CD45.1/2+ mice that were either 
at an equivalent stage of inflammation, naïve or depleted of macrophages 
recipients to investigate: 1) their actual fate and phenotype post inflammation 
resolution, 2) to what degree the resolution environment is a determinant of 
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these features and 3) whether competition with incumbent resident 
macrophages influences these phenomena.  
 
To investigate these questions, I sought to induce a degree of peritoneal 
inflammation where both resident and monocyte derived macrophages could 
be sourced from the same resolved cavity, thus allowing me to contrast the 
phenotype and survival potential of these populations after adoptive transfer 
into mirroring inflamed or naïve recipients. Importantly, a potential drawback of 
an adoptive transfer methodology is that purified donor cells will be coated with 
antibodies which are likely to affect their functionality and survival. Hence, I set 
out to limit the number of antibodies  required by validating a dye labelling 
methodology as described by Newson et al111,120.  
 
Finally, to investigate the role of competitive pressure in shaping survival and 
phenotype of transferred cells I sought to transfer purified populations into 
recipient mice devoid of competing macrophages. This approach was similar 
to studies by van der Laar et al in which purified macrophage or monocyte 
populations where adoptively transferred into the lungs of CSF2Rb-/- mice, 
deficient of alveolar macrophages67. However, whereas CSF2Rb-/- mice are 
relatively healthy CSF1R-/- mice, the equivalent peritoneal macrophage 
survival factor receptor, are in poor health and even lethal of a C56bl/6 
background (personal communication from Dr. Clare Pridans). Alternatively, 
macrophage deficiency of GATA6 or CEBP/b has been shown to result in a 
peritoneal cavity largely devoid of resident macrophages60,63. However, in both 
mouse lines a compensatory population of macrophages is present. The effect 
these cells might have on adoptively transferred cells is unclear. Moreover, we 
did not have direct access to either of these mouse lines. Hence, I set out to 
use clodronate liposomes to deplete resident peritoneal macrophages as 
described12. Transfer into this temporarily deplete cavity would allow me to 
investigate whether the absence of resident macrophages alters survival and 
phenotype of transferred populations. Towards the end of my PhD an 
alternative transgenic line deficient in an enhancer domain of the CSF1R was 
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developed (FIRE-/-), largely devoid of peritoneal macrophages106 which I 
utilized to verify some of my findings in Chapter 4.  
 
 
Hence, in this first result chapter I set out to 
 
- Use zymosan to induce varying degrees of peritoneal inflammation and 
affect the balance between resident macrophage disappearance and 
monocyte influx and consequently the constitution of the resolution 
phase macrophage compartment. Importantly, I aimed to find a dose of 
zymosan where both resident and monocyte derived cells were present 
during resolution. 
- Optimize a dye labelling system to better delineate resident 
macrophages already present prior to inflammation from monocyte 
derived macrophages during inflammation with minimal antibody 
labelling as to prevent confounding effects of transferring antibody 
coated cells.  
- Finally, I set out to artificially deplete the peritoneal macrophage 
compartment using clodronate liposomes and carry out a proof of 
principle study to verify that donor macrophages could be transferred 
into this artificially depleted environment.  
 
Combined, these tools will serve as a ‘toolbox’ to investigate the determinants 
of monocyte derived macrophage fate and phenotype throughout this thesis.  
 
 
3.2 Dose responsiveness of the zymosan sterile peritonitis model. 
 
In order to effectively asses phenotypic conversion of inflammatory 
macrophages using an adoptive transfer methodology it was important that I 
could purify and transfer both resident and inflammatory macrophages from 
the same resolution phase donor mice to allow me to reference the fate and 
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phenotype of transferred monocyte-derived macrophages with that of 
transferred resident macrophages. As different doses of zymosan have been 
used to induce varying degrees of sterile peritoneal inflammation I first set out 
to investigate if I could find a dose where a clear population of resident 
macrophages persisted whilst monocytes infiltrated the inflamed cavity, as 
reported by Davies et al87. To this end, I treated mice with three commonly 
used doses of zymosan (10µg,100µg or 1000µg) and investigated to what 
extent these altered the peritoneal macrophage compartment by driving 
disappearance of resident peritoneal macrophages and recruitment of 
monocytes, 24 hours after administration. Since recent work from the Jenkins 
laboratory had indicated a sexual dimorphism in turnover and function of 
peritoneal macrophages42 I verified sex did not alter the parameters of 
peritoneal inflammation as has described by Davies et al87.These experiments 
were carried out in age matched male and female mice. (Figure 3.1a) 
 
To identify peritoneal macrophages within the peritoneal exudate cells I 
excluded doublets and dead cells on the basis of their FSC profile and zombie 
aqua labelling respectively. I then gated on cells expressing high levels of 
CD11b and low levels of lineage antibodies (CD3,CD19,Ly6G, SiglecF) to 
exclude T cells, B cells, neutrophils, and eosinophils and identify peritoneal 
phagocytes42 (Figure 3.1b,c) as previously published by the Jenkins 
laboratory42. Injection of zymosan caused a loss in frequency of F4/80Hi 
resident macrophages (Figure3.1c,d) in both male and female mice 
irrespective of dose. The frequency of infiltrating F4/80Lo/Int cells with variable 
levels of the monocyte marker Ly6C expanded considerably (Figure3.1c,e). 
However, the absolute numbers of both F4/80Hi and F4/88Lo/Int macrophages 
were highly variable (Figure 3.1d,e). Although absolute numbers are the only 
definitive indication of macrophage disappearance, it is likely that in these 
experiments the absolute numbers are not reliable as these experiments were 
the first peritoneal washes, I carried out independently and the quality of the 
washes was highly variable. There was also considerable variability in the PBS 
treated group indicating that this was likely due to inexperience rather than 
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treatment (Figure 3.1d, left). Importantly, after 10µg a sizeable and defined 
population of F4/80Hi macrophages persisted but also a clear population of 
F4/80Lo/Int Ly6CInt/Hi cells that phenotypically resembled described 
inflammatory macrophages87,139 (Figure 3.1c) was present. 
 
On the face of it, these data indicate that zymosan does not induce a dose-
dependent loss of resident macrophages and concurrent monocyte influx. 
However, as 10µg induced mild peritoneal inflammation with a quantifiable 
population of both resident macrophages and infiltrating monocyte derived 
macrophages I opted to use this dose for the majority of my subsequent 
experiments as it allows me to source both resident and monocyte-derived 
macrophages from the same resolution cavity.  
 
3.3 PKH26-PCL labelling delineates macrophage subsets during mild 
peritonitis short-term. 
 
During the previous experiment I had found that marker expression was 
variable even within the same treatment group. Consequently, finding a 
consistent gating strategy was challenging and at times gates fitted poorly 
across samples and groups. I considered using a more extensive flow 
cytometry panel using more novel markers such as the phosphatidylserine 
marker Tim4 and CD102 both of which label resident peritoneal 
macrophages42,63,97 or Ly6B shown to label a subset of monocyte-derived 
macrophages87,144. However, I was keen to optimise a flow cytometry panel 
using minimal antibody to circumvent potential confounding effects of adoptive 
transfer of antibody-coated cells. Hence, to help delineate myeloid subsets 
post zymosan using a limited antibody panel I adapted a labelling system as 
utilized by Newson et al111,120 that employs a particulate dye to label all 
phagocytes in the peritoneal cavity prior to inflammation. Although Newson et 
a111 had confirmed that after injection PKH26-PCL followed 24 hours later by 
0.1mg of zymosan A, cell-labelling was limited to Cx3cr1-GFPNeg F4/80Hi , 
CCR2 independent resident macrophages I wanted to confirm the specificity 
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of dye-labelling. Importantly, I wanted to confirm that 24 hours after PKH26-
PCL injection no free dye particulates remained that could be subsequently 
taken up by monocytes recruited upon zymosan injection. 
 
Indeed, 24 hours after injection of PKH26-PCL fluorescent dye practically all 
F4/80Hi resident macrophages and the majority of F4/80Lo CD226+ small 
peritoneal macrophages were labelled (Figure 3.2a,b). Of the numerically 
negligible population of F4/80Lo CD226- cells that consists predominantly of 
CD11c+ dendritic cells and immature macrophages42,95,104,139, approximately 
30% was labelled (Figure 3.2a,b). Importantly, F4/80Hi resident macrophages 
remained almost completely labelled until 5 days after dye injection whereas 
F4/80Lo MHCIIHi CD226 appeared to lose dye-labelling (Figure 3.2c), possibly 
due to higher levels of monocyte integration into this population.  
 
As PKH26-PCL forms dye aggregates dye labelling is thought to be largely 
restricted to phagocytes. In line with this, there was only minor PKH26-PCL 
labelling in Lineage+ non-macrophages (Figure 3.2a). However, using 
CD11B,MHCII,Ly6C in combination with the side scatter characteristics of 
these cells I was able to identify peritoneal B1 cells (Lineage+, 
CD11B+,MHCII+), B cells (Lineage+,CD11B-,MHCII+),eosinophils (Lineage+, 
MHCIILo, SSC-AHi), neutrophils (Lineage+, MHCIILo, SSC-AInt, Ly6CInt) and T 
cells (Lineage+, MHCIILo, SSC-ALo) within the lineage- gate, and using this 
strategy revealed that only peritoneal B1 cells appeared to have some labelling 
(Figure 3.2d,e), consistent with phagocytic and antigen presenting 
capacity158. It should be noted that the amount of PKH26-PCL labelling was 
considerably lower than that of macrophages.  
 
Next, I set out to confirm that 24 hours after injection of PKH26-PCL there were 
no longer free dye particulates which could be taken up by infiltrating cells. To 
investigate this recipient CD45.2+ were injected with PKH26-PCL and 24 hours 
later unlabelled PEC from CD45.1/2+ mice was transferred into these 
recipients (Figure 3.3a). I postulated that 2 hours would give sufficient time for 
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transferred cells to take up free floating dye particulates whilst limiting the 
uptake of dye released by dying resident macrophages. By 2 hours post 
transfer donor cells did appear to take up some residual dye but the proportion 
that had done so was relatively small (Figure 3.3b) indicating few free-floating 
dye particulates were present at the time of transfer i.e. 24 hours post PKH26-
PCL injection. 
 
I then combined the dye labelling system with the low dose zymosan model of 
peritonitis described in section 3.1 and postulated that a clearly labelled 
population of F4/80Hi resident macrophages would be present concurrent with 
an unlabelled population of F4/80Int/Lo infiltrating monocyte derived 
macrophages. To confirm this, mice were injected with PKH26-PCL and 24 
hours later received an IP injection of 10µg zymosan. By 24 hours post 
zymosan injection, F4/80Hi PKH26-PCLHi resident macrophages could be 
clearly differentiated from F4/80Int PKH26-PCLLo infiltrating cells. (Figure 3.4a) 
After 5 days F4/80HI PKH26-PCLHI could still be delineated from F4/80Int 
PKh26-PCLLo infiltrating cells with relative ease. (Figure 3.4a,b) 
 
The phosphatidylserine receptor Tim4 has been used as an alternative marker 
expressed by the majority of peritoneal resident macrophages and largely 
absent from infiltrating cells64,87. Hence to further validate the dye labelling 
methodology I confirmed that F4/80Hi PKH26-PCLHi cells I had identified as 
resident macrophages almost exclusively expressed high levels of Tim4 at 
both timepoints. Importantly, resident macrophages identified this way 5 days 
post zymosan expressed similar levels as PBS controls indicating no off target 
labelling of Tim4- infiltrating cells (Figure 3.4c). In contrast, F4/80Int PKH26-
PCLLo infiltrating cells expressed high levels of the monocyte marker Ly6C 24 
hours after zymosan which was largely lost after 24 hours as cells acquired 
the F4/80Int inflammatory macrophage phenotype. (Figure 3.4a). Importantly, 
only a very minor population of F4/80Int PKH26-PCLLo cells expressed Tim4, 
possibly indicative of minor contamination by Tim4+ resident macrophages. 
Moreover, whereas after 24 hours post zymosan there was a very striking 
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difference between labelled and non-labelled populations with a clear 
distinction between the two subsets, the difference was less apparent by day 
5 which might be due to gain of PKH26-PCL fluorescence by the infiltrating 
cells (Compare Figure 3.4b 24h vs 5d). 
 
Hence, dye labelling proved to be a powerful tool to help delineate resident 
from infiltrating macrophages but by day 5 monocyte-derived macrophages 
acquire low levels of labelling, likely released from resident macrophages that 
have died.   
 
3.3.1 Tissue protected BM chimeras corroborate PKH26-PCL labelling of 
resident macrophages during mild peritonitis. 
Although my previous study had used the peritoneal cavity 5 days post 
zymosan as the latest timepoint, work by Davies et al87 indicated that after low 
dose zymosan neutrophilia was already resolved by day 3. As this is defined 
as the resolution of inflammation, I focused my subsequent experiments on 
the day 3 timepoint.   
 
To further validate that I correctly identified resident and infiltrating cells at this 
stage of peritonitis I proceeded to generate partial bone marrow chimeras with 
the help of my supervisor, Dr. Steve Jenkins. Briefly, the hindlegs of CD45.2+ 
recipient mice were irradiated with lead shielding used to protect the upper 
body and, importantly, the peritoneal cavity. Mice were reconstituted with 
CD45.1/2+ bone marrow and left for 8 weeks. After 8 weeks they received a 
single injection of PKH26-PCL followed 24 hours later by 10µg of zymosan or 
PBS. By 3 days post zymosan mice were sacrificed and the peritoneal exudate 
cells investigated using flow cytometry (Figure 3.5a). The chimerism of 
circulating Ly6cHi monocytes was approximately 20% and was unaltered by 
zymosan treatment (Figure 3.5b). The chimerism observed in peritoneal 
subsets was normalized to the chimerism of circulating Ly6CHi monocytes 
(referred to as normalized chimerism) as described42.  
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Using a similar gating strategy as described in 3.3 I found that by day 3 there 
was very low levels of chimerism in the population of F4/80Hi PKH26-PCLHi 
macrophages I postulated to be resident macrophages (Figure 3.5c,d). 
Importantly the level of chimerism was equal to that of F4/80Hi PKH26Hi 
macrophages in PBS treated mice indicative of no or negligible contribution of 
monocyte derived cells to this population. (Figure 3.5d). In line with published 
work I divided the infiltrating PKH26-PCLLo/Int cells into F4/80Int cells with 
variable levels of Ly6C, most likely inflammatory macrophages and a minor 
fraction of cells with the classic Ly6CHi monocyte phenotype (Figure 3.5c). 
Both of the populations identified had approximately 100% chimerism 
indicative of their monocytic origin (Figure 3.5d). Similar to the day 5 data 
presented earlier I found that approximately 80% of resident F4/80Hi PKH26-
PCLHi cells expressed Tim4 and that this proportion was not altered after 
zymosan treatment (Figure 3.5e). Moreover, the minor fraction PKH26-
PCLLo/Int cells that expressed Tim4, I postulated to be contaminating resident 
cells in the previous section were highly chimeric suggesting these cells were 
also predominantly of monocyte origin (Figure 3.5f,right). 
 
Taken together, these data indicate that by using a gating strategy based on 
PKH26-PCL, F4/80 and Ly6C I can delineate macrophage subsets 3 days post 
10µg zymosan with a high degree of certainty and using minimal number of 
antibodies. For the remainder of the text PKH26-PCL+  F4/80Hi resident 
macrophages will be referred to as RMacZ10 and PKH26-PCLLo F4/80Int 
inflammatory macrophages as IMacZ10.  
 
In these experiments I had noticed that in some PBS injected control samples 
there appeared to be some MHCII upregulation by resident macrophages 
indicating of some degree of inflammation. Similarly, the resident macrophage 
chimerism of approximately 20% in partial BM chimeras (Figure 3.5d) slightly 
higher as we would have expected based on earlier work by our lab42. 
Moreover, previous work by Jenkins et al found indication that IP injection with 
PBS alone already caused minute inflammation and small loss of resident 
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macrophages146. Hence, for the remainder of the text I will be using complete 
naïve mice as control group to source naïve resident macrophages unless 
otherwise indicated.  
 
 
3.3.2 Macrophage dynamics during in mild peritonitis following PKH26-
PCL labeling of resident macrophages.  
Next, I set out to replicate some of the dynamics of early peritoneal 
inflammation described122,139 using the dye labelling methodology. Mice 
received a single injection of PKH26-PCL followed 24 hours later by IP 
injection of 10µg zymosan. In these experiments, the population of RMac had 
reduced considerably in number by 4 hours post zymosan while an almost 
equivalent number of Ly6C+ monocytes had infiltrated the cavity (Figure 
3.6a,b). By day 3 the population of RMac had partly recovered but was still 
reduced compared to its homeostatic level and the number of these cells was 
roughly equivalent to that of IMacZ10 that inhabited the cavity at this time 
(Figure 3.6a,b). As described by Davies et al87 neutrophils had largely 
disappeared indicating inflammation had resolved whereas monocytes had 
largely adopted the F4/80Int inflammatory macrophage phenotype (Figure 
3.6c) 
 
In summary, I have established a dye labelling strategy which can be utilized 
in conjunction with a minimal number of surface markers to definitively 
delineate incumbent resident macrophages and infiltrating monocyte-derived 
cells during the earlier phases of low dose zymosan induced peritonitis until 
resolution.  
 
3.3.3 Excluded samples and exclusion criteria 
A drawback of using IP injections to deliver substances is that it is not possible 
to visually confirm that the injection was carried out successfully. As the failure 
rate of IP injections is thought to be 10-20%159,160 and has been shown to 
directly affect experimental variability and experimental results161 this is likely 
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to influence my experiments as well. In line with the described failure rate, in 
the dataset presented in Figure 3.6 one out of the 9 samples (11%) in the naïve 
group had no PKH26-PCL dye labelling clearly indicative of failed IP injection. 
Moreover, one sample out of 10 (10%) in both the 4 hour and 3 days post 
zymosan treatment group showed no signs of monocyte infiltration. Hence, I 
excluded these samples from experimental analysis and for subsequent 
studies defined the absence of dye labelling or the absence of infiltrating 
monocytes shortly after zymosan treatment as valid exclusion criteria.  
 
3.4 Developing an assay to test the fate potential of inflammatory 
macrophages  
 
A number of papers investigating the earlier phases of zymosan induced 
peritonitis suggested that long-term contribution of monocyte derived cells was 
unlikely to occur. Most notably, at the onset of resolution they observed high 
levels of proliferation by resident macrophages whereas inflammatory 
macrophages appeared to undergo little proliferation87,144. These observations 
are consistent with a model in which resident macrophages proliferate to 
reconstitute the peritoneal macrophage compartment and in doing so inhibit 
inflammatory macrophage survival, similar to what occurs in the liver after 
acetaminophen overdose83. However, in the liver it had been found that 
although monocyte-derived macrophages are normally outcompeted by 
Kupffer cells following inflammation, monocytes are able to reconstitute the 
macrophage niche and completely adopt a Kupffer cell identity after artificial 
depletion of incumbent Kupffer cells38,68. Hence, I set out to develop an assay 
that would allow me to investigate if monocytes infiltrating the peritoneal cavity 
have the capacity to repopulate a cavity devoid of resident macrophages and 
give rise to bona fide resident macrophages irrespective of whether they do so 
during normal resolution. 
  
At the time of the start of my PhD two transgenic mouse lines were available 
that lacked peritoneal macrophages. Both lines used the 
macrophage/neutrophil specific Lysm-cre crossed to floxed lineage 
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determining transcription factors mouse lines, the CEBP/bfl/fl 60 or GATAfl/fl 63-
65. It should be noted that in both these models peritoneal macrophages are 
not completely absent, but instead the peritoneal cavity is inhabited by a 
smaller population of F4/80 intermediate resident-like macrophages. This 
compensatory population in combination with the fact that we did not have the 
opportunity to rapidly acquire either one of these lines led me to investigate 
the use of clodronate liposomes to deplete peritoneal macrophages instead. 
Clodronate liposomes have been used extensively for the targeted depletion 
of phagocytes in various tissues including the peritoneal cavity12,132.  
 
To generate an artificially depleted peritoneal cavity which would be amenable 
to adoptive transfer experiments there where two key criteria: 
1) The dose had to be sufficient to completely deplete resident peritoneal 
macrophages. 
2) At the time of transfer, no or negligible amounts of free-floating 
liposomes should be present in the cavity. 
 
I first set out to trial the dose used by Wang et al12 and if, similar to their study, 
I could effectively deplete peritoneal macrophages 7 days post administration. 
As I was aiming to use the minimal concentration of clodronate liposomes 
required I trialled several lower doses as well. Indeed, I found that injection of 
0.5mg as used by Wang et al12 effectively depleted all F4/80Hi resident 
peritoneal macrophages but appeared to lead to an influx of neutrophils 
(Figure 3.7a,b). Moreover, 0.5mg appeared to be excessive as 0.125mg of 
clodronate liposomes, the lowest dose trialed, also completely depleted 
peritoneal macrophages but without the associated neutrophil influx (Figure 
3.7b). 
 
Hence, I repeated the experiment using 0.125mg as the highest dose and 
further titrating down the concentration of clodronate liposomes required. 
Doing this I found that the lowest doses of 0.0156 mg and 0.03125mg 
decreased the number of F4/80Hi resident macrophages but that the depletion 
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was not as complete as the depletion induced by 0.0625mg and 0.125mg of 
clodronate liposomes (Figure 3.7c). Hence, I decided to proceed using the 
dose of 0.0625mg as this was the lowest dose where complete depletion 
occurred and with which the fewest free-floating liposomes should theoretically 
be present by day 7. In subsequent validation experiments I found that already 
24 hours after injection with 0.0625mg clodronate liposomes virtually all 
F4/80Hi RMac were depleted and remained so until day 7 (Figure 3.7d). 
Notably, whereas by 24 hours a population of Ly6c+ monocytes was present, 
suggesting a degree of repopulation, these were largely absent by day 7 and 
the majority of CD11b+ myeloid cells were F4/80Lo CD226+ cells that resemble 
SPM (Figure 3.7d). 
 
As IP delivery of Clodronate liposomes has been used to deplete Kupffer cells 
in the liver12, I investigated if using the treatment protocol, I optimized for 
peritoneal phagocyte depletion also depleted Kupffer cells. Indeed, whereas 
after PBS treatment Tim4+ Kupffer cells were clearly discernible and 
accounted for approximately 20% of all live cells, these cells were largely lost, 
24 hours after treatment with clodronate liposomes, suggesting that clodronate 
liposomes are rapidly drained form the peritoneal cavity after administration. 
Critically, the one sample where peritoneal cavity macrophages were depleted 
incompletely (Figure 3.7d datapoint in red) was also poorly depleted in the 
liver (Figure 3.7e, datapoint in red). As repopulating monocytes that infiltrate 
the liver after Kupffer cell depletion are exclusively Tim4-38 I interpreted the 
presence of Tim4+ Kupffer cells in the liver as indicative of a failed IP injection 
in this mouse. Moreover, since the inability of monocyte-derived Kupffer cells 
to acquire Tim4 persists for many weeks38 I postulated that the absence of 
Tim4+ Kupffer cells in the liver could be used as a readout to confirm successful 
IP injection of clodronate liposomes long-term. 
 
Next, as proof of principle I depleted the peritoneal cavity of CD45.1/2+ mice 
using 0.0625mg of clodronate liposomes and 7 days later adoptively 
transferred 100.000 purified PKH26-PCL labelled RMac sourced from naïve 
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mice or equivalent numbers of Ly6CHi monocytes sourced 4 hours post 
zymosan. By 8 days post transfer both transferred cell populations had 
persisted and contributed to the CD11B+ Lineage-  macrophage compartment 
with donor RMac seemingly contributing more than transferred monocytes 
(Figure 3.8a). Clodronate depletion only temporarily depleted peritoneal 
macrophages and consistent with repopulation by host monocytes (Figure 
3.7d) the absolute number of CD11B+ myeloid cells was equivalent between 
depleted and non-depleted mice at this stage, irrespective of the transferred 
population (Figure 3.8b). Whereas in non-depleted mice the majority of 
F4/80Hi macrophages expressed Tim4, after clodronate treatment F4/80Hi 
macrophages largely lacked Tim4 (Figure 3.8c,d), consistent with their 
monocytic origin42. This loss of peritoneal macrophages expressing Tim4 
corresponded to loss of Tim4+ Kupffer cells in the liver (Figure 3.8e) indicative 
of successful depletion in all samples. Combined, these data show that levels 
of Tim4 on host peritoneal macrophages can be utilized as surrogate readout 
of successful clodronate depletion. Hence, for studies where cells will be 
adoptively transferred into clodronate depleted recipients the absence of host 
Tim4+ macrophages will be considered indicative of successful depletion and 
will be further analyzed.  
 
In summary, I have established a method to artificially deplete the peritoneal 
macrophage compartment and found that using a dose of 0.0625mg of 
clodronate liposomes leads to effective depletion of peritoneal cavity resident 
F4/80Hi macrophages with sufficiently few liposomes remaining by day 7 to 





Here I set out to optimize a ‘toolbox’ which would allow me to investigate 
determinants of fate and phenotype of inflammatory macrophages following 
resolution of inflammation. By using a combination of PKH26-PCL dye labeling 
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of resident phagocytes in combination with traditional macrophage and 
monocyte markers F4/80 and Ly6C I was able to identify labelled F4/80Hi 
resident macrophages and unlabeled F4/80Int inflammatory macrophages 
during resolution low dose zymosan induced peritonitis. The identity of resident 
and inflammatory macrophages identified this way was confirmed by 
expression of Tim4, a marker largely restricted to embryonically seeded 
resident macrophages42, and using partial bone marrow chimeras to confirm 
that inflammatory macrophages exhibited a high degree of chimerism and 
hence were exclusively of BM origin, while dye-positive resident macrophages 
exhibited low chimerism. It should be noted that by using the PKH26-PCL dye 
labelling the number of antibodies required to identify macrophage subsets 
was minimized, thus limiting confounding results of transferring antibody 
coated cells. However, PKH26-PCL dye particulates are sequestered in the 
phagolysosome of macrophages and are retained for long periods of time111. 
Little is known about how this dye persistence may potentially affect the 
functionality or activation state of labelled phagocytes. This is especially 
important as the PKH26-PCL labelling might affect the comparison between 
PKH26-PCL labelled resident macrophages and PKH26-PCL negative 
inflammatory macrophages in my experimental system.  
 
In order to investigate the potential of inflammatory macrophages to persist 
long-term in the absence of competing incumbent resident macrophages I 
optimized a clodronate liposomes treatment protocol to deplete host F4/80Hi 
resident macrophages. To this end, I titrated down clodronate liposomes to the 
lowest dose where complete depletion takes place and found that this depleted 
cavity is indeed amenable to adoptive transfer of macrophages. This 
methodology has two potential drawbacks. First off, the cavity will likely contain 
large numbers of dying cells at the time of adoptive transfer which may affect 
the survival and phenotype of transferred cells. Secondly, immediately 
following depletion of peritoneal macrophages high numbers of monocytes will 
start infiltrating the cavity112,132. Consequently, transferred cells will be 
competing with infiltrating monocytes for residency in the peritoneal cavity. 
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Indeed, donor monocytes persisted relatively poor following transfer into 
clodronate-depleted recipients, which may be due to their impaired capacity of 
these cells to compete with infiltrating, developmentally equivalent, host 
monocytes. In contrast, transferred resident macrophages, which are more 
mature cells that are exquisitely suited to the peritoneal microenvironment, 
persisted better following transfer into clodronate-depleted recipients, possibly 
due to heightened capacity to compete with infiltrating monocytes.  
 
In the next chapter I set out to assess whether purified monocyte derived 
inflammatory macrophages are capable of integrating into the peritoneal 
macrophage compartment and whether the post-resolution environment alters 
this capacity. Furthermore, using the depleted niche I have generated will allow 
me to investigate if competition with incumbent resident macrophages alters 










Figure 3.1 Zymosan induces resident macrophage disappearance in 
male and female mice. 
(a) Experimental scheme for IP delivery of indicated doses of PBS or Zymosan 
A into male or female mice.(b) Representative gating strategy used to identity 
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single (FSC-A vs FSC-H), live (Zombie aqua-) peritoneal macrophages 
(CD11B+ Lineage-) (c) Representative expression of F4/80, MHCII and Ly6c 
on CD11B+Lineage-myeloid cells in the cavity, 24 hours post PBS 
administration or administration of the indicated dose of zymosan A. Myeloid 
cells are identified as shown in panel b. (d).Proportion of live cells and absolute 
number of F4/80Hi macrophages in male (blue) and female (red) 24 hours post: 
PBS (male n=4, female n=4), 10µg zymosan (male n=4, female n=4),100µg 
zymosan (male n=4, female n=4),1000µg zymosan (male n=2, female n=3). 
**p<0.01 ***p<0.001 determined by two ANOVA with Sidak’s multiple 
comparisons test. (e) Proportion of live cells and absolute number of F4/80Lo/Int 
macrophages in male (blue) and female (red) 24 hours post: PBS (male n=4, 
female n=4), 10µg zymosan (male n=4, female n=4),100µg zymosan (male 
n=4, female n=4),1000µg zymosan (male n=2, female n=3). **p<0.01 
***p<0.001 determined by two ANOVA with Sidak’s multiple comparisons test. 
Data are presented as mean ± standard deviation with each symbol 






Figure 3.2 PKH26-PCL labels peritoneal phagocytes. 
(a) Representative gating of F4/80HI MHCIILO resident peritoneal macrophages 
and F4/80LO MHCIIHI CD226+ small peritoneal macrophage and CD226-
dendritic cel l(DC) / immature macrophage subsets. (b) PKH26-PCL-labelling 
of F4/80HI MHCIILO resident macrophages (black), F4/80LOMHCIIHI CD226+ 
small peritoneal macrophages (green) or CD226- DCs/immature macrophages 
(purple) 24 hours after IP injection of PKH26-PCL (n=3). **p<0.01 determined 
by one-way ANOVA with Tukey’s multiple comparisons test. (c) Proportion of 
F4/80HI MHCIILO resident macrophages (black) and F4/80LOMHCIIHI CD226+ 
small peritoneal macrophages (green) that are PKH26-PCL labelled, 24 hours 
and 5 days after IP administration of PKH26-PCL (n=3/timepoint). 
****p<0.0001 determined by student’s t test. (d) Representative gating strategy 
to identify non-myeloid Lineage+ cells in the cavity (e) Proportion of each of the 
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non-myeloid lineage_ cells in the cavity that are PKH26-PCL-labelled, 24 
hours post PKH26-PCL administration (n=3). For each population the 
unlabelled, vehicle control injected, PKH26-PCL labelling intensity is shown as 
black line in the histogram. Data shown as mean ± standard deviation. Each 




Figure 3.3 By 24 hours, marginal free-floating PKH26-PCL remains. 
(a) Experimental outline for adoptive transfer of unlabelled CD45.1/2+ 
peritoneal exudate cells via IP injection into CD45.2+ mice that were IP injected 
with PKH26-PCL 24 hours prior. (b) Representative PKH26-PCL-labelling of 
donor F4/80hi macrophages prior to transfer (grey; n=3) and 2 hours following 
transfer (red; n=3), compared to host F4/80Hi macrophages (black; bottom). 
****p<0.0001 determined by one-way ANOVA with Tukey’s multiple 
comparisons test. Data shown as mean ± standard deviation. Each symbol 




Figure 3.4 PKH26-PCL-labelling discriminates resident macrophages 
from infiltrating cells following zymosan treatment. 
(a) Representative PKH26-PCL-labelling of peritoneal CD11B+Lineage- 
myeloid cells in conjunction with   macrophage markers F4/80, Tim4 and the 
monocyte marker Ly6c (b) PKH26-PCL labelling of CD11B+Lineage- myeloid 
cells at indicated timepoints. Bottom histogram is representative PKH26-PCL 
labelling in a control mouse injected with vehicle alone. (c)Proportion of 
F4/80HI PKH26-PCLHi resident macrophages that express the embryonic 
macrophage marker Tim4+ (gated as shown in a) at indicated time-points after 
IP injection with zymosan (striped bar) or PBS (blank bar). Data shown as 







Figure 3.5 PKH26-PCL delineates low-chimerism resident macrophages 
from high-chimerism monocyte-derived macrophages. 
(a) Experimental outline to generate tissue-protected bone marrow chimeras. 
The hindlegs of CD45.2+ mice were irradiated whilst the upper body was 
protected. Mice were reconstituted using CD45.1/2+ bone marrow for 8 weeks. 
Following reconstitution mice received IP injection of PKH26-PCL followed 24 
hours later by treatment with the indicated dose of zymosan. (b) Proportion of 
circulating blood LycHi monocytes that are of donor origin (chimerism) prior to 
experimental intervention (pre-treatment; left side) and at the experimental 
endpoint (endpoint; right side). PBS treated mice in white, zymosan treated 
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mice in black. (c) Representative PKH26-PCL-labelling of peritoneal 
CD11B+Lineage- myeloid cells in conjunction with   macrophage markers 
F4/80, Tim4 and the monocyte marker Ly6c (d) Chimerism detected within the 
indicated peritoneal macrophage population as gated in (c) normalized to the 
chimerism in circulating blood LycHi monocytes (Normalized chimerism), 3 
days following IP administration of PBS (white bar) or zymosan (striped bar) 
(e) Proportion of indicated populations, as gated in (c), that are Tim4+, 3 days 
after IP administration of PBS (white bar) or zymosan (striped bar). (f) 
Normalized chimerism of F4/80HiPKH26-PCL+ Tim4+ macrophages and  
F4/80IntPKH26-PCL- Tim4+ macrophages, 3 days after IP administration of 
zymosan. Data shown as mean ± standard deviation. Each symbol represents 




Figure 3.6 PKH26-PCL discriminates resident macrophages at different 
stages of zymosan-induced peritonitis. 
(a) Representative expression of F4/80, Ly6C antibody staining of 
CD11B+Lineage- myeloid cells in the cavity in conjunction with PKH26-PCL-
labelling. Indicated gates identity F4/80HI PKH26-PCLHI resident 
macrophages, PKH26-PCLLO Ly6c+ monocytes and PKH26-PCLLO F4/80INT 
inflammatory macrophages in naïve mice or mice IP treated with 10µg 
zymosan at indicated times. (b) Absolute number of RMac, Monocytes, IMac 
in the the naïve peritoneal cavity (n=8), 4 hours post zymosan (n=9) and 3 
days post zymosan (n=9). *<0.05, ****p<0.0001 determined by one-way 
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ANOVA with Tukey’s multiple comparisons test. (c) Number of neutrophils 
(gated as detailed in Figure 3.2d) in the naïve peritoneal cavity (n=8), 4 hours 
post zymosan (n=9) and 3 days post zymosan (n=9). ****p<0.0001 determined 
by one-way ANOVA with Tukey’s multiple comparisons test. Data shown as 
mean ± standard deviation. Each symbol represents an individual animal. Data 








Figure 3.7 Clodronate liposomes deplete peritoneal macrophages.  
(a) Representative Identification of peritoneal macrophages/monocytes on the 
basis of F4/80, MHCII and Ly6c (top) and neutrophils (bottom) (b) Proportion 
of live peritoneal cells that are F4/80HiMHCIILo resident macrophages (left) and 
neutrophils (right) 7 days after IP administration of clodronate liposomes.  (c) 
Absolute number of F4/80Hi MHCIILo macrophages 7 days after IP injection 
with the indicated dose of clodronate liposomes. ***p<0.001 determined by 
one-way ANOVA with Sidak’s multiple comparisons test. (d) Representative 
identification (left) and quantification (right) of F4/80Hi resident macrophages 
(black) 24 hours after IP injection of PBS (n=3) or 0.0625mg of clodronate 
liposomes (n=4) and 7 days post IP injection with 0.0625mg clodronate 
liposome (n=4). **p<0.01 determined by one-way ANOVA and Dunnet’s 
multiple comparisons test. (e) Representative gating strategy to identify 
F4/80HiCD11BInt liver Kupffer. At the bottom, proportion of live cells that are 
Tim4+ Kupffer cells, 24 hours after IP delivery of PBS (n=3) or clodronate 
liposomes (n=4) and 7 days after IP delivery of clodronate liposomes (n=4). 
**p<0.01 determined by one-way ANOVA and Dunnet’s multiple comparisons 
test. Data shown as mean ± standard deviation except for (b) which is 
presented without standard deviation. Each symbol represents an individual 
animal. Data were pooled from 2 independent experiments, except (a,b) which 





Figure 3.8 Peritoneal macrophages persist following transfer into 
clodronate-depleted recipients. 
(a) Representative identification of proportion of CD11B+Lineage- cells that are 
of donor origin 8 day after transfer of monocytes (left) or RMac (right). *p<0.05 
determined by student’s t test. (b) Absolute number of total (donor+host) 
CD11B+Lineage- myeloid cells 8 days after transfer. (c) Representative 
expression of F4/80, MHCII and Tim4 by host cells in non-depleted (top) and 
depleted (bottom) mice 8 days after transfer. (d) Proportion of host peritoneal 
F4/80Hi macrophages that express Tim4, 8 days following adoptive transfer. 
***p<0.001 determined by one way ANOVA with Dunnett’s multiple 
comparisons test. (e) Proportion of Kupffer cells that express Tim4, 8 days 
following adoptive transfer of indicated populations. ****p<0.0001 determined 
by one way ANOVA with Dunnett’s multiple comparisons test. Data shown as 







Investigating inflammatory macrophage survival and identity 






In the previous chapter, I optimized a ‘toolbox’ to investigate the survival and 
identity of inflammatory macrophages after zymosan induced peritonitis. 
Moreover, the low dose zymosan model of peritonitis allowed purification of 
resident and inflammatory macrophages 3 days post zymosan from the 
resolved cavity and subsequent transfer into various recipient mice. 
 
Importantly, the overall size of the peritoneal macrophage compartment, 
including both resident and inflammatory macrophages combined, is enlarged 
at this timepoint compared to pre-inflammation139, yet this inflammation driven 
expansion is temporary as the peritoneal compartment contracts back to pre-
inflammation size over the succeeding week162. Moreover, during contraction 
resident macrophages undergo high levels of proliferation, whereas only a 
minor subset of inflammatory macrophages proliferates87,144. The combination 
of these two phenomena is likely to dictate the survival and conversion 
potential of inflammatory macrophages over this period. Hence, for my first 
studies I decided to focus on the survival and phenotype of inflammatory 
macrophages shortly following resolution.   
  
The rate at which inflammatory macrophages can undergo phenotypic 
conversion and consequently the extent to which this occurs during this post 
resolution contraction period is unknown. The only published study that gives 
an estimate of the rate at which conversion into resident macrophages can 
occur are SPM transfer studies, carried out by Cain et al. Briefly, under naïve 
conditions small peritoneal macrophages are largely monocyte-derived cells, 
that are thought to give rise to resident peritoneal F4/80Hi macrophages42. 
Using C/EBPb-/- mice that are deplete of resident F4/80Hi macrophages, Cain 
et al show that transferred F4/80Lo SPM largely acquire a resident like F4/80Hi 
MHCIILo phenotype within an 8-day period after transfer60. Inflammatory 
macrophages present during resolution of zymosan induced peritonitis by day 
3 are characterized by an F4/80Int MHCIIHi phenotype139 , somewhat similar to 
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SPM. Hence, I postulated that conversion into an F4/80Hi MHCIILo phenotype 
should be possible over an 8-day period. As this 8-day period post-resolution 
coincides with the period during which the cavity macrophage compartment 
contracts back to steady-state levels I decided to focus my studies on this 
specific time-point.   
 
In this chapter I sought to investigate if inflammatory macrophages present 
during resolution of inflammation, persist following the contraction of the 
macrophage compartment that occurs in the succeeding 8 days and if so, 
whether they convert into a resident like phenotype. Moreover, I sought to 
ascertain whether the survival and fate of inflammatory macrophages are 
dictated by the post-inflammatory environment and, if so, whether competition 
with incumbent resident macrophages plays affects the phenotype of these 
cells. To assess the phenotypic conversion potential of inflammatory 
macrophages I focussed on the markers F4/80 and MHCII, as these markers 
are commonly used in the literature to identity inflammatory macrophages. In 
addition, I investigated levels of GATA6, as this is the key peritoneal 
macrophage identity determining transcription factor highly expressed by 
resident macrophages63-65. Moreover, I assessed expression of CD102, a 
GATA6 independent marker highly expressed by resident peritoneal 
macrophages63 and Tim4, expression of which is thought to be largely limited 
to embryonically seeded resident macrophages42.  
 
4.2 The post resolution environment allows inflammatory macrophage 
survival but inhibits phenotypic conversion. 
 
To investigate if inflammatory macrophages survive after resolution of 
inflammation and if they remained phenotypically distinct from resident 
macrophages, 100,000 CD45.2+ resident or inflammatory macrophages, 
present 3 days post-zymosan injection were purified, as described in chapter 
2, and adoptively transferred into recipient CD45.1/2+ mice at the same stage 
of peritoneal inflammation (Figure 4.1a). Using this methodology allowed 
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identification of donor cells on the basis of their CD45.2+ mismatch. By day 8, 
transferred donor cells accounted for approximately 1.5% of the total CD11b+ 
Lineage- myeloid cell compartment irrespective of type of macrophage 
transferred (Figure 4.1B, left). To better describe their ability to survive I 
calculated the engraftment efficiency, defined as the percentage of transferred 
cells that were present at the experimental endpoint (Figure 4.1B, bottom). 
Although variable, the engraftment efficiency of RMacZ10 was marginally higher 
than that of IMacZ10 (Figure 4.1b, right), indicating that RMacZ10 had a slight 
survival advantage following resolution. Moreover, IMacZ10 largely failed to 
acquire the F4/80HiMHCIILo phenotype that characterizes resident 
macrophages under steady-state conditions and donor RMacZ10 at this stage. 
Consequently, these markers could be used as a rudimentary method to 
discriminate between the two populations (Figure 4.1c). Similar to work by 
Davies et al87. within the host macrophage compartment, two subsets of 
macrophages could be identified. These subsets aligned to donor RMacZ10 
(F4/80Hi MHCIILo) and IMacZ10 (F4/80Int MHCIIHi). In addition, a minor 
population of F4/80Lo MHCIIHi cells that phenotypically resembled F4/80Lo 
MHCIIHi SPM, present under steady-state conditions42, was present but did not 
appear to originate from either donor population (Figure 4.1c). Importantly, the 
balance between host F4/80Hi MHCIILo and F4/80Int MHCIIHi macrophages was 
equivalent irrespective of the type of donor cell transferred. This suggests that 
transferred populations do not differentially affect the cavity into which they 
have been transferred (Figure 4.1c). 
 
As described, a large part of the peritoneal macrophage identity is driven by 
the transcription factor GATA663-65. By day 8, both donor RMacZ10 and IMacZ10 
were almost universally positive for GATA6, although the level of expression 
was significantly lower in IMacZ10 (Figure 4.1d,e), as determined by the mfi of 
expression in each population. Moreover, the subsets of host macrophages 
showed a similar pattern with resident-like F4/80Hi MHCIILo cells expressing 
higher levels of GATA-6 than inflammatory-like F4/80Int MHCIIHi macrophages, 
whereas F4/80LoMHCIIHi cells largely lacked GATA6 consistent with an SPM 
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identity (Figure 4.1d,f). I also investigated the expression of two additional 
markers expressed by resident peritoneal macrophage markers, CD10263,97 
and Tim442,97. RMacZ10 expressed high levels of both markers, whereas 
IMacZ10 expressed equivalently high levels of CD102, but largely lacked Tim4 
(Figure 4.1g). 
 
In summary, using the adoptive transfer methodology I was able to ascertain 
that inflammatory macrophages persist short-term after resolution of 
inflammation, albeit somewhat less well than their resident counterparts. 
During this period, they maintain an inflammatory macrophage phenotype, 
characterized by intermediate levels of F4/80 and high levels of MHCII but also 
express resident markers GATA6 and CD102. 
 
In these experiments 2 out of the 10 RMacZ10 samples and 1 out of the 9 
IMacZ10 sample were excluded as no donor cells were present in these 
animals. In both RMacZ10 animals failure of cell transfer could be confirmed 
due to the complete absence of dye in any recipient cells. 
 
4.3 The post resolution environment does not dictate inflammatory 
macrophage survival and phenotype. 
 
As both monocytes and macrophages are thought to be highly responsive to 
environmental signals7,9 I set out to investigate if the impaired survival and 
unique identity of inflammatory macrophages is determined by the post-
resolution environment or if these phenomena are pre-determined features, 
imprinted on inflammatory macrophages earlier in their development. Hence, 
I used the same adoptive transfer methodology as described in 4.1, but 
transferred purified ImacZ10 and RmacZ10 into naïve recipient mice thus 
removing the post-resolution environment as a possible factor in their survival 
and phenotype (Figure 4.2a). 
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As naïve recipient mice have a completely intact macrophage compartment, it 
was surprising to find that IMacZ10 persisted similarly to transferred 
RMacZ10(Figure 4.2b). IMacZ10 remained phenotypically distinct and could 
largely be differentiated from RMacZ10 on the basis of their F4/80Int MHCIIHi 
phenotype following transfer into naïve recipients (Figure 4.2c). However, 
unlike in recipient mice that had been pre-treated with zymosan, the host 
macrophage compartment of naïve recipient mice largely comprised an 
F4/80Hi MHCIILo population comparable to RMacZ10, but with no population 
corresponding to F4/80Int MHCIIHi IMacZ10 (Figure 4.2c). Again, similar to their 
phenotype in the native environment IMacZ10 were also almost exclusively 
GATA6+, although levels were lower than detected in RMacZ10(Figure 4.2d, 
e). Moreover, virtually all RMacZ10 expressed CD102 and Tim4, unlike IMacZ10 
which were CD102+ but largely Tim4- (Figure 4.2f). 
 
In conclusion, the post-resolution environment does not appear to greatly 
affect the survival and conversion potential of transferred inflammatory 
macrophages. 
 
4.4 Competition with incumbent resident macrophages inhibits 
proliferation of inflammatory macrophage and conversion. 
 
In the previous experiments transferred IMacZ10 were placed in environments 
in which they directly competed with incumbent resident macrophages. 
Considering competition for niche space is thought to be an important regulator 
of monocyte to macrophage conversion in solid organs, for example the 
liver38,73 it is possible that the presence of competing resident macrophages 
affects the fate of IMacZ10. Consistent with this hypothesis, SPM transferred 
into recipient mice, largely deplete of resident macrophages (C/EPBb-/- 
recipient mice), adopted a resident like F4/80Hi MHCIILo phenotype, but failed 




Hence, I postulated that competition with resident macrophages would not 
affect survival of IMacZ10 but could be inhibiting conversion of transferred 
IMacZ10. To test this hypothesis, I adoptively transferred RMacZ10 or IMacZ10 
into recipient mice pre-treated with clodronate 7 days prior to transfer (Figure 
4.3a). By day 8, IMacZ10 accounted for approximately 20% of the total 
CD11B+Lineage- macrophage compartment with an engraftment efficiency of 
approximately 250%, suggesting these cells had expanded considerably 
(Figure 4.3b). Conversely, RMacZ10 appeared unable to undergo a similar 
expansion with an engraftment efficiency of approximately 90%, indicating 
that, although these cells persisted somewhat better than they did in the 
competitive settings of the inflamed or uninflamed cavities, they did not expand 
to the same degree as IMacZ10 (Figure 4.3b). Critically, IMacZ10 more fully 
downregulated MHCII adopting a more resident like phenotype (Figure 4.3c). 
Notably, the host macrophage compartment (Figure 4.3c) resembled the 
macrophage compartment post inflammation based on F4/80 and MHCII 
(Figure 4.1c), suggesting that monocyte-derived macrophages had 
repopulated the cavity following depletion of the resident cells (Figure 3.7d). 
Moreover, IMacZ10 almost exclusively expressed GATA6+, but the level of 
expression remained lower than in RMacZ10(Figure 4.3d,e). Again, RMacZ10 
almost exclusively expressed CD102 and Tim4, whereas IMacZ10 expressed 
equivalent levels of CD102, but did not express Tim4 (Figure 4.3f). However, 
I did notice that the fraction of RMacZ10 that expressed Tim4 appeared more 
variable and on the whole lower than on RMacZ10 transferred into mirroring 
inflamed or naïve recipients (Compare 4.1g to 4.2f to 4,3f). 
 
Hence, these data indicate that the presence of competing resident 
macrophages inhibits the ability of IMacZ10 to undergo conversion to an MHCIIlo 
phenotype and suppresses the proliferative capacity of IMacZ10. 
 
In these experiments 2 out of 10 RMacZ10 samples were excluded due to 
incomplete depletion and 2 out of the 8 IMacZ10 samples were excluded, one 
because of incomplete depletion and the other one because the gut was 
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severely inflamed, both indicative of failed IP injection.  
 
4.5 PKH26-PCL dye labelling does not inhibit resident macrophage 
proliferation. 
 
The ability of IMacZ10 to proliferate after transfer into depleted recipients and 
the apparent inability of RMacZ10 to do so was surprising. To interpret this data 
correctly I wanted to verify that PKH26-PCL labeling did not affect cell 
proliferation as transferred RMacZ10 were labelled and seemingly did not 
proliferate whereas transferred IMacZ10 were unlabeled and proliferated.  
 
I was unable to find any published data that investigated or described an 
inhibitory effect of PKH26-PCL dye on cell proliferation. However, during my 
earliest trial experiments presented in Figure 3.8, during which I adoptively 
transferred dye labelled RMac sourced from naïve donor mice into depleted 
recipients I had stained purified RMac directly after sorting and prior to 
adoptive transfer for Tim4 to verify the purity on the day. As I had also included 
Tim4 in the panel at the experimental endpoint I was able to quantify if the 
fraction of RMac that expressed Tim4 was altered between the time of transfer 
and at the time of collection. If so, this could also help explain the variable and 
lower levels of Tim4 on RMacZ10 after transfer into depleted recipients 
discussed in the previous section. Critically, under naïve homeostatic 
conditions the absence of Tim4 has been shown to label a minor fraction of 
resident peritoneal macrophages that are of monocyte origin and that have 
higher levels of proliferation42. Hence, I postulated that after transfer into 
depleted recipients the Tim4- fraction of RMac should proliferate more thus 
providing evidence that PKH26-PCL labelling does not inhibit the capacity of 
labelled cells to proliferate.  
 
To investigate this, I pooled the data from the RMac transfer presented in 
Figure 3.8.  with one additional repeat experiment where I transferred RMac 
into clodronate pre-treated recipients. (Figure 4.4a). I confirmed that the 
 113 
purified RMac population at the time of transfer largely consisted of Tim4+ 
macrophages (Figure 4.4b,c) and importantly that the Tim4+ and Tim4- 
fraction were equivalently labelled with PKH26-PCL (Figure 4.4b,c). By day 8 
post transfer the Tim4- fraction appeared to have become enriched within the 
transfer population (Figure 4.4d)  
 
It has been described that Tim4 is slowly acquired by macrophages42 and in 
my hands appears to be acquired minimally by IMacZ10 over an 8 day period 
even after transfer into depleted recipients (Figure 4.3). Hence, I made the 
assumption that over the 8 days proliferating Tim4- RMac would largely give 
rise to Tim4- offspring, whereas proliferating Tim4+ RMac would predominantly 
give rise to Tim4+ RMac. Hence, I quantified a separate engraftment efficiency 
for Tim4- RMac and Tim4+ RMac. This analysis indicated that Tim4- RMac had 
a proliferative capacity somewhat similar to that identified for IMacZ10, with an 
engraftment efficiency of approximately 290%, whereas Tim4+RMac appeared 
less able to proliferate, with an engraftment efficiency of approximately 150% 
(Figure 4.4e).   
 
There are currently no data available on how PKH26-PCL labelling dilutes after 
cell division. However, it has been shown that intracellular particles 
sequestered in macrophages are equally divided between daughter cells upon 
cell division, unless microbial or environmental factors promote unequal 
distribution163. Consistent with PKH26-PCL labelling being divided equally 
between daughter cells Tim4- RMac had lost more PKH26-PCL labelling 
compared to the Tim4+ RMac fraction (Figure 4.4f) likely as a result of higher 
levels of proliferation in the former population. 
 
Moreover, work by Cain et al carried out experiments where they transferred 
80.000 purified F4/80HiLPM into macrophage deplete C/EPBb-/- recipient mice 
or C/EPBb+/+ recipient mice and quantified the number of donor cells retrieved 
up until 30 days post transfer60. The authors kindly provided me with the 
published dataset and have given me permission to include these data in my 
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thesis. In the publication they presented the absolute number of donor cells 
which were hard to compare directly to my results. Hence, I calculated an 
engraftment efficiency based on their absolute cell counts, allowing easy 
comparison between my adoptive transfer studies and the ones published by 
Cain et al. The overall engraftment efficiency in their experiment was 
approximately 12%, somewhat lower than in the experiments I carried out. 
Importantly, there did not appear to be a great difference in the number of 
donor LPM retrieved after transfer into C/EPBb-/- or C/EPBb+/+ mice (Figure 
4.4g). These data suggest that, similar to my findings, transferred LPM were 
unable to expand considerably after transfer into macrophage deplete 
recipients. Critically, in their study they did not use a dye labelling methodology 
suggesting that the apparent inability to expand in my hands is unlikely to be 
due to confounding effects of PKH26-PCL labelling.  
 
4.6 Transferred cells migrate into the omentum of clodronate pre-
treated recipients.  
 
The omentum is thought to be an important source of CSF1, vital for the 
survival and proliferation of peritoneal macrophages. Moreover, the omentum 
is thought to be the predominant source of retinoic acid in the peritoneal cavity, 
which has been shown to drive expression of the peritoneal identity 
determining transcription factor GATA663. In addition, the omentum is thought 
to produce additional, poorly defined, factors that are required for maintenance 
of the peritoneal macrophage identity. In vitro studies indicate that secreted 
omentum factors drive part of the peritoneal macrophage identity, but also that 
a small proportion of peritoneal macrophage identity genes requires the direct 
interaction between peritoneal macrophages and the omentum99. The 
importance and extent of interplay between the omentum and peritoneal 
macrophages in vivo is poorly understood. Peritoneal cells have been shown 
to interact with the omentum in vivo during homeostasis164. Moreover, GATA6 
signalling, predominantly driven by omental retinoic acid, has been suggested 
to be required for macrophages to exit the omentum and enter the peritoneal 
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cavity. It has been postulated that migration through the omentum is required 
for maintenance of the GATA6+ peritoneal macrophage population63. 
However, no migration of macrophages from the peritoneal cavity into the 
omentum or vice versa has been definitively shown to occur under steady state 
conditions. In the context of peritoneal inflammation it has been suggested that 
inflammatory monocytes/macrophages could be migrating from the omentum 
into the peritoneal cavity and vice versa after LPS treatment63 zymosan 
treatment 165 or S.Typhi immunization166. However, these datasets draw this 
conclusion largely on the basis of markers63, or indirectly from the observation 
that monocyte derived cells accumulate in the omentum165 prior to 
accumulation peritoneal cavity166. Critically, none of these datasets directly 
shows migration from macrophages or monocytes present 
 
As the adoptive methodology I developed was exquisitely adapted to 
investigate migration from the peritoneal cavity into the omentum I set out to 
determine if in the experiments presented in the previous sections RMacZ10 or 
IMacZ10 had indeed migrated into the omentum. I postulated that post 
resolution IMacZ10 would not migrate and consequently why they failed to 
acquire a F4/80HiMHCIILo resident phenotype whereas after clodronate pre-
treatment IMacZ10 could migrate into the depleted omentum and acquire 
proliferation and differentiation factors. 
 
The omental CD11B+ Lineage- myeloid compartment can divided into CD102+ 
GATA6+ ‘peritoneal like’ macrophages, CD102- F4/80+ omental macrophages 
and F4/80- CD102- monocytes and cDCs42. As there was no indication to which 
population transferred cells might contribute, the myeloid compartment was 
rudimentary split into two populations namely: macrophages (F4/80+ and/or 
CD102+) and monocytes (F4/80-/CD102-) (Figure 4.5a). The population of 
macrophages can be divided into CD102+ MHCIILo ‘peritoneal like’ 
macrophages and CD102- MHCIIHi macrophages thought to be omental 
macrophages (Figure 4.5a)97. Of note, the cell counts obtained after omentum 
preparation using the CASY counter proved highly variable, partially because 
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of the debris present after preparation. Hence, the data presented here are 
quantified as proportions rather than absolute numbers. After transfer into 
mirroring inflamed or naive recipients neither donor RMacZ10 nor IMacZ10 were 
detectable within the omental macrophage or monocyte fraction (Figure 
4.5b,c) suggesting that negligible migration from the peritoneal cavity occurs 
during homeostasis and shortly after resolution of inflammation. 
 
Intraperitoneal injection with clodronate liposomes has been used to deplete 
omental phagocytes102. As I had not previously investigated the depletion of 
phagocytes in the omentum in my hands, I first verified that by D15 post-
clodronate treatment the proportion of omentum macrophages that express 
Tim4 was reduced as a rudimentary readout of successful depletion. Indeed, 
by D15 the proportion of Tim4-expressing omental macrophages was reduced 
compared to control mice (Figure 4.5d) although the effect was less striking 
than observed in liver Kupffer cells (Figure 3.7e) or host peritoneal 
macrophages. Hence, it would appear that clodronate treatment, at least 
partially, depleted omentum macrophages.  
 
After transfer into clodronate pre-treated recipients both donor RMacZ10 and 
IMacZ10 were detectable within the omentum macrophage compartment, but 
not the F4/80-CD102- monocyte/cDC 8 days post transfer. (Figure 4.5f). 
Whereas RMacZ10 phenotypically resembled the CD102+ MHCIILo fraction of 
omental ‘peritoneal like’ macrophages, approximately half of IMacZ10 
expressed this phenotype, while the remaining cells exhibited a 
CD102LoMHCIIHi phenotype aligning with the remainder of omental 
macrophages (Figure 4.5g). In earlier experiments I had collected the 
omentum after transfer of IMacZ10 or naïve RMac into clodronate depleted 
recipients. During the first rounds of experiments there were some issues with 
variability of the zymosan and I was unable to consistently source RMacZ10 for 
transfer during these experiments. Hence, only IMacZ10 and naïve RMac were 
transferred in these experiments. Surprisingly, in these earlier experiments 
IMacZ10 seemingly migrated into the omentum more efficiently than RMac 
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(Figure 4.5h). Indeed, when pooling these data (squares) with the dataset 
previously presented in Figure 4.5f (circles) it would appear that donor IMacZ10 
might be migrating more readily into the omentum than RMac (Figure 4.5h) 
although there is a high degree of variability between the datasets 
 
In summary, using the adoptive transfer methodology I was able to ascertain 
that after partial depletion of omentum macrophages both resident and 
inflammatory macrophages migrate into the omentum.  
 
4.7 Inflammatory macrophage phenotype is responsive to retinoic-acid 
and omentum factors in vitro. 
 
The data I generated suggested that by 8 days post transfer (11 days post 
zymosan) inflammatory macrophages were capable of adopting a more 
resident like MHCIILo phenotype, but only in the absence of competing resident 
macrophages. This ability to convert coincided with some degree of migration 
of inflammatory macrophages into the macrophage deplete omentum. 
However, the fraction of IMacZ10 that migrated into the omentum seemed minor 
compared to the expanded population of cells retained in the peritoneal cavity. 
Although IMacZ10 could be continuously migrating in and out of the omentum, 
another possibility is that the more complete conversion of IMacZ10 and 
possibly the proliferation occurs because of secreted omentum factors. This 
would be consistent with in vitro data indicating that the omentum 
predominantly affects peritoneal macrophage identity via secretion of retinoic 
acid and omentum factors, while direct interaction is only required to drive a 
relatively minor fraction of peritoneal identity genes99. 
 
Hence, I postulated that retinoic-acid and omentum factors secreted into the 
peritoneal cavity by the omentum drive inflammatory macrophage conversion 
through up and downregulation of F4/80 and MHCII respectively. To 
investigate this, I collected peritoneal exudate cells 11 days after injection of 
low dose zymosan. Importantly, at this timepoint transferred IMacZ10 were 
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characterized by an F4/80Int MHCIIHi phenotype in their native post resolution 
environment, but were capable of downregulating MHCII in the clodronate 
depleted environment. Macrophages were then adherence purified and 
treated for 24 hours with 250ul cell culture media containing all trans retinoic-
acid (ATRA; 1µm), Omentum factors (Om factors), produced as described by 
Okabe et al63, both ATRA and Om factors or neither (Ctrl) and investigated 
using flow cytometry (Figure 4.6a). 
 
During earlier adoptive transfer experiments I had found that CD102 and Tim4 
expression delineated RMac from IMacZ10irrespective of the recipient 
environment (Figure 4.3f). Hence, I opted to use a combination of these 
markers as a surrogate method to identify resident (CD102+ Tim4+) and 
inflammatory macrophages (CD102+ Tim4-) after culture. Importantly, none of 
the treatments altered the proportion of CD102 and Tim defined macrophages 
based on these markers. (Figure 4.6b).  Culture with ATRA  led to increased 
expression of the GATA6 responsive marker F4/8063 by CD102+/Tim4+ 
(resident) and CD102+Tim4-  (inflammatory) macrophages, but not down-
regulation of MHCII (Figure 4.6c,d). Surprisingly, F4/80 was not upregulated 
in response to treatment with both ATRA and omentum supernatant. Culture 
with omental supernatant with or without ATRA led to downregulation of MHCII 
by CD102+Tim4-  inflammatory macrophages (Figure 4.6d) 
 
In summary, these data indicate that inflammatory macrophage F4/80 
expression is responsive to retinoic acid, whereas MHCII expression is 
responsive to other omentum factors. Combined these data suggest that  
post-resolution inflammatory macrophages might be unable to compete for 
omentum derived factors and consequently fail to adopt a resident like F4/80Hi 




4.8 Retinoic-acid drives expression of GATA6 and F4/80 by monocyte-
derived macrophages in vivo 
 
Combined the in vivo and in vitro experiments suggested that IMacZ10 might 
be failing to compete with resident macrophages for ATRA and/or omentum 
factors and consequently fail to adopt a resident like phenotype. To ascertain 
whether this competitive disadvantage was indeed limiting phenotypic 
conversion I attempted to adapt a protocol published by Gundra et al145 to 
investigate whether treatment with excess ATRA would allow inflammatory 
macrophages to upregulate GATA6 to equivalent level as their resident 
counterparts. In their publication Gundra et al145 injected ATRA IP to 
successfully induce expression of F4/80 on peritoneal macrophage after 
thioglycolate induced peritonitis. In their protocol ATRA was dissolved in 
DMSO and injected IP. However, during trial experiments I found that both 
injection of DMSO alone and ATRA in DMSO caused significant discomfort to 
the mice, as indicated by hunched posture and temporary paralysis of the 
hindlegs. In addition, the wash collected after either treatment regimen was 
consistently contaminated with blood irrespective of the treatment group, 
suggesting DMSO might be disrupting peritoneal vasculature. Hence, I altered 
the protocol and prepared a high concentration ATRA stock in DMSO which I 
then dissolved in corn oil to prepare a working solution for injection as 
suggested by the manufacturer and used previously167,168. I then proceeded to 
carry out an adoptive transfer protocol similar to that presented in Figure 4.1 
transferring RMacZ10 or IMacZ10 into equivalently inflamed recipients that 
subsequently received 250µg ATRA or vehicle (20% DMSO/ 80% corn oil) 
every other day IP until harvest at day 8 (Figure 4.7a).  
 
Following collection of the samples the omentum was no longer discernible 
irrespective of the treatment group. Instead, it looked like the omentum had 
been encapsulated into one large clump of fat. Preparation of a single cell 
suspension from this apparent adipose tissue using the omentum preparation 
protocol yielded no viable cells. Furthermore, neither RMacZ10 nor IMacZ10 
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were detectable in peritoneal lavage fluid, irrespective of the treatment group 
indicating that the peritoneal macrophage compartment per se had been 
replaced by monocyte derived cells due to the vehicle treatment (Figure 4.7b). 
Consistent with an inflammatory event high numbers of neutrophils were 
present in cavity of vehicle treated mice, with approximately twice as many in 
the ATRA treated mice (Figure 4.7c). Despite driving inflammation, ATRA 
treatment significantly expanded the number of CD11B+ Lineage- host 
macrophages expressing high or intermediate levels of GATA6 but not GATA6 
negative macrophages (Figure 4.7e) compared with treatment with oil vehicle 
alone. Moreover, ATRA treatment did not affect the levels of MHCII on these 
GATA6-defined subsets consistent with in vitro findings. (Figure 4.7f) 
 
4.9 Inflammatory macrophages expand following transfer into FIRE-/- 
mice devoid of peritoneal resident macrophages. 
 
A drawback of using clodronate liposomes as a depletion method is that host 
monocytes infiltrate the cavity and consequently transferred cells are 
repopulating the peritoneal cavity in parallel with infiltrating host monocytes. I 
was keen to validate the expansion of IMacZ10 and migration into the 
omentum using FIRE-/- recipient mice, devoid of peritoneal and omental 
macrophages106. The FIRE-/-mice were on a mixed C57BL/6-CBA 
background. Unfortunately, as we were backcrossing to C57BL/6 we 
discovered that deletion of the FIRE domain is lethal on a pure C57BL/6 
background. Importantly, Dr. Clare Pridans confirmed that despite being on a 
mixed C57BL/6-CBA background FIRE-/- mice and littermate controls 
exclusively expressed the H-2Kk MHC class I alloantigen (personal 
communication) indicating that transfer of littermate cells into FIRE-/- 
recipients was possible. Hence, I set out to use the FIRE-/- mice on a mixed 
background to validate my earlier findings. Unfortunately, I was unable to use 
the tracking methodology utilized in the previous experiments. However, as 
FIRE-/- mice were almost completely devoid of peritoneal macrophages a 
method to track donor cells was not strictly necessary as any cells present 
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would originate predominantly from donor cells. In addition, expression of the 
CD115 (CSF1R) was largely absent FIRE-/- mice106 whereas both RMacZ10 
and IMacZ10 expressed high levels of CD115 (Figure 4.8a).  
 
Hence, I carried out an adoptive transfer experiment where I transferred 
RMacZ10 or IMacZ10 sourced from FIRE+/+or FIRE+/- control mice and 
transferred these cells into FIRE-/- recipients (Figure 4.8a). By day 8, the 
small fraction of F4/80Hi CD115- macrophages present in PBS treated non-
transferred FIRE-/- mice was complemented by a clear population of donor 
PKH26-PCL+ RMacZ10 or PKH26-PCLLo IMacZ10, both of which expressed 
high levels of CD115 (Figure 4.8b). However, as definitive discrimination 
between host and donor cells was not possible, the size of the whole myeloid 
compartment 8 days post transfer (CD11B+ Lineage-) was quantified. This 
analysis suggested an expansion of the myeloid compartment after transfer 
RMacZ10 but more so after transfer of IMacZ10 (Figure 4.8c), similar to 
IMacZ10 expansion observed after transfer into clodronate-depleted recipients 
(Figure 4.3b). However, the data was highly variable and although in each 
experiment IMacZ10 had expanded more than RMacZ10 the data indicated no 
significant differences. This experiment would have to be repeated to be 
sure. IMacZ10 appeared to have higher levels of proliferation as measured by 
Ki67 (Figure 4.8d). Finally, after transfer into FIRE-/- recipient mice IMacZ10 
downregulated MHCII (Figure 4.5e) consistent with earlier transfer studies 
into clodronate-depleted recipients (Figure 4.3c).  
 
4.9.1 Inflammatory macrophages migrate into the omentum of FIRE-/- 
recipient mice  
During preliminary experiments my supervisor Dr. Steve Jenkins found that 
the omentum of FIRE-/- mice is largely devoid of macrophages. As I had found 
earlier that RMacZ10 and IMacZ10 migrated into the partially-depleted omentum, 
I set out to investigate if migration occurred into the omentum of FIRE-/- 
recipient mice.  
 
 122 
Indeed, upon investigation of the omentum I found that transferred cells 
appeared to have migrated into the omentum (Figure 4.9a). In PBS injected 
mice FIRE-/-  omental macrophages (F4/80+/CD102+) were virtually absent, but 
after transfer of RMacZ10 or IMacZ10 a clear population was detectable, likely 
derived from transferred cells (Figure 4.9a). However, as donor cells could not 
be definitively identified, I quantified the size of the complete omental myeloid 
cell compartment. This analysis indicated that RMacZ10 and IMacZ10 both 
expanded the complete myeloid-cell compartment (Figure 4.9b). Intriguingly, 
this myeloid expansion after RMacZ10 transfer did not appear to coincide with 
an increase in the proportion of cells with a macrophage F4/80+/CD102+ 
phenotype, whereas transfer of IMacZ10 did lead to the presence of an 
expanded F4/80+/CD102+ macrophage population (Figure 4.9a,c). These 
data would suggest that transfer of RMacZ10 leads to expansion of the CD102-
/F4/80- monocyte compartment. This is likely through increased infiltration of 
monocytes, as levels of Ki67 detectable in CD102-/F4/80- cells were equivalent 




In this chapter I sought to establish if inflammatory macrophages present 
during the resolution of inflammation persist through the succeeding period 
during which the overall size of the macrophage compartment contracts to pre-
inflammation levels. By adoptively transferring RMacZ10 and IMacZ10 into 
mirroring inflamed recipients I found that IMacZ10 persist through this period, 
albeit less well than RMacZ10, and that they are characterized by an 
F4/80IntMHCIIHi phenotype. Surprisingly after transfer into naïve recipient mice, 
IMacZ10 seemingly persisted equally well as RMacZ10 despite competing with a 
completely intact host macrophage compartment. This discrepancy could be 
due to the myeloid compartment expansion at the time of transfer, 3 days post 
zymosan, compared to naïve mice. However, it is likely that IP injection of 
donor cells itself induces loss of resident macrophages, thus allowing donor 
IMacZ10 and RMacZ10 to persist. Indeed, IP injection with PBS has been shown 
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to drive a minor loss of resident macrophages146 (Personal communication Dr. 
Steve Jenkins). Over the succeeding 8 days post transfer the compartment 
contracted back to pre-inflammation levels. As IMacZ10 seemingly persisted 
less during this contraction period than their RMacZ10 counterparts this could 
indicate that competitive pressure from both resident and other inflammatory 
macrophages limits, but does not prevent IMacZ10 survival. Indeed, IMacZ10 
transferred into recipient mice deplete of peritoneal macrophages expanded 
considerably and adopted a more resident like F4/80Hi MHCIILo phenotype. 
When transferring RMacZ10 or IMacZ10 into clodronate-depleted recipient mice, 
donor cells were transferred into a cavity containing high numbers of death 
cells and placed in direct competition with infiltrating host monocytes for 
peritoneal cavity residency. However, these phenomena are unlikely to have 
affected the experimental readouts as adoptive transfer experiments into 
FIRE-/- recipients, devoid of resident macrophages and infiltrating monocytes, 
suggested a similar ability of IMacZ10 to expand and downregulate MHCII 
expression. Hence, competition with incumbent resident macrophages after 
resolution of inflammation does not prevent the survival of inflammatory 
macrophages, but seemingly inhibits the proliferation and phenotypic 
conversion of these cells. 
 
The ability of inflammatory macrophages to undergo more complete 
conversion in the resident macrophage deplete environment could be related 
to their capacity to acquire omental differentiation factors in this environment. 
Indeed, in vitro the inflammatory macrophage phenotype is responsive to 
retinoic acid and other omentum factors, indicating that their impaired capacity 
to convert in vivo is not due to an inability to respond to these cues but likely 
due to an inability to acquire these factors whilst competing with incumbent 
resident macrophages. However, as both RMacZ10 and IMacZ10 were capable 
of migrating into the macrophage deplete omentum,  the latter seemingly doing 
so more readily, it cannot be excluded that migration into, or interaction with, 
the omentum rather than uptake of secreted omentum factors from the cavity 
microenvironment, is underlying the inability of IMacZ10 to undergo phenotypic 
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conversion when competing with resident macrophages. Alternatively, the 
seemingly increased migration capacity of IMacZ10 might account for the 
striking expansion of these cells in the peritoneal cavity after transfer into mice 
deplete of resident macrophages. As little is known about the mechanisms 
regulating this migration it is challenging to design an experiment to test this 
hypothesis. In addition, it remains unclear whether donor cells found in the 
omentum subsequently migrate back into the peritoneal cavity or remain 
sequestered in the omentum. Combined these data indicate a potential role 
for the omentum in shaping the post resolution identity of inflammatory 
macrophages, but the exact mechanisms via which this may occur remain 
unclear. 
 
By injecting retinoic-acid into the post zymosan cavity I attempted to 
investigate if excess retinoic acid would indeed drive GATA6 expression on 
IMacZ10 to levels equivalent to RMacZ10. When I carried out this experiment 
there were no published data on the inflammatory effects of IP injection with 
corn oil. Hence, interpretation of these data was complex without additional 
experimentation. Due to time constraints I chose to focus on other parts of my 
project and did not repeat this experiment or carry out additional experiments 
to verify the inflammatory effects of oil. Recent work indicated that IP injection 
with oil causes chronic inflammation and monocyte infiltration169. Specifically, 
IP delivery of corn oil causes complete loss of Tim4+ resident macrophages. 
These findings support the idea that the corn oil vehicle used in this experiment 
led to complete replacement of macrophage compartment as indicated by the 
complete absence of transferred cells. Hence, these data would suggest that 
retinoic-acid in vivo drives expression of GATA6 by monocyte-derived 
inflammatory macrophages recruited during oil induced peritonitis. Hence, 
these data support the hypothesis that the inability of IMacZ10 to acquire 
equivalent levels of GATA6 as RMAcZ10 after zymosan induced peritonitis 
might be due to an impaired ability to compete for retinoic-acid.  
 
To investigate the survival and conversion potential of inflammatory 
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macrophages I have chosen to use an adoptive transfer method. This method 
is powerful as it allows transfer into varying recipient environment. However, a 
potential drawback of the adoptive transfer methodology is that by transferring 
in donor cells the environment is altered, thus affecting experimental results. 
As donor cells accounted for a relatively small proportion of the macrophage 
compartment in all transfer experiments, they are unlikely to significantly affect 
the cavity as a whole. Moreover, the transfer of RMacZ10 or IMacZ10 did not 
differentially affect the host macrophage compartment indicating that if donor 
cells affected the cavity both donor populations did so similarly. During later 
studies I carried out a time-course experiment investigating the peritoneal 
cavity at different timepoints after zymosan induced peritonitis. These studies 
allowed me to verify that features found here using the adoptive transfer 
methodology are not affected by the transfer itself. 
 
In summary, these data indicate that inflammatory macrophages present 
during resolution of peritonitis survive and remain phenotypically distinct. This 
is a direct result of competition with incumbent resident macrophages for 











Figure 4.1 Inflammatory macrophages survive after resolution. 
(a) Experimental outline for IP delivery of CD45.2+ RMacZ10 or IMacZ10 into 
inflamed CD45.1/2+ recipient mice. For a more detailed gating strategy see 
Figure 3.6a (b) Proportion of  CD11B+ Lineage- cells that are of donor origin 
(RMacZ10 in blue; IMacZ10 in orange) by 8 days after transfer. To the right, 
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engraftment efficiency of donor RMacZ10 (n=6) and IMacZ10 (n=8) 8 days after 
transfer. Engraftment efficiency was calculated based on absolute numbers as 
described in the M&M section. *p<0.05 determined by Mann-Whitney test. (c) 
Expression of F4/80 and MHCII on donor RMacZ10 (n=6), IMacZ10 (n=8) and 
host (n=14) myeloid cells 8 days after transfer. ****p<0.0001 determined by 
two-way ANOVA and post hoc Tukey test (d)  GATA6 MFI on indicated donor 
populations 8 days after transfer. On the bottom, GATA6 MFI on equivalent 
host macrophage subsets identified on the basis of F4/80 and MHCII as 
indicated.  (e) Proportion of donor RMacZ10(n=4), IMacZ10 (n=5) that express 
GATA6 and normalized levels of GATA6 MFI. (f) Proportion of host 
macrophage subsets that express GATA6 11 days after zymosan treatment (8 
days after cell transfer; n=9) ****p<0.0001 determined by one-way ANOVA 
with Tukey’s multiple comparisons test. (g) Proportion of donor RMacZ10(n=7) 
and IMacZ10(n=8) that are CD102+/Tim4+ 8 days after transfer. ****p<0.0001 
determined by one-way ANOVA and Sidak’s multiple comparisons test. Data 
shown as mean ± standard deviation. Each symbol represents an individual 





Figure 4.2 Inflammatory macrophages survive following transfer into  
naïve recipients. 
(a) Experimental outline for IP delivery of CD45.2+ RMacZ10 or IMacZ10 into 
naive CD45.1/2+ recipient mice. (b) Proportion of CD11B+ Lineage- cells that 
are donor (RMacZ10 in blue; IMacZ10 in orange) 8 days post transfer. To the 
right, engraftment efficiency of transferred RMacZ10 (n=7) and IMacZ10 (n=7) 8 
days following transfer. (c) Expression of F4/80 and MHCII on donor RMacZ10 
(n=7), IMacZ10 (n=7) or host (n=14) lineage- cells 8 days following transfer. 
.****p<0.0001 determined by two-way ANOVA and post hoc Tukey test (d) 
GATA6 MFI on donor populations 8 days after transfer. (e) Proportion of donor 
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RMacZ10 (n=4) and IMacZ10 (n=5) that express GATA6 and GATA6 MFI 8 days 
post transfer. ****p<0.0001 determined by student’s t test. (f) Donor 
RMacZ10(n=7) and IMacZ10(n=7) that express CD102/ Tim4+ 8 days after 
transfer. ****p<0.0001 determined by one-way ANOVA and Sidak’s multiple 
comparisons test. Data shown as mean ± standard deviation. Each symbol 









Figure 4.3 Inflammatory macrophages expand and undergo phenotypic 
conversion following transfer into clodronate-depleted recipients.  
(a) Experimental outline for IP delivery of donor CD45.2+ RMacZ10 or IMacZ10 
into clodronate liposomes pre-treated CD45.1/2+ recipient mice. (b) Proportion 
of CD11B+ Lineage- cells that are of donor origin (RMacZ10 in blue; IMacZ10 in 
orange) 8 days after transfer. To the right, engraftment efficiency of donor 
RMacZ10 (n=8) and IMacZ10 (n=6) 8 days post-transfer. (c) F4/80 and MHCII 
expression on donor RMacZ10 (RMacZ10 n=8), IMacZ10 (n=6) or host (n=14) 
lineage- cells 8 days after transfer. ****p<0.0001 determined by two-way 
ANOVA and post hoc Tukey test. (d) GATA6 expression levels on indicated 
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donor populations 8 days post transfer. (e) Donor RMacZ10 (n=6) and IMacZ10 
(n=5) that express GATA6 and GATA6 MFI 8 days after transfer. ****p<0.0001 
determined by student’s t test. (f) Proportion of donor RMacZ10(n=8) and 
IMacZ10(n=6) that express CD102/Tim4 8 days after transfer. ****p<0.0001 
determined by one-way ANOVA and Sidak’s multiple comparisons test. Data 
shown as mean ± standard deviation. Each symbol represents an individual 





Figure 4.4 PKH26-PCL labelling does not impair proliferation. 
(a) Experimental outline for IP transfer of CD45.2+ RMac into clodronate pre-
treated CD45.1/2+ recipient mice. (b) Representative Tim4 antibody labelling 
and PKH26-PCL dye labelling on purified donor RMac prior to transfer. (c) 
Proportion of purified donor RMac (n=6) express Tim4+ or do not. To the right, 
MFI of PKH26-PCL on purified Tim4+ or Tim4- donor RMac (n=6) ****p<0.0001 
determined by paired student’s t test. (d) Representative Tim4 antibody 
staining on donor RMac 8 days after transfer into clodronate-depleted 
recipients. (e) Engraftment efficiency of transferred Tim4+ RMac and Tim4- 
RMac 8 days post-transfer into clodronate-depleted recipients(n=6). 
***p<0.001 determined by paired student’s t test. (f) PKH26-PCL MFI on donor 
Tim4+/Tim4-  RMac (n=6), 8 days post transfer **p<0.01 determined by paired 
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student’s t test. 
(g) Engraftment efficiency of F4/80HiGFP+ LPM transferred into C/EPB+/+ 
(n=4,2,3,2 for each timepoint respectively) or C/EPB-/- (n=4,2,2,2 for each 
timepoint respectively) recipient mice. Data adapted from Cain et al60 with 
permission from the authors. Data shown as mean ± standard deviation. Each 






Figure 4.5 Inflammatory macrophages infiltrate the clodronate-depleted 
Omentum. 
(a)  Representative gating strategy to identify macrophages and monocytes in 
the omentum. (b) Identification of CD451-CD45.2+donor IMacZ10 within the 
indicated populations of omental myeloid cells. (c) Proportion of omentum 
macrophages or monocytes that are donor, 8 days after transfer of RMacZ10 or 
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IMacZ10 into inflamed (left, n= 4,5) or naïve recipients (right, n=5,5) 8 days prior. 
(d) Proportion of omentum macrophages that express Tim4, in naïve mice 
(n=4), or mice pre-treated with clodronate liposomes (n=3), 15 days prior. 
**p<0.01 determined by student’s t test. (e) Identification of donor IMacZ10 
within the  indicated populations of omental myeloid cells. (f) Proportion of 
omentum macrophages or monocytes that are of donor origin 8 days after 
transfer of RMacZ10(n=6) or IMacZ10(n=4) into depleted recipients. **p<0.01 
determined by two way ANOVA followed by Sidak’s multiple comparisons test. 
(g) Proportion of RMacZ10 (n=6) or IMacZ10 (n=4) present in the omentum 8 
days post transfer into depleted recipient that are CD102+ MHCIIInt . *p<0.05 
determined by student’s t test. (h) Proportion of omentum macrophages or 
monocytes that are of donor origin 8 days after transfer of naïve RMac (n=6) 
or IMacZ10(n=5) **p<0.01 determined by student’s t (i)  Combined datasets 
presented in (f) and (h) indicating the proportion of omentum macrophages or 
monocytes that are of donor origin, 8 days after transfer of RMac (n=12, RMac 
in black, RMAcZ10 in blue) or IMacZ10(n=10), into depleted recipients. Statistical 
significance determined by student’s t test. Data shown as mean ± standard 
deviation. Each symbol represents an individual animal. Data were pooled 






Figure 4.6 Inflammatory macrophages are retinoic-acid and omentum 
factor responsive. 
(a) Experimental outline for isolation of complete peritoneal exudate cells 11 
days after zymosan treatment, followed by adherence purification and 
treatment as indicated. (b) Proportion of adhered macrophages that express 
CD102 and Tim4 , 24 hours after culture in media supplemented with control-
media (n=8), omentum factors (n=4), ATRA (n=8) or omentum factors and 
ATRA (n=4). (c) F4/80 MFI on indicated macrophage subsets after 24 hours 
culture in media supplemented with indicated treatment. **p<0.01 determined 
by one way ANOVA and Dunnet’s multiple comparisons test for each subset 
individually, followed by Bonferroni adjustment. (d) Proportion of macrophage 
subsets that express MHCII after 24 hours of culture with indicated treatment. 
**p<0.01 determined by one way ANOVA and Dunnet’s multiple comparisons 
test for each subset individually, followed by Bonferroni adjustment. Data 
shown as mean ± standard deviation. Each symbol represents an individual 
 137 
animal per culture-condition. Data were pooled from 2 independent 
experiments except.  
 
 
Figure 4.7 Oil-elicited inflammatory macrophages are retinoic-acid 
responsive.  
(a) Experimental outline for IP delivery of purified (For gating see Figure 3.6a) 
CD45.2+ RMacZ10 or IMacZ10 into equivalent inflamed CD45.1/2+ recipient 
mice, followed by ATRA or vehicle treatment every other day, as indicated. (b) 
Proportion of myeloid CD11B+ Lineage- cells that are donor, after transfer of 
RMacZ10 or IMacZ10 followed by indicated treatment. (c) Absolute number of 
neutrophils present after adoptive transfer followed by vehicle (n=5) or ATRA 
treatment (n=6). Datapoints in orange are IMacZ10 recipients, datapoints in blue 
are RMacZ10 recipient mice. **p<0.01 determined by student’s t test. 
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(d) Representative expression of GATA6 and F4/80 by host CD11B+ Lineage- 
cells after adoptive transfer followed by indicated treatment. (e) Absolute 
number of GATA6Hi, GATA6Int and GATA6Neg macrophages after adoptive 
transfer followed by vehicle (n=5) or ATRA treatment (n=6). Datapoints in 
orange are IMacZ10 recipients, datapoints in blue are RMacZ10 recipient mice. 
*p<0.05 **p<0.01 determined by student’s t test. (f) Proportion of host 
GATA6Hi, GATA6Int and GATA6Lo macrophages that are MHCII+ after adoptive 
transfer followed by vehicle (n=5) or ATRA treatment (n=6). Datapoints in 
orange are IMacZ10 recipients, datapoints in blue are RMacZ10. Data shown as 




Figure 4.8 Inflammatory appear to expand and downregulate MHCII, 
following transfer into FIRE-/- recipients. 
(a) Experimental outline for IP delivery of CD115+ RMacZ10 or CD115+ IMacZ10 
sourced from FIRE+/- or FIRE+/+ donors into macrophage deplete FIRE-/- 
recipient mice. (b) Representative expression of F4/80 and CD115 and 
PKH26-PCL labelling, 8 days post transfer of indicated populations. (c) 
Absolute number of CD11B+Lineage- myeloid cells 8 days post transfer of 
indicated cell populations. (d) Proportion of F4/80Hi macrophages that are 
Ki67+ 8 days post transfer of the indicated cell populations. Statistical 
significance determined by student’s t test. (e) Proportion of F4/80Hi 
macrophages that are MHCII+ 8 days post transfer of the indicated cell 
populations. Each symbol represents an individual animal. Data were pooled 




Figure 4.9 Macrophage subsets migrate into the omentum following 
transfer into FIRE-/- recipients. 
(a) Representative gating strategy to identify macrophages and monocytes in 
the omentum. (b) Proportion of live cells that are omental CD11B+Lineage- 
myeloid cells, 8 days post transfer of indicated cell populations. (c) Proportion 
of omental CD11B+Lineage- myeloid cells that are macrophages (F4/80+ or 
CD102+), 8 days post transfer of indicated cell populations.(d) Proportion of 
omental macrophages that are Ki67+,8 days post transfer of indicated cell 
populations. (e) Proportion of omental CD102-F4/80- myeloid cells that are 
Ki67+, 8 days post transfer of indicated cell populations. Statistical significance 
determined by student’s t test. Each symbol represents an individual animal. 
Data were pooled from 3 independent experiments; each symbol denotes an 












Examining long-term survival and identity of inflammatory 





Having found that inflammatory macrophages persisted immediately following 
resolution the question arose whether these cells were long-lived and would 
persist long-term. Observations published by Yona et et al suggest that after 
thioglycolate induced peritonitis the proportion of monocyte-derived 
macrophages in the cavity seemingly peaks 3 weeks after the inflammatory 
event28. Conversely, using a dye labeling methodology Newson et al indicated 
that monocyte derived cells present shortly after zymosan-induced peritonitis 
largely persisted up until 8 weeks111. Neither of these studies carried out an in-
depth analysis to determine to what degree monocyte-derived macrophages 
recruited during the inflammatory event persisted long-term and to determine 
their phenotypic identity. The most detailed analysis of monocyte-derived 
macrophage phenotype post-inflammation comes from work by Gundra et 
al145. Using transgenic Cx3cr1CreERT2-IRES-EYFP mice to track infiltrating 
monocytes they showed that monocytes recruited after thioglycolate-induced 
peritonitis and treatment with IL-4 are characterized by an F4/80Int CD206+PD-
L2+MHCIIHi phenotype 4 weeks after the inflammatory event. By week 8 these 
cells had upregulated F4/80 and downregulated the latter 3 markers, 
seemingly adopting a more resident like phenotype. However, due to the co-
treatment with IL-4 it is hard to understand to what degree these findings are 
representative of ‘normal’ resolution of peritonitis without Il4 co-treatment. 
 
Hence, in this chapter I set out to investigate if inflammatory macrophages 
present during resolution persist in the succeeding 8 weeks and whether they 
adopt a more resident F4/80Hi MHCIILo phenotype in this time. If these cells did 
persist, I sought to ascertain whether this phenotypic conversion is indicative 
of a greater transcriptional integration into the resident macrophage 
population. Moreover, I set out to investigate if, similar to the short-term 
experiments in chapter 4, competition with incumbent resident macrophages 
inhibits inflammatory macrophage conversion. 
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5.2 Inflammatory macrophages persist long-term and remain 
phenotypically distinct. 
 
I first set out to investigate if transferred IMacZ10 and RMacZ10 persisted until 8 
weeks post-inflammation. However, I adapted the basic adoptive transfer 
methodology to include an additional group where I sourced RMac from naïve 
donor mice and transferred them into naïve recipient mice (Figure 5.1a) to 
ascertain if survival and phenotype of resident macrophages is altered after 
undergoing an inflammatory event. Moreover, to increase the chance of 
sourcing sufficient donor cells for more in depth transcriptional analysis I 
increased the number of transferred cells from 100,000, as used in the short-
term experiments, to 200,000. 
 
By 8 weeks post-transfer into equivalently inflamed recipients, all 3 donor 
populations had persisted with an engraftment efficiency of approximately 35% 
(Figure 5.1b). However, retrospective pooling of all the datapoints I generated 
for this time-point indicated that RMacZ10 persisted marginally more readily 
than IMacZ10  (Figure 5.1c), similar to the 8 day time-point (Figure 4.1b). By 
week 8, IMacZ10 had seemingly adopted an F4/80Hi MHICIILo phenotype and 
could not readily be distinguished on the basis of these markers from 
RMacZ10(Figure 5.1d). However, IMacZ10 retained higher levels of MHCII and 
slightly lower levels of F4/80 even at this time point (Figure 5.1e). Similar to 
the earlier time point, IMacZ10 expressed were almost universally CD102+ 
(Figure 5.1f). Moreover, the expression of GATA6 was strikingly similar to that 
observed at the 8 day timepoint, in that ImacZ10 were almost exclusively 
positive for GATA6, but their overall expression level was lower than that of 
RMacZ10 (Figure 5.1g). 
 
During these experiments I found that, on average, only about 70% of the 
transferred RMacZ10 had retained PKH26-PCL labelling, while some host 
macrophages had acquired detectable levels of PKH26-PCL labelling (Figure 
5.1h). These findings emphasize that PKH26-PCL labelling should not be used 
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for long-term lineage tracing studies and that care should be taken when 
interpreting results from studies using this methodology for long-term studies. 
 
In these experiments, 2 out of 11 RMacZ10 recipient samples had very few 
donor cells present. This is likely due to incomplete IP injection, but as some 
residual dye was present these samples were not excluded from analysis. 
 
5.3 Persistent inflammatory macrophages remain transcriptionally 
distinct  
 
To investigate if this apparent phenotypic conversion was indicative of a 
greater transcriptional conversion into a resident identity, I re-purified donor 
RMac, RMacZ10 and IMacZ10 after 8 weeks and investigated their 
transcriptome, using a Nanostring mouse myeloid panel. Using this analysis, I 
found that of the 372 genes that were detected, none were differentially 
expressed between RMac and RMacZ10. However, approximately a fifth of all 
detected genes (78), were differentially expressed between RMacZ10 and 
IMacZ10 (adjusted p value <0.05) (Figure 5.2a). Moreover, of the 13 genes 
included in the Nanostring panel considered unique to peritoneal tissue-
resident macrophages 11 were differentially expressed (Figure 5.2b). 
Although the Nanostring panel only assessed a relatively small set of genes, 
these data indicate that historic inflammation does not alter the transcriptional 
profile of enduring resident macrophages. Moreover, these data indicated that 
persistent inflammatory macrophages largely fail to adopt a resident 
macrophage transcriptional profile.  
 
5.3.1 Transcriptional identity of inflammatory macrophages is partially 
due to impaired capacity to acquire retinoic acid. 
Gene expression analysis using Nanostring indicated that GATA6 was 
differentially expressed between IMacZ10 and RMacZ10 (Figure 5.2b), but that 
the change was relatively small (Log2FC -0.7). This pattern resembled my 
earlier findings indicating that IMacZ10 were largely GATA6+, but expression 
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was somewhat lower than on RMacZ10 (Figure 5.1g). As GATA6 is thought to 
regulate a significant portion of peritoneal macrophage genes63-65, I postulated 
that part of the altered gene signature of IMacZ10 could be due to lower 
expression levels of GATA6. Using the three published datasets that 
investigated transcriptional changes in GATA6KO LPM compared to GATA6WT 
LPM, I generated a gene list of GATA6 regulated genes. Genes were 
considered GATA6 regulated if they were differentially expressed (adj p 
value<0.05) in at least 2 of the published datasets. This list was split on genes 
upregulated and downregulated in GATA6KO LPM. I then used GSEA analysis 
to investigate if GATA6-regulated genes were enriched within the Nanostring 
dataset. Indeed, genes upregulated in GATA6KO LPM were positively enriched 
in IMacZ10, whereas genes downregulated in GATA6KO LPM were negatively 
enriched (Figure 5.3a).  
 
Retinoic-acid is thought to be an important driver of GATA6 expression. 
Indeed, in Chapter 4 I had found that retinoic-acid treatment appeared to drive 
expression of the GATA6 responsive gene F4/80 in vitro and GATA6 in vivo. 
Retinoic acid signaling is thought to take place, in part, via retinoic X receptor 
(RXRs)98. In the peritoneal cavity macrophages exclusively express RXRa and 
RXRb. Indeed, in macrophage-specific RXRaKO-RXRb KO (RXRAB-/-) mice, the 
peritoneal macrophage compartment is radically altered98. Notably, there is a 
loss of LPM and a concurrent increase in SPM98. This contrasts with the 
phenotype of GATA6KO mice, which have reduced number of ‘LPM like’ cells 
that exhibit altered expression of approximate 40% of LPM-specific genes, and 
normal numbers of SPM63-65. Hence, complete lack of GATA6 appears to 
affect LPM survival and phenotype more severely than a lack retinoic-acid 
signaling. Indeed, the transcriptional profile of the few LPM that remained in 
RXRABKO mice did not fully overlap with that of GATA6KO LPM, suggesting 
that RXRa/RXRb signaling affects gene expression independently of GATA6 
as well as via GATA698. Hence, to investigate if GATA6-independent RXR 
signaling could also be dictating part of the IMacZ10 gene signature, I re-
analyzed the dataset published by Casanova-Acebes98, comparing the 
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transcriptional profile of RXRABWT versus RXRABKO LPM. I then selected only 
differentially expressed genes that are not GATA6 regulated, using the gene 
list of GATA-6 dependent genes I had generated. This analysis generated a 
list of genes, expression of which, is RXRa/RXRb-responsive, but independent 
of GATA6. I then used GSEA analysis to investigate if these RXRa/RXRb-
regulated genes were enriched in the Nanostring dataset. Indeed, genes 
upregulated in RXRABKO LPM were positively enriched in IMacZ10, but genes 
that were downregulated RXRABKO were not negatively enriched (Figure 
5.3b).  
 
By combining the analysis of GATA6KO and RXRABKO LPM it became 
apparent that of the 72 genes differentially expressed between RMacZ10 and 
IMacZ10, almost half are thought to be regulated by retinoic-acid either via 
GATA6 (19 genes, 24%) or via RXRAB signaling independent of GATA6 (14 
genes 18%) (Figure 5.3c). Indeed, the expression pattern observed between 
RMacZ10 and IMacZ10 overlapped almost completely with the pattern between 
WT and GATA6KO or RXRABKO LPM with the exception of Marco, Serpinb6a 
(GATA6-regulated) and Ctsl (RXRAB-regulated) (Figure 5.3c).  
 
 
5.3.2 Transcriptional profile of inflammatory macrophages resembles 
that of steady state monocyte-derived macrophages 
Around this point in my PhD, I was involved in another research project in the 
laboratory, aiming to understand the sex dimorphism between male and 
female peritoneal macrophages. For this project I purified the complete 
CD11B+ Lineage- myeloid compartment from the peritoneal cavity of male and 
female mice and these were analyzed using 10x single cell sequencing. These 
data have been published and I will be referring to the published dataset as I 
did not carry out this analysis myself. 
 
Our single cell analysis indicated that in both male and females F4/80Hi 
MHCIILo LPM comprised 3 distinct clusters97. The largest of these clusters 
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consisted predominantly of embryonically seeded resident macrophages, 
whereas the two remaining clusters comprised predominantly of monocyte-
derived resident macrophages, as determined by subsequent fate-mapping 
experiments97. I postulated that the transcriptional profile of IMacZ10 might not 
be unique, but might overlap with the signature of monocyte-derived resident 
macrophages present under uninflamed steady state conditions. Hence, I 
investigated if the 78 genes that delineated IMacZ10 from RMacZ10 (Figure 
5.2a) overlapped with cluster genes unique to each of the single cell clusters. 
This analysis indicated that the gene profile of IMacZ10 overlapped 
considerably with cluster 3, that comprised the most recently monocyte-
derived LPM present in the naïve female cavity (most notably genes related to 
MHCII presentation) (Figure 5.4a). 
 
As the IMacZ10 signature appeared to be regulated by retinoic-acid (Figure 
5.3c), I quantified what proportion of cluster markers from steady-state LPM 
overlapped with GATA6 or RXRAB-regulated genes. Indeed, the cluster genes 
that identified monocyte derived LPM (cluster 3) showed considerable overlap 
with genes upregulated in GATA6KO LPM compared to GATA6WT LPM (e.g. 
Folr2, Mrc1), but less with genes upregulated in RXRABKO LPM compared to 
RXRABWT (Figure 5.4b). Conversely, the cluster genes that identified 
embryonically seeded LPM (Cluster 5) overlapped considerably with genes 
upregulated in GATA6WT LPM compared to GATA6KO LPM (e.g. Serpinb2, 
ApoC1) (Figure 5.4b). Similarly these cluster genes overlapped with genes 
upregulated in RXRABWT LPM compared to RXRABKO LPM (e.g. Gata6 and 
C4b)(Figure 5.4b). Combined these analyses indicate that under homeostatic 
conditions approximately 65% of the genes that define embryonic LPM from 
recently recruited monocyte-derived LPM are responsive to retinoic-acid either 
via GATA6 or independently of GATA6 and their expression profile suggests 
effective uptake of retinoic-acid. Conversely, approximately 30% of the genes 
that define monocyte-derived LPM are retinoic acid responsive, almost 
exclusively via GATA6 and their profile would suggest less effective uptake of 
retinoic-acid by these cells. 
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In summary, persistent inflammatory macrophages retain a unique 
transcriptional profile, that delineates them from RMacZ10 and which resembles 
monocyte-derived LPM present under naïve homeostatic conditions. 
Furthermore, it would appear that lower expression levels of GATA6 
significantly impact the transcriptional profile of both IMacZ10 and steady state 
monocyte-derived LPM. 
 
5.4 Long-term competition with incumbent resident macrophage 
inhibits inflammatory macrophage conversion.  
 
By day 8, the failure of inflammatory macrophages to downregulate MHCII and 
upregulate F4/80 was in part due to the presence of incumbent resident 
macrophages. Similarly, by week 8 IMacZ10 in their native competitive 
environment failed to completely adopt an F/80Hi MHCIILo resident phenotype. 
This failure to undergo phenotypic conversion coincided with a failure to adopt 
a transcriptional resident profile. To investigate whether this long-term failure 
to convert was also due to the presence of competing resident macrophages 
RMac, RMacZ10 or IMacZ10 were adoptively transferred into clodronate-
depleted recipients and investigated 8 weeks post-transfer (Figure 5.5a). 
 
Similar to the 8-day time-point data, transferred IMacZ10 had expanded 
considerably with an engraftment efficiency of approximately 300% (Figure 
5.5b). Indeed, the similarity between the expansion after 8 days and 8 weeks 
suggests that the proliferative event occurred shortly after transfer and does 
not affect IMacZ10 survival long-term. Similar earlier experiments investigating 
the phenotype of IMacZ10 after 8 weeks in their native environment (Figure 
5.1d) IMacZ10 could not readily distinguished on the basis of F4/80 and MHCII 
(Figure 5.5c). However, contrary to their phenotype in the native environment 
at this time, IMacZ10 expressed similar levels of MHCII and F4/80 and as 
RMacZ10 (Figure 5.5d). Similar to the native environment IMacZ10 were almost 
universally CD102+ (Figure 5.5e).  Moreover, GATA6, which, in the native 
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environment was responsible for part of the unique IMacZ10 signature, was 
expressed at equal levels by IMacZ10 to their resident macrophage 
counterparts (Figure 5.5f). Hence, the impaired capacity of IMacZ10 to acquire 
GATA6 driving signals, like retinoic-acid, is likely due to the presence of 
competing resident macrophages.  
 
In these experiments in 3 out of 11 IMacZ10 and 2 out of 12 for both RMac and 
RMacZ10 samples were excluded due to incomplete depletion or complete 
absence of donor cells. 
 
5.5 Inflammatory macrophages adopt a resident transcriptional identity 
following transfer into clodronate-depleted recipients. 
 
Using the same methodology as described in section 5.3, I re-purified donor 
RMac, RMacZ10 and IMacZ10 8 weeks after transfer into depleted recipients and 
investigated their transcriptome using a Nanostring mouse myeloid panel. This 
analysis identified no transcriptional differences between RMac and RMacZ10, 
but indicated that IMacZ10 adopted a more resident-like transcriptome, with 
expression of only 8 genes differentiating between RMacZ10 and 
IMacZ10(adjusted p value <0.05) (Figure 5.6a). By overlapping the IMacZ10 
gene signature in their native environment (Figure 5.2a) and the depleted 
environment (Figure 5.6a) genes could be divided into:   
 
1) Environment-regulated genes, some of which are responsive to competitive 
pressure. These are genes that were differentiated IMacZ10 in their native 
environment, but not in the depleted environment (Figure 5.6b, blue).  
 
2) Cell-intrinsically-regulated genes, that appear to be unresponsive to 
environmental cues and competitive pressure. These are genes that 
differentiated IMacZ10 in both their native and the depleted environments 
(Figure 5.6b, red).  
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The majority of the IMacZ10 transcriptional signature (71) consisted of 
environment regulated genes including Gata6, the GATA6 and RXR-regulated 
genes, and genes related to MHCII function. However, a small part of the 
IMacZ10 signature consisted of genes that appear to be cell-intrinsically 
regulated, including Timd4 (encoding for Tim4), Sema4a and Marco. Finally, 
Ndufa7 was only differentially expressed between RMacZ10 and IMacZ10 in the 
depleted environment only. The change was relatively modest (log2FC -0.39) 
and likely an artefact of the artificially-depleted environment (Figure 5.6b).  
 
Another explanation for the observed effect was that in the depleted 
environment resident macrophages adopted a more inflammatory-like 
transcriptional profile and as a consequence the RMacZ10 and IMacZ10 
appeared more transcriptionally similar. This could be occurring as I previously 
found that the Tim4- monocyte-derived LPM fraction of RMac expanded more 
than their Tim4+ embryonically-seeded LPM counterparts 8 days after transfer 
into depleted recipient (Figure 4.4e). As the transfer experiments into native 
and depleted environment were not carried out at the same time, it was not 
possible to directly compare the transcriptional profile of RMac in their native 
and depleted environment. However, Galatro et al described a method to 
qualitatively asses transcriptional similarity between published datasets 
obtained at different times and using different techniques155. The 
corresponding author Prof. Eggen kindly provided me with additional details to 
replicate this methodology. Briefly, all the genes detected were ordered on 
mRNA expression level and each gene was assigned a percentile score based 
on their rank in the gene list. Then, for each gene a delta gene rank percentile 
was calculated (Percentile rank in native environment – Percentile rank in 
depleted environment). Hence, genes altered by the depleted environment 
would have a large delta gene rank percentile score indicating that their 
relative position in the native environment gene list differed from their relative 
position in the depleted environment gene list. Conversely, genes unaltered by 
the depleted environment would have a relatively small delta gene rank 
percentile score, indicating that their relative position in the genelist is similar 
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in the native environment and the depleted environment. This analysis 
indicated that transfer into depleted recipients had relatively little impact on the 
expression profile of either RMac or RmacZ10  populations, with only few genes 
changing their relative percentile by more than 5% whereas the gene profile of 
IMacZ10 was more profoundly affected (Figure 5.6c). 
 
5.6 Inflammatory macrophages remain phenotypically distinct following 
transfer into native or depleted recipients. 
 
At this stage, it had become apparent that by week 8, GATA6, F4/80 and 
MHCII protein expression by IMacZ10 was indeed dictated by environmental 
factors as suggested by the combined Nanostring and protein expression 
analysis. To validate additional genes that appeared environment-responsive 
and some that appeared to be cell-intrinsically regulated, I repeated the 
adoptive transfer of RMac, RMacZ10 and IMacZ10 into native or clodronate pre-
treated recipients and investigated expression after 8 weeks using flow 
cytometry. 
 
Consistent with divergent expression of Timd4, Sema4a, Sell and Ccr5 
identified using Nanostring, by week 8 IMacZ10 in their native environment 
expressed lower levels of Tim4 and higher levels of Sema4a, CD62L and 
CCR5 than either RMac population (Figure 5.7a, b). Moreover, after transfer 
into depleted recipients IMacZ10 expressed lower levels of Tim4 and higher 
levels of Sema4a and CD62L (Figure 5.7b), consistent with Nanostring 
findings indicating that expression is intrinsically regulated. Contrary, CCR5 
expression on IMacZ10 was highly variable and on the whole lower in the 
depleted environment such that it did not differ compared to either RMac 
population, consistent with Nanostring findings indicating that expression is 
regulated by environmental cues (Figure 5.7b).   
 
As the purification protocol takes a significant amount of time, it was 
challenging to carry out the transfer into the native and the depleted 
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environment side by side. Therefore, only one of the two experimental repeats 
contains both native and depleted recipients side by side. To confirm that 
indeed gene expression of these markers was not altered on RMac by the 
environment post transfer, as indicated by the ranking analysis (Figure 5.7c), 
I plotted separately the experiment where both native and depleted transfers 
were carried out side by side. Indeed, there was no indication that either of the 
RMac populations altered the expression of Tim4, Sema4a, CD62L or CCR5 
after transfer into depleted recipients (Figure 5.7c). Expression Tim4, Sem4a, 
CD62L on IMacZ10 appeared unaltered, again consistent with cell intrinsic 
regulation, but the CCR5 expression was noticeably lower, although this was 
not statistically significant after p value adjustment (Figure 5.7c). 
 
Since IMacZ10 appeared to transcriptionally resemble monocyte derived LPM 
present under homeostatic conditions (Figure 5.4), I validated some additional 
surface markers, known to be highly expressed by monocyte-derived LPM 
(Folate receptor B (FRb)) or embryonically-seeded LPM (CD209b and V-set 
immunoglobulin domain-containing 4 (VSIG4)) that were not included in the 
Nanostring panel97,170. The latter two of these are unlikely to be regulated by 
retinoic-acid as their expression was unaltered in GATA6KO and RXRABKO 
LPM63,98. Indeed, CD209b and VSIG4 were expressed by a subset of both 
RMac populations, but were largely absent on IMacZ10 irrespective of the 
recipient environment (Figure 5.7d). In contrast, IMacZ10 expressed high levels 
of FRb in their native environment, but expression was largely lost after 
transfer into depleted recipients, suggesting down-regulation by environmental 
cues consistent with negative regulation of Folr2 by GATA665.   
 
5.7 Inflammatory macrophages are long-lived and gradually acquire the 
resident identity. 
 
Next, to investigate if IMacZ10 persisted long-term and if more complete 
reprogramming might occur naturally over their lifespan, I tracked transferred 
RMac, RMacZ10 and IMacZ10 until 5 months post-inflammation in their native 
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environment. By 5 months IMacZ10 were still present in the peritoneal cavity, 
but their overall engraftment had decreased to approximately 20% down from 
30% at the 8-week timepoint (Figure 5.8a). Surprisingly at this timepoint naïve 
RMac seemingly engrafted equivalent to the 8-week timepoint (± 35% at week 
22 versus ±40% at week 8), whereas RMacZ10 also engrafted less well (±20% 
at week 22 versus ±40% at week 8) (Figure 5.8b). Even at this stage IMacZ10 
remained distinct with high expression of Sema4a and CCR5, although the 
latter had seemingly reduced compared to expression levels 8-week post 
transfer (±38% at week 22 versus ±70% at week 8) (Figure 5.8b). Moreover, 
IMacZ10 still expressed lower levels of GATA6, but the difference appeared less 
apparent than after 8 weeks (Figure 5.8c). Similarly, IMacZ10 did not express 
equivalently high levels of Tim4 and CD209b as their RMac counterparts, but 
expression of Tim4 appeared to have increased compared to 8 weeks (±55% 
at week 22 versus ±30% at week 8) (Figure 5.8). Moreover, after 5 months 
IMacZ10 expressed equivalent levels of MHCII, Frbb and VSIG4 as their RMac 
counterparts (Figure 5.8b,d). 
 
Combined these data indicate that IMacZ10 persist long-term and with time 
adopt a more resident-like phenotype by altering expression of both 




In this chapter I set out to answer three key questions of my PhD: 1) Do 
inflammatory macrophages present during resolution of peritonitis persist long-
term, despite the presence of competing resident macrophages and 2) to what 
extent can and do these cells adopt a resident identity and 3) which factors 
dictate inflammatory macrophage conversion into a resident identity. 
 
Briefly, in chapter 4 I investigated the phase directly following resolution when 
the macrophage compartment contracts to pre-inflammation size. During this 
phase inflammatory macrophages persisted and retained a unique F4/80Int 
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MHCIIHi phenotype. This was largely due to competition with incumbent 
resident macrophages as inflammatory macrophages adopted a more 
resident-like phenotype after transfer into clodronate-depleted recipients. 
 
In this chapter I expanded on these findings by investigating the long-term 
survival and phenotype of inflammatory macrophages. Here I found that 
IMacZ10 that had persisted through this initial contraction phase largely 
survived long-term. Even after 8 weeks IMacZ10 retained lower levels of F4/80 
and GATA6 and relatively high levels of MHCII. This failure to adopt a resident 
phenotype proved indicative of a failure to adopt a resident transcriptional 
identity. Approximately 20% of the 372 genes detected by Nanostring 
transcriptional profiling differentiated IMacZ10 from their resident counterparts. 
Importantly, the number of genes investigated using Nanostring assay was 
relatively limited and hence this methodology is not detecting the full degree 
to which RMacZ10 and IMacZ10 are transcriptionally divergent. However, those 
genes that were included in the Nanostring panel are known regulators of 
myeloid biology and are likely to have a functional role. Hence, although the 
complete transcriptional divergence between RMacZ10 and IMacZ10 is unclear 
these data suggest these cells likely differ functionally from one another. In 
silico analysis indicated that approximately half of the differentially-expressed 
genes could be attributed to impaired retinoic-acid signalling either directly or 
indirectly via GATA6, suggesting that environmental retinoic acid strongly 
impacts IMacZ10 identity, consistent with my findings described in chapter 4. 
However, this in silico analysis compared the transcriptional profile of GATA6 
intermediate IMacZ10 to that of transgenic GATA6KO peritoneal macrophages. 
Although this analysis highlights a role for GATA6 in shaping the IMacZ10 gene 
signature it does not account for the possibility that part of the IMacZ10 gene 
signature could be driven by lower (but not absent) levels of transcription 
factors such as GATA6. Unfortunately, at present there are limited tools 
available to investigate how divergent levels of transcription factors, such as 
GATA6, affect gene expression.  
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Finally, the transcriptional profile of MacZ10 largely overlapped with monocyte-
derived LPM present under homeostatic conditions. Again, although the 
number of genes assessed was relatively limited, these data suggest that 
persistent inflammatory macrophages do not give rise to a wholly unique 
population of macrophages, but expands a numerically minor fraction of 
monocyte-derived LPM present under homeostatic conditions. Indeed, in silico 
analysis suggests that the identity of monocyte-derived LPM present under 
steady-state conditions appears to be largely due to impaired retinoic-acid 
signalling similar to the inflammatory macrophage signature.  
 
Throughout the experiments presented in chapter 4 and 5 it has become 
apparent that a subset of IMacZ10 did adopt a more resident-like phenotype. 
As these converted cells only represent a relatively minor population, I have 
chosen not to focus on these IMacZ10 that had seemingly adopted a more 
resident phenotype. Single cell transcriptional analysis of all IMacZ10 would 
have been very valuable to ascertain the degree to which this more resident-
like subset of IMacZ10 transcriptionally resembles resident macrophages and 
investigate which signals have established this resident-like identity.  
 
Similar to my findings at 8 days, by 8 weeks post-transfer into a macrophage-
depleted environment IMacZ10 had expanded considerably In this environment, 
IMacZ10 adopted a more F4/80Hi GATAHi MHCIILo resident phenotype and 
transcriptional identity with only 8 genes differentiating IMacZ10 from their 
resident counterparts. Using flow cytometry, I found that consistent with the 
Nanostring findings that IMacZ10 retained high expression of Sema4a, CCR5 
and Frb, the latter two of which were downregulated after transfer into depleted 
recipients. In contrast, IMacZ10 expressed marginal levels of Tim4, CD209B 
and VSIG4 and were unable to acquire these features even after transfer into 
depleted recipients. However, after 5 months in their native environment, 
IMacZ10 adopted a more resident-like phenotype, as indicated by lower 
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expression of MHCII, Frb and higher expression of VSIG4, indicating that 
gradual conversions occurs over time despite competitive pressure.  
 
Combined these data indicate that inflammatory macrophages persist long-
term and that their phenotype is a combination of: 1) Intrinsically regulated 
features retained over time and not reprogrammed by environmental signals 
(Sema4a), 2) Features that do not reprogram due to an inability to compete 
with RMacZ10 for environmental cues but are reprogrammed with time (MHCII, 
GATA6, CCR5, FRβ) and 3) Features related to time-of-residency irrespective 









Figure 5.1 Inflammatory macrophages persist long-term following 
zymosan-induced peritonitis. 
(a) Experimental outline for the transfer of donor RMac into naïve recipients or 
RMacZ10 and IMacZ10 into inflamed recipients. Populations gated as shown in 
Figure 3.6a (b) Engraftment efficiency of RMac, RMacZ10 and IMacZ10, 8 weeks 
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following transfer into mirroring recipient mice (left; n=13, n=9, n=9) (c) Pooled 
engraftment efficiency of RMacZ10 and IMacZ10 8 weeks following transfer 
inflamed recipients. Symbols denote independently carried out experiment. 
*p<0.05 determined by student’s t test. (d) Proportion of RMac, RMacZ10 and 
IMacZ10 that are F4/80Hi MHCIILo, after transfer into mirroring (n= 12,11,11) 
recipients. (e) RMac (n=13), RMacZ10 (n=11) and IMacZ10 (n=11) that express 
MHCII, 8 weeks following transfer into mirroring recipients. ***p<0.001 
determined by one-way ANOVA and Tukey’s multiple comparisons test. To the 
right. Expression of F4/80 on RMac , RMacZ10and IMacZ10, 8 weeks following  
transfer into mirroring recipients( n=12,11,11). MFI is normalized to mean 
F4/80 MFI of RMac. *p<0.05 determined by student’s t test. (f) Proportion of 
F4/80Hi MHCIILo: RMac, RMacZ10 or IMacZ10 that express CD102, 8 weeks 
following transfer into mirroring recipients (n= 12,11,11) 
(g)  GATA6 MFI on donor RMac, RMacZ10 or IMacZ10 8 weeks following transfer 
into mirroring recipients (n=12,11,11). ****p<0.0001 determined by one-way 
ANOVA and Tukey’s multiple comparisons test.(h) Proportion of  donor 
CD45.2+ F4/80Hi RMacZ10 and host CD45.1/2+ F4/80Hi macrophages that have 
been PKH26-PCL labelled,  8 weeks after transfer into inflamed recipients 
(n=8). Data shown as mean ± standard deviation. Each symbol represents an 






Figure 5.2 Inflammatory macrophages remain transcriptionally distinct. 
(a) Volcano plot indicating Log2Fold change (x-axis) and adjusted p-value (y-
axis) of IMacZ10 in gene expression relative to expression levels exhibited by 
RMacZ10, 8 weeks after transfer into inflamed recipients.  (b) Heatmap 
indicating normalized gene expression of peritoneal macrophage specific 
genes included on the Nanostring panel on indicated donor populations (top) 






Figure 5.3 The inflammatory macrophage gene-signature suggests 
impaired retinoic-acid signalling. 
(a) GSEA analysis of genes expressed by RMacZ10and IMacZ10,8 weeks 
following transfer into inflamed recipients, relative to genes up or 
downregulated in GATA6KO LPM (in reference to GATA6WT LPM). (b) GSEA 
analysis of genes expressed by RMacZ10and IMacZ10,8 weeks following 
transfer into inflamed recipients, relative to genes up or downregulated in 
RXRABKO LPM (in reference to RXRABWT LPM). (c) Proportion of differentially 
expressed genes between RMacZ10 and IMacZ10,8 weeks following transfer 
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into inflamed recipients, that are known to be regulated by GATA6 (green) or 
RXRAB (orange). The middle heatmaps denote the direction of gene-
expression of GATA6 and RXRAB-regulated genes between RMacZ10 and 
IMacZ10. Heatmap to the right denotes the direction of gene-expression of 
GATA6KO and RXRABKO LPM in reference to their WT counterparts. 
Transcriptional data for analysis of GATA6-regulated genes63-65 and RXRAB-
regulated genes98 was sourced from published work and analysed as 





Figure 5.4 The monocyte-derived macrophage gene signature suggests 
impaired retinoic-acid signalling. 
(a) Circus plot indicating genes that are differentially expressed between 
RMacZ10 and IMacZ10 (left side of the circus plot; genes more highly expressed 
by IMacZ10 in red, genes more highly expressed by RMacZ10 in blue) that are 
cluster-specific for subsets of peritoneal macrophages (right side of the circus 
plot), identified using single cell-sequencing. Single-cell data was sourced 
from published work by Bain et al97. (b) Cluster-genes that identify peritoneal 
macrophages of monocyte origin or embryonic origin which are regulated by 
GATA6 (green) or RXRAB (orange). To the right, direction of gene-expression 
for GATA6 and RXRAB regulated genes between GATA6KO or RXRABKO LPM 
relative to WT LPM. Transcriptional data for analysis of GATA6-regulated 
genes63-65 and RXRAB-regulated genes98 was sourced from published work 





Figure 5.5 Inflammatory macrophages transferred into macrophage-
deplete recipients adopt a resident phenotype. 
(a) Experimental outline for transfer of RMac, RMacZ10 and IMacZ10 (gated as 
shown in Figure 3.6a) into clodronate-depleted recipients. (b) Engraftment 
efficiency of RMac, RMacZ10and IMacZ10 8 weeks following transfer clodronate-
depleted recipients (left; n=10, n=10, n=8). **p<0.01 determined by one-way 
ANOVA and Tukey’s multiple comparisons test (c) Proportion of RMac, 
RMacZ10 and IMacZ10 that are F4/80Hi MHCIILo, 8 weeks after transfer into 
clodronate-depleted recipients (n= 12,11,11). (d) Proportion of  RMac (n=10) , 
RMacZ10 (n=10) and IMacZ10 (n=8) that express MHCII, 8 weeks following 
transfer into clodronate-depleted recipients. To the right. normalized F4/80 
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MFI on donor RMac , RMacZ10and IMacZ10, 8 weeks following transfer into 
clodronate-depleted recipients (n=10,10,8). MFI is normalized to mean F4/80 
MFI on RMac. (e) Proportion of F4/80Hi MHCIILo RMac, RMacZ10 or IMacZ10 
that express CD102, 8 weeks following transfer into clodronate-depleted 
recipients (n= 10,8,8). (g) GATA6 MFI on RMac, RMacZ10 or IMacZ10, 8 weeks 
following transfer into clodronate-depleted recipients (n= 10,8,8). Data shown 
as mean ± standard deviation. Each symbol represents an individual animal. 





Figure 5.6 Inflammatory macrophages adopt a resident identity 
following transfer into clodronate-depleted recipients. 
(a) Volcano plot indicating Log2Fold change (x-axis) and adjusted p-value (y-
axis) of IMacZ10 in gene expression relative to expression levels exhibited by 
RMacZ10, 8 weeks after transfer into clodronate-depleted recipients. (b) 
Number of genes that are differentially expressed between RMacZ10and 
IMacZ10  (adj p value <0.05), 8 weeks following transfer into native (left, in blue) 
or clodronate-depleted recipients (right, in red). (c) Changes to percentile rank 
(DGene rank percentile = Percentile rank in native environment – Percentile 
rank in clodronate-depleted environment) for each detected genes. Dashed 
lines indicate a percentile change of 5%. This analysis was adapted from 
Galatro et al155. 
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Figure 5.7 Inflammatory macrophages adopt a resident phenotype 
following transfer into clodronate-depleted recipients.  
(a)  Proportion of RMac (black), RMacZ10 or IMacZ10 that express Tim4, 
Sema4a, CD62L and CCR5, 8 weeks following transfer into native recipients. 
(b) Proportion of CD102+ RMac (black), RMacZ10 (blue) and IMacZ10 (orange) 
that express Tim4, Sema4a, CD62L and CCR5, 8 weeks following transfer into 
native (left; n=7,6,6) or clodronate-depleted recipients (right; n= 5, 5, 4). 
**p<0.01, **p<0.01 ***p<0.001 determined by one way ANOVA and Dunnet’s 
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multiple comparisons test for each marker separately, followed by Bonferroni 
adjustment. (c) Proportion of CD102+ or F4/80+ RMac (black) RMacZ10 (blue), 
IMacZ10 (orange) that express Tim4, Sema4a, CD62L and CCR5, 8 weeks 
following transfer into native (n=4,3,3) or clodronate-depleted recipients 
(n=2,3,2). This dataset is a subset of the datasets presented in (a) and (b) in 
which datapoints were shown shown as square symbols. In this experiment 
the adoptive transfer of RMac (black) RMacZ10 (blue), IMacZ10 (orange)  into 
native and into clodronate-depleted recipients was carried out in the same 
experiment and can therefore be directly compared. *p<0.05 determined by 
one way ANOVA and Dunnet’s multiple comparisons test for each marker 
separately, followed by Bonferroni adjustment. (d) Proportion of CD102+ or 
F4/80+ donor RMac, RMacZ10 or IMacZ10 that express CD209b, VSIG4 and Frb, 
8 weeks following transfer into native (n=4,3,3)  or clodronate-depleted 
recipients (n=2,3,2).  **p<0.01 determined by one-way Anova and Dunnet’s 
multiple comparisons test for each marker separately, followed by Bonferroni 
adjustment. Data shown as mean ± standard deviation. Each symbol 
represents an individual animal. Data were pooled from 2 independent 





Figure 5.8 Inflammatory macrophages persist until 5 months after 
inflammation and adopt a more resident-like phenotype. 
(a) Engraftment efficiency of RMac, RMacZ10 and IMacZ10, 5 months following 
transfer into inflamed recipients (n=4, 5, 5). *p<0.05 determined by one-way 
ANOVA and Tukey’s multiple comparisons test (b) Proportion of CD102+ 
RMac (black), RMacZ10 (blue) and IMacZ10 (orange) that express Tim4, Sema4, 
CD62L, CCR5 and MHCII, 5 months following transfer into inflamed (n=4, 5, 
5) recipients. **p<0.01 ***p<0.001 determined by one way ANOVA and 
Dunnet’s multiple comparisons test for each marker separately followed by 
Bonferroni adjustment. (c) GATA6 MFI on donor RMac, RMacZ10or IMacZ10   5 
months following transfer into inflamed recipients (n=4, 5, 5). *p<0.05 
determined by one-way ANOVA and Tukey’s multiple comparisons test (d) 
Proportion of CD102+ or F4/80+ donor RMac (black; n=4) RMacZ10 (blue; n=5), 
IMacZ10 (orange; n=5) that express CD209b, VSIG4 and Frb, 5 months 
following transfer into inflamed recipients.  **p<0.01 determined by one-way 
Anova and Dunnet’s multiple comparisons test for each marker separately, 
followed by Bonferroni adjustment. Data shown as mean ± standard deviation. 
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Each symbol represents an individual animal. Data were pooled from 2 





Investigating the long-term consequences of inflammatory 
macrophage integration.  
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6.1 Introduction  
 
In the previous chapter I found definitive evidence for long-term integration of 
phenotypically distinct inflammatory macrophages into the macrophage 
compartment after mild zymosan induced peritonitis. Persistent inflammatory 
macrophages largely lacked expression of numerous surface proteins 
important for internalization of pathogens, most notably the complement 
receptor VSIG4, shown to enhance internalization of complement-opsonized 
particles170 and the pattern recognition receptor CD209B, shown to play a role 
in peritoneal clearance of Streptococcus pneumoniae97,171. Hence, their 
phenotype alone would indicate that persistent inflammatory macrophages are 
likely to be functionally divergent from their resident counterparts upon 
stimulation. The only published data investigating the responsiveness of the 
peritoneal cavity after historic zymosan-induced peritonitis is work by Newson 
et al111. They found that neutrophil recruitment in response to IP injection of S. 
pneumoniae is dampened in mice pre-treated with zymosan 8 weeks prior. 
However, in this study they did not attribute the altered response to changes 
in functionality of peritoneal macrophages. 
 
These data raise the question whether the macrophages could be responsible 
for this dampened responsiveness, or if other peritoneal cells could be 
responsible for this phenomenon. In a subsequent study, Newson et al found 
that up to 21 days post-zymosan peritonitis infiltrating NK cells produce IFNg 
resulting in prostaglandin E2 production by myeloid cells and a reduced mouse 
sickness score after subsequent S. pneumoniae treatment120. These data 
highlight that inflammation indeed alters the peritoneal cavity responsiveness 
long-term and that various cells in the cavity could be functionally altered after 
a historic inflammatory event which may impact the response of the cavity as 
a whole. However, whether changes to the macrophage compartment found 
in my studies alter the functional profile of the macrophage compartment 
remains unclear.  
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In patients with decompensated cirrhosis two populations of macrophages 
have been characterized in the peritoneal cavity172,173. One population 
resembles large peritoneal macrophages and is characterized by high levels 
of VSIG4 and GATA6, whereas the other population largely lacks VSIG4 and 
expresses lower levels of GATA6 and higher levels of CCR5173 and seemingly 
resembles inflammatory macrophages found in my studies. This population of 
‘inflammatory-like’ macrophages was found to have lower granularity and less 
or equal phagocytic capacity as their resident counterparts172,173. Moreover, in 
response to in vitro LPS treatment ‘inflammatory-like’ macrophages produced 
less TNFa than their resident counterparts172 . Combined, these data not only 
suggest that inflammatory macrophage integration may be occurring in 
humans, but also that it is likely that inflammatory macrophage are indeed 
functionally distinct from their resident counterparts in response to 
inflammatory stimuli.  
 
However, inflammatory macrophages are likely functionally divergent under 
unstimulated steady state conditions. Indeed, Bain et al show that there is a 
degree of ontogeny-related functional heterogeneity in the murine resting 
steady state cavity. Tim4- monocyte-derived LPM are undergoing high levels 
of proliferation whereas established Tim4+ LPM proliferate less 42. Moreover, I 
found that inflammatory macrophages had the capacity to expand 
considerably and repopulate a depleted cavity, indicating a high degree of 
proliferative capacity.  Moreover, inflammatory macrophages appear to 
transcriptionally and phenotypically resemble the highly proliferative 
monocyte-derived LPM present under homeostatic conditions. Hence, it is 
likely that inflammatory macrophages could have similar heightened baseline 
proliferation compared to their resident counterparts. A key difference I found 
was that persistent inflammatory macrophages largely failed to acquire Tim4 
expression. Tim4 is expressed by the majority of resident macrophages and 
has been found to mediate immunologically silent uptake of apoptotic cells by 
LPM20,21, thus playing a key role in maintaining peritoneal homeostasis. 
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As discussed in the introduction, inflammation driven integration of monocytes 
into the macrophage compartment has been found to occur in various sites. 
The degree to which these integrated monocytes were able acquire a resident 
functionality appears to be tissue and stimulation dependent. In the majority of 
these studies monocyte integration occurred after almost complete loss of the 
resident macrophage populations. My studies indicated that competition with 
incumbent resident macrophages strongly inhibits the capacity of inflammatory 
macrophages to acquire a resident identity. Hence, I postulated that in this 
competitive context persistent inflammatory macrophages would remain 
functionally distinct.  
 
Moreover, the transcriptional and phenotypic identity resembles that of 
monocyte-derived LPM present under homeostatic conditions. Hence, it is 
likely that under steady state conditions functionally distinct macrophage 
subsets inhabit the peritoneal cavity and that following inflammation this 
functional heterogeneity is enhanced due to inflammatory macrophage 
integration.  
 
Hence in this chapter I set out to: 
• Ascertain the baseline proliferation levels of persistent inflammatory 
macrophages and their monocyte counterparts in the naïve and post-
zymosan cavity. 
• Investigate whether, similar to human peritoneal phagocytes, persistent 
inflammatory macrophages are less granular and less phagocytic than 
their resident counterparts. 
• Establish whether persistent inflammatory macrophages respond 
differently to resident macrophages to challenge with LPS, but similarly 
to monocyte-derived resident macrophages present in the naïve cavity. 
• Explore whether persistent inflammatory macrophages respond 
transcriptionally and functionally similar to their resident counterparts to 
LPS in vivo. To exclude confounding effects of changes to the 
peritoneal cavity following historic zymosan induced peritonitis, which 
 174 
could affect subsequent LPS responsiveness, purified resident or 
inflammatory macrophages were transferred into naïve recipients 
followed by LPS injection.  
 
6.2 Developing a marker-based gating strategy to identity inflammatory 
macrophages long-term. 
 
The most definitive method to identify persistent inflammatory macrophages 
was using the adoptive transfer methodology. However, a drawback of this 
method was that too few donor cells were present for functional studies in vitro. 
Hence, I first set out to develop a gating strategy to identify inflammatory 
macrophages long-term. As I had not found a marker unique to either resident 
or inflammatory macrophages, I opted to use the two most exclusive markers 
Tim4 and Sema4a I had identified after 8 weeks in prior experiments (Figure 
5.7b). 
 
Combined analysis of these markers on RMacZ10 and IMacZ10 8 weeks post-
transfer into native recipients identified 4 distinct quadrants. Whereas RMacZ10 
almost exclusively contributed to the Tim4+ Sema4aLo quadrant, IMacZ10 
largely contributed to the Tim4- Sema4aH quadrant (Figure 6.1a). Moreover 
within the host macrophage compartment there was a quantifiable loss of 
Tim4+ Sema4aLo macrophages, consistent with loss of resident macrophages 
and gain of Tim4- Sema4aHi macrophages in line with inflammatory 
macrophage integration 8 and 22 weeks post zymosan (Figure 6.1a,b). 
Importantly, in separate experiments performed without cell transfer or dye-
labelling, a similar loss of Tim4+ Sema4aLo macrophages and gain of Tim4- 
Sema4aHi inflammatory macrophages occurred following low-dose zymosan 
injection (Figure 6.1a,b) confirming that dye labelling nor adoptive cell 
transfers alter the composition of the macrophage compartment following 
zymosan-induced peritonitis. As inflammatory macrophage-derived 
macrophages resembled monocyte-derived macrophages present under 
homeostatic conditions I examined whether Tim4- Sema4aHi macrophages 
expressed higher levels of MHCII, which demarks resident macrophages of 
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recent monocyte origin42 . Indeed, in both naïve and zymosan-injected mice, 
the Tim4- Sema4aHi quadrant R3 expressed high levels of MHCII (Figure 
6.1c). Hence, I concluded that using this combination of markers the majority 
of inflammatory macrophage derived large peritoneal macrophages could be 
identified on the basis of their Tim4- Sema4aHi phenotype at least until 8 weeks 
post-zymosan injection (referred to as MoZ10-LPM) whereas in naïve mice 
Tim4- Sema4aHi cells largely correspond to large peritoneal macrophages of 
recent monocyte origin (referred to as Mo-LPM). In contrast Tim4+ Sema4aLo 
cells corresponded to incumbent resident large peritoneal macrophages in 
naïve (referred to as RM-LPM) and zymosan-treated mice (referred to as 
RMZ10-LPM) (Figure 6.1d).  
 
6.3 Heightened proliferation is a feature of monocyte-derived 
macrophages per se. 
 
As Bain et al42 previously described that Tim4- monocyte-derived LPM present 
under steady state conditions exhibit heightened proliferation, and since this 
population largely overlaps in phenotype with persistent inflammatory 
macrophages, I first set out to investigate whether Mo-LPM and MoZ10-LPM 
identified based on Tim4- Sema4a+ expression had higher baseline levels of 
proliferation as their resident counterparts. Indeed, in naïve mice Mo-LPM had 
significantly higher levels of proliferation than RM-LPM (Figure 6.2a,b) 
consistent with earlier work42, based on the proliferation marker Ki67. 
Moreover MoZ10-LPM similarly exhibited higher levels of baseline proliferation 
than RMZ10-LPM (Figure 6.2a,b) indicating that differentiation of monocytes 
under inflammatory conditions does not dictate their capacity to maintain 





6.4 Monocyte-derived macrophages are characterized by low 
granularity and phagocytic capacity.  
 
Human studies indicated that a subset of peritoneal cavity macrophages that 
resembled resident macrophages had discrete granularity and phagocytic 
capacity172. Hence, I set out to investigate these features and ascertain 
whether murine resident and monocyte-derived macrophages present long-
term following zymosan-induced peritonitis had similar heterogeneity. 
 
To examine granularity, RMZ10-LPM and MoZ10-LPM were purified 8 weeks 
post zymosan injection and stained using Haematoxylin and Eosin. MoZ10-LPM 
appeared to have less vacuoles and an overall less granular structure than 
RMZ10-LPM (Figure 6.3a), possibly indicative of impaired phagocytic capacity. 
Using flow cytometry, I confirmed that MoZ10-LPM and Mo-LPM had 
significantly lower side-scatter characteristics than their resident counterparts 
consistent with lower granularity (Figure 6.3b). To investigate if the contrasting 
morphology indeed reflected a difference in phagocytic capacity, peritoneal 
cells where cultured with pHrodo-labelled Escherichia coli particles. This 
analysis indicated that Tim4+ LPM mice phagocytosed significantly more 
Escherichia coli particles than Tim4- LPM (Figure 6.3c), irrespective of 
whether macrophages originated from naïve or 8-week post-zymosan treated 
mice. It should be noted that in these experiments incubating cells at 37oC for 
1 hour caused rapid acquisition of surface Sema4a by Tim4+ macrophages 
rendering this marker unusable. 
 
This difference in phagocytic potential prompted me to re-analyse my earlier 
short-term (8 day) adoptive transfer experiments, where naïve or inflamed 
recipient mice had received labelled RMacZ10. In these experiments I found an 
RMacZ10 engraftment efficiency of approximately 35%, indicating that 
approximately 65% of donor cells had disappeared and likely had died (Figure 
4.1b). As transferred RMacZ10 were labelled with PKH26-PCL, any 
phagocytosis of these cells by host macrophages would consequently lead to 
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acquisition of PKH26-PCL labelling. Hence, PKH26-PCL dye uptake by host 
cells could be utilized as indicator of phagocytic capacity. Consistent with my 
in vitro findings, Tim4+ host macrophages efficiently acquired PKH26-PCL by 
8 days following transfer of labelled RMacZ10 into naïve or zymosan-treated 
recipients, consistent with phagocytosis of dying donor cells, whereas Tim4- 
host macrophages did not (Figure 6.3d). Moreover, Tim4- host macrophages 
also failed to phagocytose dying cells after inflammation when the number of 
Tim4+ macrophages was reduced ,suggesting that Tim4+ macrophages are 
more efficiently phagocytosing dying cells even when their number is 
decreased (Figure 6.3e). Combined with my earlier findings indicating that 
free-floating PKH26-PCL dye particles were not phagocytosed more 
effectively by Tim4+ macrophages (Figure 4.4) these data indicate that under 
steady state conditions or between 3 to 11 days following zymosan injection, 
Tim4+ macrophages are more efficient at phagocytosing dying cells than their 
Tim4- counterparts.   
 
6.5 Altered cytokine production by monocyte-derived macrophages in 
response to LPS in vitro.  
 
Published work using human peritoneal macrophages found evidence for 
divergent cytokine production, most notably TNFa172, between those 
populations of human peritoneal macrophages that seemingly corresponded 
to resident and monocyte-derived LPM in my studies. To investigate this, I 
measured cytokine production by RMZ10-LPM and MoZ10-LPM in response to 
LPS. Briefly, for this assay 10.000 cells of the indicated populations were 
sorted on the basis of Tim4 and Sema4a. Importantly, RMZ10-LPM and MoZ10-
LPM purified this way had equivalent post-sort viability (Figure 6.4a). Cells 
were then allowed to adhere for 2 hours, after which the media was careful 
removed. Then, treatment medium containing LPS (1ng/ml) or vehicle control 
was added and cells were incubated for 14 hours. After, medium was collected 
and assessed for cytokine production using a LEGENDplex bead-based 
immunoassay (Figure 6.4a).   
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During trial experiments I had found that by culturing 10,000 macrophages with 
LPS in a total of 75µl of medium resulted in detectable levels of most analytes 
within range of the LEGENDplex assay. Ideally, 10,000 cells would have been 
sorted and treated without the additional adherence step. However, when 
sorting cells every purified cell is contained in a droplet of flow cytometry fluid 
(PBS) which, when sorting 10,000 cells, equated to a total volume of 50µl of 
flow cytometry fluid. Direct treatment in a total volume of 75µl would have 
resulted in a very diluted medium and adversely affected cell viability. Hence, 
I opted to include a cell adherence step. After the adherence the sort-medium 
mixture was gently removed and replaced with treatment medium.   
 
Purified RMZ10-LPM secreted significantly more CXCL1, TNFa CCL2, CCL5, 
Il1b, CXCL10, GM-CSF, Il10 and Il6 after treatment with LPS than following 
culture with vehicle alone (Figure 6.4b).  Similarly, with the exception of 
CXCL10, MoZ10-LPM also secreted these cytokines and chemokines in 
response to LPS (Figure 6.4b). Hence, I concluded that these LPS responsive 
cytokines/chemokines could be detected and measured after LPS treatment 
using this assay. It should be noted that both Il-12(p70)174 and IFNa,b,y175,176 
are known to be secreted by LPS-treated peritoneal macrophages in vitro but, 
were not detectable in this assay. Of note, both RMZ10-LPM and MoZ10-LPM 
produced high levels of Il6 in response to culture alone. After culture with LPS 
levels of this Il6 were above the detectable limit of the assay. Hence, Il6 was 
excluded from further analysis. 
 
When directly comparing supernatant levels of these LPS-driven cytokines 
between RMZ10-LPM and MoZ10-LPM, it became apparent that MoZ10-LPM 
produced significantly more Il10 and GM-CSF than RMZ10-LPM (Figure 
6.4c,left). Conversely MoZ10-LPM produced less CCL5, TNFa and CXCL10. 
Purified Mo-LPM sourced from naïve mice similarly secreted higher levels of 
Il-10 than their RM counterparts, but also secreted higher levels of Il1b (Figure 
6.4c, right). It should be noted that in both the analyses shown in Figure 6.4c, 
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cytokine levels produced in response to LPS were not normalized to baseline 
levels produced in control PBS treated cells. This was because Mo-LPM in 
naïve mice are so rare (Figure 6.1b) that sufficient cells could not be obtained 
to treat with PBS and LPS and consequently only LPS treatment was carried 
out. However, as post-zymosan MoZ10-LPM were much more abundant 
(Figure 6.1b) sufficient cells could be sourced to carry out both PBS and LPS 
treatment. This analysis indicated that baseline production for most LPS-
driven cytokines was equivalent between MoZ10-LPM and RMZ10-LPM (Figure 
6.4d). However, MoZ10-LPM did produce less CCL5, TNFa and more CXCL1 
than RMZ10-LPM (Figure 6.4d). For these 3 factors I confirmed that after 
normalization to PBS production levels MoZ10-LPM still produced less CCL5 
and TNFa in response to LPS and that the difference observed was not 
because of baseline differences in secretion (Figure 6.4e). 
 
Using a similar methodology, I then set out to investigate whether the response 
of resident or monocyte-derived macrophages to LPS was altered after historic 
zymosan-induced peritonitis. Of note, a different cytokine array was used 
because that included many analytes found to be differentially expressed 
between monocyte-derived and resident LPM, but also included some 
additional analytes not yet assessed. To source sufficient Mo-LPM from naïve 
mice for PBS and LPS treatment, Mo-LPM from different mice were purified 
for PBS and LPS treatment. Whereas RM-LPM and RMZ10-LPM had 
equivalent baseline production of all analytes, MoZ10-LPM produced somewhat 
less IL1b, IL6 and GM-CSF than Mo-LPM (Figure 6.5a). The decreased 
baseline production of IL1b might explain why previously I had found that Mo-
LPM produced more IL1b than RM-LPM, but MoZ10 -LPM did not appear to 
produce less than RMZ10-LPM (Figure 6.4c). For each analyte, levels detected 
in response to LPS were normalized to mean levels produced by 
corresponding populations in response to PBS to provide a measurement of 
LPS-induced cytokine production. In response to LPS, the cytokine profile of 
resident and monocyte-derived LPM sourced from the naïve or post-zymosan 
cavity was, except Il12, largely equivalent indicating that historic zymosan-
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induced peritonitis does not significantly alter the LPS responsiveness of either 
population (Figure 6.5b).  
 
  
6.6 Investigating monocyte-derived macrophage responsiveness in 
vivo 
 
Next, I wanted to investigate if the different responsiveness of MoZ10-LPM and 
RMZ10-LPM to LPS also occurred in vivo and if the presence of MoZ10-LPM 
would alter the responsiveness of the cavity as a whole. To examine this I 
purified Tim4 and Sema4a-defined RMZ10-LPM and MoZ10 LPM from mice 
treated 8 weeks prior with zymosan and then adoptively transferred 250,000 
of each population into naïve recipient mice (Figure 6.6a). Mice were left to 
recuperate for 2 days after cell transfer before receiving IP injection with 5µg 
LPS, a dose which was relatively low compared to similar studies by Li et al 
that used a higher dose (approximately 40µg) of the same LPS serotype 
(O111:B4) to induce systemic inflammation177. However, during trial 
experiments I had found that 5µg LPS already induced discomfort to the 
animals as indicated by hunched posture and squinted eyes following injection. 
As 5µg LPS induced quantifiable neutrophil recruitment I opted to use this 
comparatively low dose (Figure 6.6a) as to limit discomfort for experimental 
animals.  
 
2 Days post-LPS both donor populations were detectable, although MoZ10 LPM 
appeared to persist somewhat less well than RMZ10-LPM (Figure 6.6b). 
Irrespective, both donor populations accounted for approximately 5% of the 
complete F4/80Hi macrophage compartment (Figure 6.6b). Irrespective of cell 
transfer, injection of LPS caused rapid weight loss over the succeeding 8 hours 
(Figure 6.6c), indicative of systemic inflammation. Surprisingly, mice that had 
received either donor population recruited fewer neutrophils into the peritoneal 
cavity than mice that received no donor cells (PBS) (Figure 6.6d). This effect 
was surprising, given that donor populations accounted for only a minor 
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fraction of the macrophage compartment.   
 
6.6.1 Impaired TNFa production by monocyte-derived macrophages in 
vivo 
When performing this experiment, I carried out intracellular staining for TNFa  
and Il10, the production secretion of which, in vitro, differentiated MoZ10-LPM 
from their RM counterparts (Figure 6.4c). Unfortunately, Il10 staining is 
notoriously hard and, in my hands, proved very variable and could not be 
trusted. Intracellular TNFa was readily detectable and analysis indicated that 
a smaller portion of MoZ10-LPM produced TNFa  than RMZ10-LPM (Figure 
6.6e,f), consistent with the lower overall production of TNFa by MoZ10-LPM 
detected in vitro. However, those MoZ10-LPM that produced TNFa appeared 
to produce more TNFa on a per cell basis than RMZ10-LPM (Figure 6.6e,f, 
right). Moreover, a smaller proportion of MoZ10-LPM produced TNFa than 
F4/80Hi host macrophages in the same cavity, comprising predominantly of 
RM-LPM, whereas the proportion of RMZ10-LPM that produced TNFa  was 
similar to the corresponding F4/80Hi host macrophage population (Figure 
6.6g).  
 
During these experiments the peritoneal lavage fluid and serum were collected 
from treated mice. These samples were analysed for levels of Il1b, Il6, CCL2 
and TNFa by Dr. Georgia Perona Wright and Ms. Holly Webster. This analysis 
indicated that cell-transfer had no effect on the lavage or serum levels of these 
analytes (Figure 6.7a,b).  
 
6.6.2 Dampened transcriptional response by monocyte-derived 
macrophages   
To investigate whether the transcriptional signature of MoZ10-LPM was similar 
to RMZ10-LPM in response to LPS, I re-purified the donor cells 8 hours post 
LPS injection and investigated their transcriptome using a Nanostring Mouse 
inflammation panel. This analysis indicated that 38 out of 269 detected genes 
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differentiated between RMZ10-LPM and MoZ10 LPS. Importantly, because of the 
long sorting times required for this experiment I had not included mice that 
received either donor population and PBS vehicle instead of LPS in this 
experiment. Hence, a control PBS treated group to directly identify LPS-driven 
genes was missing from this experimental analysis. Hence, for the 
interpretation of this Nanostring dataset I carried out the following steps. By 
overlapping this geneset with my previous Nanostring dataset (presented in 
section 5.3) I found that 8 out of the 38 differentially expressed genes were not 
differentially expressed between RMacZ10 and IMacZ10 at baseline in the 
original dataset, but were differentially expressed between RMZ10-LPM and 
MoZ10-LPM post-stimulation with LPS (Figure 6.8ai). This indicates that 
differential expression of these genes was likely related to the LPS challenge. 
Conversely, 13 out of the 38 differentially expressed genes (e.g. genes related 
to MHCII presentation, Ccr5 and Marco) were differentially expressed between 
RMacZ10 and IMacZ10 ex vivo as well as between post-LPS RMZ10-LPM and 
MoZ10-LPM in this dataset (Figure 6.8aii) and consequently are likely related 
to baseline differences in gene expression in these cells rather than 
differences in response to the LPS challenge. Moreover, 5 out of the 38 
differentially expressed genes have been shown to LPS-responsive in 
peritoneal macrophages177 (Figure 6.8aiii) and expression differences are 
likely related to LPS treatment. For the remaining 12 differentially expressed 
genes it cannot be ascertained whether they differentially expressed between 
MoZ10-LPM and RMZ10-LPM in response to LPS or at baseline (Figure 6.8aiiii). 
 
For those differentially expressed genes likely to be driven by LPS stimulation 
(Figure 6.8ai&iii), expression by MoZ10-LPM was universally lower than 
RMZ10-LPM, suggestive of a dampened ability to respond to LPS. Notably, 
although expression of TLR4, the main LPS receptor178-180, was equivalent 
between the two populations, expression of CD14 and CD55 encoding 
accessory proteins was lower on MoZ10-LPM (Figure 6.8ai&iii).   
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I then generated a gene list, excluding those genes that were differentially 
expressed at baseline between RMacZ10 and IMacZ10. It should be noted that 
although the resulting list will include a number of genes differentially 
expressed prior to the inflammatory insult that were not included in the original 
Nanostring panel. GSEA analysis of this gene list compared to the gene 
ontology gene-sets available at the Molecular Signatures Database indicated 
possible negative enrichment in MoZ10-LPM for genes positively regulated in 
humoral response (FDR<0.25) (Figure 6.8b). Indeed MoZ10-LPM appeared to 
express lower levels of complement components C2,C1ra,C1qbp, but also low 
levels of CD55, thought to inhibit complement activation181. It should be noted 
that GSEA analysis includes all detected genes and identifies enriched genes 
on the basis of their relative difference in expression level between groups 
instead of based on a list of differentially- expressed gene. Consequently, 
GSEA identified some genes, potentially of interest (C1ra, C1qbp) that were 
not differentially expressed in the Nanostring analysis. With a Log2FC of -3.4 
CD55 was the most altered differentially expressed gene.  
 
Although only a single gene-set was enriched with an FDR<0.25, 17 gene-sets 
were potentially enriched with nominal p<0.05. GSEA analysis can be 
expanded upon by investigating if certain genes are overrepresented in all the 
potentially enriched gene-sets using leading edge analysis. These genes are 
more likely to be of biological relevance as their expression impacts multiple 
known pathways. This analysis indicated that lower expression of CD55 by 
MoZ10-LPM is likely to have biological implications as lower CD55 affected 6 
out of the 17 potentially differentially expressed gene-sets (Figure 6.8c). 
 
In summary, these data indicate that MoZ10-LPM are functionally distinct from 
RMZ10-LPM, as they produce less TNFa and have a distinct, seemingly 




In this chapter I set out to ascertain to what extent persistent inflammatory 
macrophages are functionally similar to their embryonically-seeded resident 
counterparts. Utilizing a combination of markers identified using the adoptive 
transfer methodology I developed a gating strategy to identify RMZ10-LPM 
(Tim4+ Sema4aLo) and Mo Z10-LPM (Tim4- Sema4aHi) after 8 weeks post-
injection of zymosan and the equivalent populations in naïve mice. Critically, 
this gating strategy allowed me to ascertain whether the functional profile of 
MoZ10-LPM resembles that of Mo-LPM, as their transcriptional and phenotypic 
identity overlaps, and how the functional profile of Mo-LPM and Mo Z10-LPM 
differs from their established resident counterparts. As discussed in the 
previous chapter this gating strategy does exclude the, numerically minor, 
population of IMacZ10 that did upregulate Tim4 and are more likely to have a 
resident-like functionality. Hence, in these studies the functional divergence 
between RMZ10-LPM and MoZ10-LPM and their naïve counterparts is potentially 
overestimated. 
 
Monocyte-derived LPM were more proliferative than their resident 
counterparts, irrespective of whether they had differentiated under steady-
state or inflammatory conditions. This was somewhat surprising as MoZ10-LPM 
accounted for a considerably larger population than found under naïve 
homeostatic conditions. These findings are consistent with earlier work from 
our lab  42, indicating that the Tim4- fraction of resident macrophages present 
in the naïve cavity is characterized by high baseline levels of proliferation. 
Hence, heightened proliferation appears to be a characteristic shared between 
MoZ10-LPM and Mo-LPM.  
 
In patients with decompensated cirrhosis two subsets of macrophages inhabit 
the peritoneal cavity172,173. These subsets appear to overlap with resident and 
monocyte-derived LPM in my experimental work. Consistent with the 
equivalent human population, Mo-LPM had less vacuoles and lower 
granularity indicative of lower phagocytic capacity. Moreover, Mo-LPM, 
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irrespective of their differentiation conditions, less readily phagocytosed 
Escherichia coli particles ex vivo similar to the equivalent human peritoneal 
macrophage subset173. Hence, murine monocyte-derived LPM appear to 
functionally mirror a subset of human peritoneal macrophages that after LPS 
stimulation in vitro produce a unique cocktail of cytokines. The decreased and 
increased secretion of TNFa and Il10 respectively by MoZ10-LPM compared to 
their resident counterparts seemingly indicates a more anti-inflammatory 
profile.  
 
Notably, in vitro assessment of cytokine production also revealed that Mo-LPM 
produced more Il1b than their RM-LPM counterparts, whilst the difference in 
Il1b secretion was only marginal between post-zymosan MoZ10-LPM and 
RMZ10-LPM. However, no difference in Il1b secretion could be detected when 
MoZ10-LPM and Mo-LPM, or RMZ10-LPM and RM-LPM were directly compared, 
in response to LPS. These finding questions the robustness of Il1b 
measurements or suggests any difference in production of this cytokine must 
be minor. Surprisingly, baseline production of Il1b, Il6 and GM-CSF was 
elevated in Mo-LPM compared to MoZ10-LPM although the difference was 
relatively small. Moreover, baseline cytokine production between RM-LPM and 
RMZ10-LPM was equivalent, although after LPS stimulation RMZ10-LPM 
seemingly produced more Il12-(p70). A possibly explanation for divergent 
cytokine production between monocyte-derived and resident macrophages 
sourced from naïve mice and their counterparts sourced from zymosan treated 
mice could be generation of innate immune memory in macrophages post-
zymosan. Indeed, in vitro studies indicated that, predominantly monocyte-
derived, macrophages present after thioglycolate-induced peritonitis are able 
to establish immune memory and can be sensitized to subsequent LPS 
stimulation in vitro by pre-treatment with purified b-glucan components but, 
surprisingly not by pre-treatment with zymosan A, despite consisting largely of 
b-glucans154. In vivo it has been found that microglia are able to establish 
immune memory after peripheral LPS challenge which is retained up to 6 
months, modulating responsiveness to neurophatologies182. Little is known 
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about how trained immunity may be influencing baseline production levels of 
inflammatory mediators. Further studies to what degree this may be occurring 
after peritonitis are needed. 
 
It should be noted that although my findings suggest that RM-LPM and RMZ10-
LPM and Mo-LPM and MoZ10-LPM resemble one another transcriptionally and 
functionally my studies are insufficient to definitively draw this conclusion. 
Future studies should investigate the complete transcriptional and epigenetic 
profile of these populations to definitively ascertain that these populations are 
indeed equivalent or if there are (subtle) differences between them. Indeed, it 
is possible that, having differentiated under inflammatory conditions, MoZ10-
LPM may carry epigenetic memory183 that differentiates them from their naïve 
Mo-LPM counterparts. 
 
Consistent with lower TNFa secretion by MoZ10-LPM in vitro they also 
appeared to produce less TNFa in vivo in response to LPS stimulation.  
However, those cells that did produce TNFa  appeared to produce higher 
levels than RMZ10-LPM. This discrepancy might explain why in Nanostring 
analysis of MoZ10-LPM and RMZ10-LPM stimulated in vivo with LPS, expression 
of Tnf was seemingly unaltered between these populations. Genes encoding 
for cytokines differentially secreted in vitro by MoZ10-LPM and RMZ10-LPM in 
response to LPS were either not differentially expressed (Il1b, Tnf, Ccl5, 
Cxcl10) or below the detection limit (Il10, Csf2) when examined by Nanostring 
in purified populations stimulated in vivo.  However, MoZ10-LPM did appear to 
express less Il6 in response to LPS stimulation consistent with a less 
inflammatory role, but this did not correspond with changes in peritoneal 
lavage or serum levels of Il6. Indeed, none of the cytokines assessed in the 
peritoneal lavage or the serum of treated mice (Il6, Il1b,Ccl2, TNFa) appeared 
to be altered, despite donor cells seemingly inhibiting neutrophil recruitment. 
A possible explanation for this phenomenon could be that by artificially 
increasing the number of phagocytes in the cavity LPS was more cleared and 
consequently, less neutrophils were recruited. Alternatively, dying transferred 
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cells could be altering the responsiveness of host macrophages to LPS 
stimulation. Due to time constraints, I did not carry out additional studies to 
exclude these possibilities. A potential follow-up experiment would be to 
adoptively transfer equivalent numbers of non-phagocytic peritoneal cells, 
such as T cells, into naïve mice followed by LPS stimulation to ascertain 
whether adoptive transfer of cells, irrespective of cell type, modulates LPS 
responsiveness If no changes are found, this would indicate that the altered 
neutrophil recruitment observed is due to an expanded phagocyte population. 
 
In summary, the data presented here indicate discrete LPS responsiveness of 
MoZ10-LPM compared to RMZ10-LPM in vitro and in vivo. These findings 
highlight that the impact MoZ10-LPM may have on the cavity as a whole during 
subsequent inflammatory stimuli remains unclear. 
 
On the whole the post-LPS transcriptional profile of MoZ10-LPM seemingly 
indicated an impaired ability to respond to LPS, as all LPS-driven gene 
differences were due to impaired expression by MoZ10-LPM. This was 
surprising as expression of TLR4 was equivalent between RMZ10-LPM and 
MoZ10-LP, although the latter did express lower levels of genes encoding for 
TLR4 accessory proteins (e.g CD14, CD55). Moreover, MoZ10-LPM expressed 
lower levels of Fcgr1 and Fcgr3. Complete Fcgr ligation has been shown to 
promote an anti-inflammatory profile in macrophages and increase Il10 
production 184 whereas loss Fcgr3 is thought to inhibit the responsiveness of 
peritoneal macrophages to LPS in vitro185.  
 
One key shortcoming of both the in vitro and the vivo experiments presented 
in this chapter is that the antibodies for Tim4 and Sema4a that were used to 
purify RMZ10-LPM and MoZ10-LPM, or their naïve counterparts, are blocking 
antibodies110,186. When carrying out these experiments I thought this to be of 
little importance as Tim4 and Sema4a are involved in clearance of apoptotic 
cells and T cell activation respectively110,186 and are unlikely to affect the early 
responsiveness to LPS in vitro or in vivo. However, with recent work identifying 
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Tim4 as a scavenger receptor, involved in the clearance of LPS187, the results 
from my experiments should be interpreted with care as the response of Tim4+ 
RM-LPM and RMZ10-LPM could be altered and ideally should be repeated 
utilizing alternative antibodies to purify the cell populations of interest.  
 
Combined the data presented in this chapter indicate that monocyte-derived 
LPM are functionally distinct from their resident counterparts, irrespective of 
whether they have differentiated under naïve or inflammatory conditions. 
Consequently, zymosan-induced peritonitis exacerbates the degree of 
functional heterogeneity of the steady-state cavity by driving integration of 
large numbers of monocyte-derived macrophages. The altered functionality of 
monocyte-derived LPM is apparent under steady-state conditions with high 
levels of baseline proliferation by monocyte-derived LPM, but becomes more 
apparent during subsequent stimulation when monocyte-derived LPM are on 
the whole less phagocytic and seemingly more anti-inflammatory than their 
resident counterparts. However, exactly how the expanded monocyte-derived 
LPM population affects the response of the peritoneal cavity to subsequent 




Figure 6.1 Identification of RM-LPM and Mo-LPM on the basis of Tim4 
and Sema4a expression. 
(a) Proportion of donor RMacZ10 (blue, n=6) and IMacZ10 (orange, n=6) with an 
(R1) Sema4aLOTim4, (R2) Sema4aHITim4+, (R3) Sema4aHiTim4- or (R4) 
Sema4aLoTim4- expression profile, 8 weeks after transfer into native 
recipients. Below host F4/80Hi MHCIILo macrophages split into the same 
quadrants are shown in grey.***p<0.001, ****p<0.0001 determined by one-way 
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ANOVA followed by Tukey’s multiple comparisons test (b) Proportion of host 
macrophages (as shown in a) with an (R1) Sema4aLOTim4, (R2) 
Sema4aHITim4+, (R3) Sema4aHiTim4- or (R4) Sema4aLoTim4- expression 
profile, 8 weeks after low-dose zymosan treatment (naïve =6, zymosan treated 
=12) or 22 weeks after low-dose zymosan treatment (graph in the middle; 
naïve = 4, zymosan treated 10). Graph to  the right, host macrophages with an 
(R1) Sema4aLOTim4, (R2) Sema4aHITim4+, (R3) Sema4aHiTim4- or (R4) 
Sema4aLoTim4- expression profile, 8 weeks after low-dose zymosan 
treatment, without adoptive transfer (naïve=15, zymosan treated = 8). 
***p<0.001**p<0.01 determined by repeated student’s t test followed by Holm-
Sidak correction. (c) Proportion of Sema4aLoTim4- (R4) and Sema4aHiTim4- 
(R3) that express MHCII, in naïve mice (n=15) or mice treated with zymosan 
8 weeks earlier (n=7). ***p<0.001****p<0.0001, paired student’s t test. (d) 
Representative gating strategy and expression of Tim4 and Sema4a on LPM 
sourced from naïve or mice treated with zymosan 8 weeks earlier. Data shown 
as mean ± standard deviation. Each symbol represents an individual animal. 





Figure 6.2 Monocyte-derived macrophages exhibit heightened baseline 
proliferation. 
(a) Representative Ki76 antibody staining on on RM-LPM (teal)/Mo-LPM(red) 
sourced from naïve mice (top) or RMZ10-LPM(teal)/MoZ10-LPM(red) sourced 
from mice treated with low dose zymosan 8 weeks prior (bottom). (b) 
Proportion of RM-LPM and Mo-LPM sourced from naïve mice (n=5) that are 
Ki67+. To the right, proportion of RMZ10-LPM and MoZ10-LPM sourced from 
mice treated 8 weeks prior with zymosan (n=8) that are Ki67+. **p<0.001, 
students t test. Data shown as mean ± standard deviation. Each symbol 







Figure 6.3 Monocyte-derived macrophages are less granular and 
phagocytic than embryonically-seeded macrophages. 
(a) Morphological appearance of FACS purified RMZ10-LPM and MoZ10-LPM 
sourced 8week after zymosan treatment. (b) Mean side-scatter of RM-LPM, 
Mo-LPM and SPM (n=5), sourced from naïve mice. To the right, mean side-
scatter of RMZ10-LPM, MoZ10-LPM and SPMZ10(n=8) sourced from mice 8 
weeks after zymosan treatment. **p<0.01, ***p<0.001 ****p<0.0001, one way 
ANOVA followed by Tukey’s multiple comparisons test. (c) Phagocytosis of 
Phrodo E. coli particles by Tim4+ and Tim4- LPM sourced from naïve mice 
(n=6)  or mice treated with zymosan, 8 week prior (n=9). Data is presented as 
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normalized Phrodo MFI (Phrodo MFI 37°C- Phrodo MFI 4°C). **p<0.01, 
***p<0.001, paired student’s t test. (d) Proportion of F4/80+Tim4+/- host 
macrophages that are PKH26-PCL labelled, 8 days after transfer of PKH26-
PCL+ RMacZ10 into naïve recipient mice (n=7) or zymosan pre-treated recipient 
mice (n=7). *p<0.05***p<0.0001, one way ANOVA followed by Sidak multiple 
comparison test. (e) Number of F4/80+Tim4+ host macrophages, 8 days after 
receiving PKH26-PCL+ RMacZ10 (n=7). **p<0.01, student’s t test. Data shown 
as mean ± standard deviation. Each symbol represents an individual animal. 







Figure 6.4 Monocyte-derived macrophages are differentially responsive 
to LPS in vitro. 
(a) Experimental outline for the purification and adherence of indicated 
macrophage subsets. To the right, post-sort viability of indicated macrophage 
subsets (n=8). (b) Assessed analytes in culture-supernatant of RMZ10-LPM 
(left; n=8) and MoZ10-LPM (right; n=8), 14 hours after culture with PBS (white) 
or LPS (1ng/ml; black). **p<0.01 ***p<0.00, repeated student’s t test followed 
by Holm-Sidak correction. Average theoretical lower and upper limits for: IFNg 
(0.845-22802), CXCL1(1.805-27840), TNFa(2.835-63779.5), CCL2(3.51-
20783), Il12(P70)( 1.385-15563), CCL5(3.105-18512.5), Il1b(1.935-27838.5), 
CXCL10(2.35-16955), GM-CSF(2.285-31797), Il10(4.485-11829), 
IFNb(6.665-31752), IFNa(2.32-15789.5), Il6(1.865-25500.5) (c) LPS-
responsive analytes detected in culture-supernatant, 14 hours after culture of 
RMZ10-LPM (n=8, teal) or MoZ10-LPM (n=8, red) with LPS (1ng/ml). Results are 
presented as log2 fold change relative to mean concentration detected in 
RMZ10-LPM supernatant. Data are presented with a box-and-whiskers plot. To 
the right, LPS-responsive analytes detected in culture-supernatant, 14 hours 
after culture of RM-LPM (n=6, teal) or Mo-LPM (n=5, red) with LPS (1ng/ml). 
Results are presented as log2 fold change relative to mean concentration 
detected in RM-LPM supernatant. Data are presented with a box-and-whiskers 
plot.*p<0.05 **p<0.01***p<0.001, repeated student’s t test followed by Holm-
Sidak correction. (d) LPS-responsive analytes detected in culture-supernatant, 
14 hours after culture of RMZ10-LPM (n=8, teal) or MoZ10-LPM (n=8, red) with 
PBS (1ng/ml) **p<0.01 ***p<0.001, repeated student’s t test followed by Holm-
Sidak correction. (e) Supernatant levels  of TNFa, CCL5, CXCL1, 14 hours 
after culture of RMZ10-LPM (n=8, teal) or MoZ10-LPM (n=8, red) with LPS 
(1ng/ml), normalized to PBS-treated baseline levels. **p<0.01 ***p<0.001, 
repeated student’s t test followed by Holm-Sidak correction. Data shown as 






Figure 6.5 Zymosan-induced inflammation does not alter LPS-
responsiveness of peritoneal macrophage subsets.  
(a) Detected analytes in culture-supernatant of RM-LPM (n=6) or RMZ10-LPM 
(n=6), 14 hours after culture with PBS. To the right, detected analytes in 
culture-supernatant of Mo-LPM (n=6) or MoZ10-LPM (n=6), 14 hours after 
culture with PBS. **p<0.01, repeated student’s t test followed by Holm-Sidak 
correction. Average theoretical lower and upper limits for: Il23 (0.895-17752), 
Il1a(0.715-1204851), IFNg(0.685-24636), TNFa(0.58- 90569.5),CCL2(0.63-
95197.5), IL12(P70)( 1.145-14185.5), Il1b(1.16-17233.5), Il10(0.8-31013.5), 
Il6(1.555-9623.5), Il27(1.215-17292), Il17a(0.73-27946.5), IFNb( 0.495-
37763), GM-CSF(0.64-58259) (b) Detected analytes in culture-supernatant 14 
hours after culture of RM-LPM (n=6) compared to RMZ10-LPM (n=6) (left) and 
Mo-LPM (n=6) compared to MoZ10-LPM (n=6), with LPS (1ng/ml), normalized 
to mean PBS-treated baseline levels. **p<0.01, repeated student’s t test 
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followed by Holm-Sidak correction. Data shown as mean ± standard deviation. 




Figure 6.6 Monocyte-derived macrophages are differentially responsive 
to LPS in vivo. 
(a) Experimental outline for the adoptive transfer of 250,000 RMZ10-LPM or 
MoZ10-LPM (Gated as shown in 6.4a) or PBS into naïve recipient mice. Mice 
received a follow-up I.P injection with LPS (5µg) 2 days after cell transfer. (b) 
Engraftment efficiency of transferred RMZ10-LPM and MoZ10-LPM. To the right, 
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proportion of F4/80Hi MHCIILo macrophages that are of donor origin after 
indicated treatment. Statistical significance determined using student’s t test. 
(c) Relative changes in body weight of treated mice, normalized to pre-
experimental weight at D0. (d) Absolute number of Neutrophils present in the 
peritoneal cavity after PBS (n=6), RMZ10-LPM (n=7) and MoZ10-LPM (n=7) 
transfer followed 2 days later by LPS-administration. *p<0.05 , one-way 
ANOVA followed by Tukey’s multiple comparisons test. (e) Representative 
intracellular TNFa staining of RMZ10-LPM and MoZ10-LPM, 8 hours following 
LPS administration. (f) Proportion of F4/80Hi donor RMZ10-LPM (n=7) and 
MoZ10-LPM (n=7) that express TNFa. To the right, normalized MFI of TNFa+ 
expression by RMZ10-LPM (n=7) and TNFa+ MoZ10-LPM (n=7). *p<0.05 
**p<0.01, student’s t test. (g) Proportion of F4/80Hi donor RMZ10-LPM (n=7) and 
F4/80Hi MoZ10-LPM (n=7) that express TNFa and the proportion of F4/80Hi host 
macrophages that express TNFa in the same cavity. **p<0.01, paired 
student’s t test. Data shown as mean ± standard deviation. Each symbol 









Figure 6.7 Transferred cells do not affect the systemic response to LPS. 
(a) Detected levels of TNfa, CCL2, Il6 and Il1b measured in the peritoneal 
lavage, 8 hours following LPS treatment of indicated groups (from the same 
experiment presented in Figure 6.6). (b) Detected levels of TNfa, CCL2,Il6 Il1b 
measured in the serum, 8 hours following LPS treatment of indicated groups. 
Theoretical detection limit for: TNfa (10-2500pg/ml), CCL2 (160-2500pg/ml), 
Il6 (40-2500pg/ml) and Il1b (20-2500pg/ml). Samples were collected by me 
and the assay was carried out by Dr. Georgia Perona Wright and Ms. Holly 
Webster. Data shown as mean ± standard deviation. Each symbol represents 






Figure 6.8 Monocyte-derived macrophages exhibit dampened 
transcriptional responsive to LPS.   
(a) Expression of mRNA transcripts that are differentially expressed between 
RMZ10-LPM and MoZ10-LPM, 8 hours following LPS treatment (from the same 
experiment presented in Figure 6.6).  Data shown in the heatmaps has been 
split into (i) Genes not differentially expressed between RMacZ10 and IMacZ10 
in prior analysis (Chapter 5), (ii) Genes known to be driven by LPS-stimulation 
on peritoneal macrophages in vivo177, (iii) Genes that are differentially 
expressed between RMacZ10 and IMacZ10 in prior analysis (Chapter 5) and  (iiii) 
Genes of which expression cannot be attributed to LPS stimulation. Categories 
are summarized below the heatmaps. (b) GSEA analysis of ranked genes 
expressed by RMZ10-LPM and MoZ10-LPM, 8 hours following LPS treatment for 
the humoral immune response GO term. (c) Leading edge analysis of GO 
terms that were enriched (nominal p value <0.05) to detect genes 









Assessing the survival and phenotype of inflammatory 






Up to this point the main focus of my project was on the long-term survival, 
phenotype and functional profile inflammatory macrophages after mild 
peritonitis. Critically, following mild peritonitis a distinct population of 
macrophages with a resident F4/80hi MHCIIlo phenotype persist through the 
inflammatory event (Figure 3.1 & 3.6)144 whereas after higher doses of 
zymosan, these cells are largely lost (Figure 3.1)64,87,111,120,139. Recent work 
has indicated that formation of clots is the main mechanism responsible for 
macrophage disappearance after zymosan induced peritonitis103. Whether 
macrophages sequestered in clots undergo apoptosis or can be released from 
the clots and repopulate the cavity is unclear. In addition to the larger degree 
of disappearance of resident-like macrophages, the inflammatory 
microenvironment after high dose zymosan treatment is very different from that 
after low dose zymosan treatment. For example, after treatment with a high 
dose of zymosan (1000µg), the peritoneal cavity lavage fluid contains high 
levels of CCL5, a chemokine which is largely absent after injection of low dose 
zymosan (10µg)122,188. Moreover, injection of higher doses of zymosan 
(100µg/1000µg) leads to infiltration of the cavity by significantly higher 
numbers of neutrophils and monocytes compared to low dose zymosan (10µg) 
treatment122,139. Consequently, the macrophage compartment as a whole 
appears to be considerably expanded following the more severe inflammation 
induced by higher doses of zymosan122,139. 
 
As more severe peritonitis seemingly leads to almost complete loss of resident 
macrophages, this could allow inflammatory macrophages to adopt a more 
resident-like identity’, somewhat similar to inflammatory macrophages 
transferred into clodronate-depleted recipients. Hence, I postulated that the 
long-term fate of inflammatory macrophages is likely dictated by the severity 




To investigate whether the severity of peritoneal inflammation indeed dictated 
inflammatory macrophage fate I aimed to ascertain if: 
• Severe sterile peritonitis induced by high-dose zymosan leads to the 
complete loss of embryonically-seeded resident macrophages. 
• Inflammatory macrophages infiltrating during severe peritonitis persist 
long-term and if they adopt a more complete resident phenotype than 
inflammatory macrophages after mild peritonitis.  
• If severe inflammation alters the peritoneal macrophage niche, and 
consequently alters the fate and phenotype of the macrophages that 
inhabit the cavity. 
 
7.2   Severe peritonitis leads to an influx of monocytes and neutrophils. 
 
Numerous publications have described the macrophage compartment after 
zymosan peritonitis but few publications have directly compared the 
macrophage compartment after mild and severe peritonitis. Generally, it has 
been assumed that during severe peritonitis resident macrophages are almost 
completely lost. However, studies that investigate this phenomenon are not 
definitive, as they utilized a dye-labelling methodology or markers, such as, 
F4/80 and CD11B122,162. These studies did indicate that peritoneal 
inflammation led to an expansion of myeloid compartment, largely due to the 
influx of high numbers of monocytes that give rise to inflammatory 
macrophages122,139,162.  
 
To investigate if I was able to replicate the expansion of the peritoneal myeloid 
compartment following injection of high-dose of zymosan, and if the peritoneal 
myeloid-compartment contracts after resolution of inflammation, I carried out 
a time-course experiment to investigate the dynamics of macrophages 
numbers after low-dose (10µg) and high-dose (1000µg) zymosan treatment. 
To confirm that high-dose zymosan induced more severe peritonitis I 
enumerated the number of neutrophils at these timepoints. Similar to my 
earlier findings, by day 3 following low-dose zymosan treatment, the absolute 
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number of myeloid cells in the cavity had increased. During the succeeding 8 
days the number of myeloid cells contracted back to pre-inflammation levels 
(Figure 7.1a). After high-dose zymosan treatment, by day 3, the myeloid 
compartment was strikingly enlarged and, similar to low dose zymosan, 
contracted considerably in the succeeding 8 days. Following high dose 
zymosan treatment, the overall size of the myeloid compartment seemingly 
remained somewhat enlarged (Figure 7.1a). Moreover, after high-dose 
zymosan treatment higher numbers of neutrophils where present by day 3 than 
after low-dose zymosan treatment, indicative of more severe inflammation. 
The number of neutrophils contracted considerably over the succeeding 8 
days (Figure 7.1b).  
 
After high-dose zymosan treatment there appeared to be a complete loss of 
F4/80Hi MHCIILo resident macrophages. This loss corresponded with a 
complete loss of Tim4+ macrophages by day 3 (Figure 7.1c). By day 11, a 
clear population of Tim4+ macrophages had reappeared, despite the apparent 
absence of macrophages with a resident F4/80Hi MHCIILo phenotype (Figure 
7.1c). This population seemingly expanded considerably during the 
succeeding weeks as by week 8 the population of Tim4+ macrophages was 
considerably larger (Figure 7.1c). 
 
As Tim4 is largely restricted to embryonic resident macrophages after mild 
peritonitis (Figure 5.7b), I set out to ascertain whether this reappearing Tim4+ 
fraction indeed consisted of repopulating embryonically-seeded resident 
macrophages. To investigate this, tissue-protected partial bone marrow 
chimeric mice were generated by my supervisor Dr. Steve Jenkins and Dr. 
Calum Bain. By day 17 after high-dose zymosan treatment, the chimerism of 
the entire myeloid compartment was equivalent to that of circulating 
monocytes (Figure 7.2a,b), indicating that the entire compartment had been 
reconstituted by monocytes. After low-dose zymosan treatment there was a 
moderate increase in chimerism of the myeloid compartment by day 17, 
consistent with inflammatory macrophage integration shown in my adoptive 
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transfer studies, but this did not reach statistical significance. This lack of 
statistical significance was largely because the study was underpowered to 
detect smaller changes in chimerism. In addition, one datapoint in the low-
dose treatment group had very low chimerism likely because of incomplete 
injection of zymosan (Figure 7.2b, square datapoint).  
 
Moreover, those Tim4+ macrophages present after high-dose zymosan were, 
contrary to Tim4+ macrophages found in naïve mice or after low-dose zymosan 
treatment almost exclusively of monocyte origin as indicated by a high degree 
of chimerism (Figure 7.2c). Hence, severe zymosan-induced peritoneal 
inflammations leads to complete loss of embryonically-seeded resident 
macrophages. Signals present shortly after severe peritoneal inflammation 
allow rapid acquisition of Tim4 by inflammatory monocyte-derived 
macrophages.  
 
Note, during these experiments tissue-protected bone marrow chimeric mice 
were injected with the indicated dose of zymosan after 8 (Figure 7.2b,c 
datapoints in circles) or 26 weeks (Figure 7.2b,c datapoints in squares). The 
reason for this discrepancy was that COVID19 lockdown rules forced me to 
postpone zymosan treatment during the second iteration of the experiment.  
 
7.3   Inflammatory macrophages persist after severe peritonitis and 
adopt a unique phenotype. 
 
Having established that after high dose zymosan the entire macrophage 
compartment was replaced by monocyte-derived macrophages I set out to 
investigate if, similar to my earlier findings in mild peritonitis, inflammatory 
macrophages recruited during the acute inflammatory response persisted after 
severe peritonitis. To investigate this, 200,000 dye-negative F4/80Int 
inflammatory macrophages were purified 3 days after injection of high-dose 
zymosan (IMacZ1000) and adoptively transferred into equivalent severely 
inflamed recipients (Figure 7.3a). In order to compare their phenotype and 
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survival with my earlier experimental findings, I adoptively transferred RMacZ10 
and IMacZ10 purified 3 days after low-dose zymosan treatment into equivalent 
mildly inflamed recipients (Figure 4.8a).  
 
By 8 weeks post transfer all three donor populations had persisted but 
IMacZ1000 had engrafted significantly poorer than IMacZ10 or RMacZ10 (Figure 
7.3b). Moreover, surviving IMacZ1000 had universally adopted an F4/80Hi 
MHCIIHi phenotype, unlike either donor population after low-dose zymosan 
treatment (Figure 7.3c). Importantly, IMacZ1000 adopted a more resident-like 
identity as they expressed equivalent levels of GATA6 as RMacZ10 (Figure 
7.3d). Since resident macrophages were completely lost after high dose 
zymosan (Figure 7.2b,c) the acquisition of high levels of GATA6 is likely due 
to lack of competition with resident macrophages in this setting. Using flow 
cytometry, I then investigated numerous markers that delineated RMacZ10 and 
IMacZ10 after mild peritonitis. This analysis revealed that IMacZ1000 phenotype 
differed greatly from that of IMacZ10 for almost every single marker assessed 
(Figure 7.3e). Notably, IMacZ1000 expressed only low levels of CCR5 and Frb 
,both of which were identified as environment-dictated features of IMAcZ10. 
Moreover, IMacZ1000 also expressed strikingly higher levels of Tim4 than 
IMacZ10 (Figure 7.3e). This was surprising given that low expression of Tim4 
by MacZ10 was regulated independent of competition with resident 
macrophages, suggesting expression of this marker by IMacZ1000 may instead 
arise due to alterations in the microenvironment (Figure 7.3e). However, 
heightened Tim4 expression did not correspond to higher expression of other 
resident markers including VSIG4 and CXCL13, both largely absent on 
IMacZ1000 (Figure 7.3e).  
 
Based on the combination of all these markers, the phenotype of IMacZ1000 
was indistinguishable from the phenotype of host macrophages in the same 
cavity (Figure 7.4a,b). This contrasts with the situation following mild 
peritonitis as neither RMacZ10 (Figure 7.4a,c)  nor IMacZ10 (Figure 7.4a,d) 
aligned perfectly with host macrophages, consistent with host cells containing 
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a mixture of both RMacZ10 and IMacZ10. Consequently, by 8 weeks after high-
dose zymosan host macrophages were, at the population level, phenotypically 
distinct from host macrophages after low-dose zymosan for every marker 
assessed (Figure 7.4e). Moreover, the CD11b+ myeloid compartment 
remained somewhat enlarged by 8 weeks after severe peritonitis compared 
with the numbers found following mild peritonitis (Figure 7.4f), as suggested 
by the time-course data previously (Figure 7.1a). In addition, I found that the 
number of naïve CD62L+ T-cells189,190 inhabiting in the cavity was significantly 
lower 8 weeks following high dose zymosan treatment, compared to mice 
treated with low dose zymosan (Figure 7.4g). 
 
Combined these data indicate that severe peritoneal inflammation results in 
striking alterations to the peritoneal macrophage compartment by altering the 
origin, number and phenotype of phagocytes that inhabit the cavity.  
 
7.4   Following severe peritonitis the peritoneal environment drives 
expression of MHCII and Tim4. 
 
A surprising finding was that, during a period of inflammation that follows 
injection of high-dose zymosan, acquisition of Tim4 expression seemingly 
occurred independently of acquisition of a resident F4/80Hi MHCIILo phenotype 
(Figure 7.1c). Even by 8 weeks after high-dose zymosan, when neutrophilic 
inflammation has seemingly resolved (Figure 7.1b), IMacZ10 almost universally 
retained an MHCIIHi phenotype whilst also largely acquiring expression of Tim4 
(Figure 7.3c,e). As F4/80 and MHCII were previously found to be rapidly 
responsive to retinoic acid and omentum factors respectively in vitro, I 
postulated that rapid acquisition of Tim4 in parallel with impaired F4/80 and 
heightened MHCII expression on infiltrating monocytes following severe 
inflammation arose from alterations in the cavity micro-environment. 
 
To examine this, 400,000 RMac sourced from naïve mice were adoptively 
transferred into recipient mice treated with high-dose zymosan 3 days prior 
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(Figure 7.5a). By day 11, transferred RMac had acquired high levels of MHCII 
and had downregulated expression of F4/80 (Figure 7.5b,c). On the basis of 
these markers, RMac appeared to be similar as monocyte-derived host 
macrophages (Figure 7.5b). Moreover, transfer of Tim4+ RMac inhibited 
acquisition of Tim4 by host cells as indicated by a drop in absolute numbers of 
Tim4+ (Figure 7.5d,left), but not Tim4- (Figure 7.5d,right) host macrophages. 
Hence, Tim4 expression appears to be driven by environmental cues after 
severe peritonitis and monocyte-derived macrophages are competitively 
disadvantaged from acquiring these cues compared to embryonically-seeded 
resident macrophages. 
 
Combined, these data indicate that shortly after severe peritonitis the 
peritoneal microenvironment does not contain the factors, most likely retinoic-
acid, required to maintain the F4/80Hi phenotype and contains factors that drive 
expression of MHCII and Tim4. 
 
7.5 Sterile peritonitis leads to impaired B1 cell expansion. 
 
One of the well-characterized functional markers seemingly not acquired by 
inflammatory macrophages irrespective of the severity of inflammation was 
CXCL1397. CXCL13 is a vital chemokine required for the homing of circulating 
B1 cells into peritoneal cavity. Genetic deletion of Cxcl13 results in almost 
complete loss of peritoneal B1 cells118 .Under homeostatic conditions the 
predominant source of CXCL13 is thought to be the resident peritoneal and 
omental macrophages97,118, although recent work characterized a population 
of omental mesothelial cells that produce CXCL13136. Hence, I decided to 
investigate whether the number of B1 cells sequestered in the peritoneal cavity 
was altered following peritonitis and the resulting integration of CXCL13-
deficient macrophages. 
 
Indeed, the exaggerated loss of CXCL13-producing after severe peritonitis 
(Figure 7.6a), correlated with fewer peritoneal B1 cells (Figure 7.6b). Previous 
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data in the lab had indicated that the number of peritoneal B1 cells increases 
with age. Hence, I postulated that the reduction of B1 cells 8 weeks after sterile 
peritonitis was due to an inability to sequester B1 cells in the cavity with time, 
rather than direct loss of B1 cells during the inflammatory event. To investigate 
this, I re-evaluated the time-course data and found that peritoneal B1 cells 
increased in number over an 8-week period in naïve mice but that this was 
marginally inhibited after mild peritonitis and completely abrogated after 
severe peritonitis (Figure 7.6c).  
 
An important function of peritoneal B1 cells is the production of natural 
antibodies, most notably against phosphorylcholine118. Recently, it was found 
that peritoneal B1 cells also produce natural antibodies against LPS-O127. 
Production of these antibodies is highly sex specific with higher levels of 
circulating antibodies in female mice compared to male mice191.Hence, we 
investigated the levels of natural antibodies in the serum of mice 8 week after 
zymosan-induced peritonitis. The serum for these experiments was collected 
by me. The ELISA to detect natural antibodies to LPS-O127 and 
phosphorylcholine was carried out by Ms. Lucia Badiola Gomez and Dr. Steve 
Jenkins. This analysis indicated that 8 weeks after severe peritonitis the levels 
of serum IgG and serum IgM against LPS-O127 were unaltered (Figure 7.6d) 
but IgM against phosphorylcholine was increased after severe peritonitis and 
anti-phosphorylcholine IgG was detectable (Figure 7.6d).  
 
Combined, these data indicate that severe peritoneal inflammation has long-
term systemic consequences by increasing levels of circulating natural 
antibodies against phosphorylcholine. This is likely resulting from altered 




In this chapter I set out to investigate the survival and phenotype of 
inflammatory macrophages following severe peritonitis. Using tissue-protected 
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marrow chimeras I found that by 17 days after severe peritonitis the complete 
peritoneal macrophage compartment is replaced by monocyte-derived cells. 
Using the adoptive transfer approach, I found that at least some inflammatory 
macrophages present by day 3 of severe peritonitis survive long-term and 
adopt a phenotype unlike resident or inflammatory macrophages inhabiting the 
cavity after mild peritonitis at the same time. By week 8, IMacZ1000 adopted a 
more complete resident-like identity. Most notably, they expressed equivalent 
levels of GATA6 as established resident macrophages, and had completely 
downregulated CCR5 and FRb, the latter of which is negatively regulated by 
GATA665. However, despite adopting a more resident-like phenotype IMacZ1000 
also retained strikingly high levels of MHCII. Phenotypically IMacZ1000 fully 
resembled the host macrophage compartment, indicating that, should 
monocytes recruited after day 3 also persist, the stage at which monocytes 
infiltrate the cavity after high-dose zymosan does not alter their phenotype. 
This is an important finding as the time of transfer that was chosen for these 
adoptive transfer experiments was not equivalent between low and high dose 
zymosan treated animals. Whereas by day 3 following low dose zymosan 
treatment inflammation is largely resolved, as indicated by resolution of 
neutrophilia, following high dose zymosan treatment there is still ongoing 
inflammation and neutrophilia is still present at this time. Consequently, the 
divergent engraftment efficiency of IMacZ10 and IMacZ1000 could simply be an 
effect of the stage of inflammation the donor populations were transferred at. 
Hence, although the phenotype of macrophages following high dose zymosan 
treatment appears unaltered by the stage at which monocyte infiltrate the 
cavity it is possible that the poorer engraftment efficiency of IMacZ1000 may be 
due to their transfer into more inflamed recipients. Additional adoptive transfer 
experiments to investigate whether the engraftment efficiency of IMacZ1000 
carried out at a timepoint at which high dose zymosan-induce peritonitis is 
resolved (i.e. around day 11-17) could prove useful and would be more 




In these adoptive transfer experiments, I also found that persistent IMacZ1000 
expressed significantly higher levels of Tim4 than IMacZ10. This was surprising 
as I had previously identified that Tim4 expression was a cell-intrinsically 
driven feature, largely absent on IMacZ10 that is slowly acquired with time. Gain 
of Tim4, at least by part of the inflammatory macrophages, appeared to occur 
relatively shortly after severe peritonitis as tissue-protected chimeras indicated 
a monocyte origin of Tim4+ macrophages present at day 17. Moreover, 
transferred resident macrophages were unable to maintain their resident 
phenotype during this period and universally adopted an ‘inflammatory like’ 
F4/80IntMHCIIHi phenotype. My earlier findings indicated that MHCII 
expression was not acquired by resident macrophages in vitro after removing 
them from the cavity micro-environment, suggesting that the MHCIIlo 
phenotype of RMac does not depend on continual exposure to inhibitory 
signals. Hence, these data support the hypothesis that following high-dose 
zymosan treatment, the peritoneal micro-environment contains factors driving 
MHCII expression. Moreover, donor RMac retained Tim4 expression following 
transfer, and their presence inhibited acquisition of Tim4 by host 
macrophages. Combined these data suggest that severe peritonitis leads to 
changes in the peritoneal micro-environment that temporarily inhibit 
macrophages from acquiring a resident-like phenotype F4/80Hi phenotype, but 
drive expression of Tim4 and MHCII.  
 
Unlike after mild peritonitis the enlarged myeloid compartment remained 
somewhat expanded after severe peritonitis, indicating a long-term expansion 
of the peritoneal macrophage niche. Despite this expansion, the number of 
cells that produce the B1 cell chemoattractant CXCL13 was reduced 
considerably. Moreover, peritoneal B1 accumulation was abrogated after 
severe peritoneal inflammation, likely due to the inability of monocyte-derived 
macrophages produce CXCL13. Surprisingly, this loss of peritoneal B1 cells 
corresponded with increased levels of natural antibodies against 
phosphorylcholine. Although peritoneal B1 cells are thought to produce natural 
antibodies191, production is much higher by B1 cells in the bone marrow and 
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the spleen192. Hence, a possible explanation for the increase in serum 
phosphorylcholine IgM in my experiments could be an inability to sequester B1 
cells in the cavity and consequent accumulation of B1 cells in the spleen, a 
tissue more permissive of natural antibody production. Unfortunately, during 
my studies I did not investigate accumulation of B1 cells in other tissue-sites. 
To examine this hypothesis, the number of B1 cells in the spleen and bone 
marrow and their capacity to produce natural antibodies following severe 
peritoneal inflammation should be investigated. 
 
The data presented in this chapter highlight that the degree of peritoneal 
inflammation is directly correlated with the degree of resident macrophage 
disappearance during acute inflammation and impacts the survival and 
phenotype of inflammatory macrophages. Moreover, after severe peritonitis 
the peritoneal niche does not effectively maintain a resident phenotype and 
drives aberrant MHCII expression. Whereas ineffective maintenance of the 
resident phenotype appears is a temporary phenomenon, aberrant MHCII 
expression is a long-term feature. Moreover, severe peritoneal inflammation 
leads to a long-term inability to sequester B1 cells in the peritoneal cavity and 








Figure 7.1 Macrophage and neutrophil dynamics after zymosan-induced 
peritonitis. 
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(a) Absolute number of CD11b+ Lineage- myeloid cells at indicated timepoints 
in naïve mice (n= 5,6,10, for each time point respectively), mice treated with 
10µg (n=6,11,20, for each time point respectively) or 1000µg (n=3,3,4, for each 
time point respectively) of zymosan. *p<0.05, **p<0.01. Statistical significance 
for naïve and 10µg zymosan treated mice was determined using two-way 
ANOVA followed by post hoc Tukey test. For 1000µg zymosan statistical 
significance was determined by one-way ANOVA followed by post hoc Tukey 
test. (b) Absolute number of neutrophils at indicated timepoints in naïve mice 
(n= 5,6,10), mice treated with 10µg zymosan (n=6,11,20) and mice treated 
with 1000µg zymosan (n=3,3,4) **p<0.01, ****p<0. Statistical significance for 
naïve and 10µg zymosan treated mice was determined using two-way ANOVA 
followed by post hoc Tukey test. For 1000µg zymosan treated mice, statistical 
significance was determined by one-way ANOVA followed by post hoc Tukey 
test. (c) Representative expression levels of  F4/80,MHCII and Tim4 (bottom) 
by peritoneal CD11B+ Lineage- myeloid cells at indicated timepoints in naïve 
or zymosan treated animals. Data shown as mean ± standard deviation. Each 
symbol represents an individual animal. Data for naïve and 10µg zymosan 





Figure 7.2 High dose zymosan leads to replacement of peritoneal 
macrophages by monocyte-derived macrophages. 
(a) Representative Tim4 and MHCII expression by CD11B+Lineage- myeloid 
cells, 17 days after tissue-protected BM chimeric mice were injected with the 
indicated dose of zymosan. (b) Normalized donor chimerism of myeloid cells, 
17 days after tissue-protected BM chimeric mice were injected with the 
indicated dose of zymosan. Chimerism was normalized to the chimerism 
detected in circulating Ly6CHi monocytes as described in the M&M. Tissue-
protected BM chimeric mice were injected with zymosan 8 weeks after 
irradiation (circle) or 26 weeks after irradiation (square) **p<0.01 determined 
by one-way ANOVA and Tukey’s multiple comparisons test (c) Normalized 
donor chimerism of Tim4+ macrophages, 17 days after tissue-protected BM 
chimeric mice were injected with the indicated dose of zymosan. Tissue-
protected BM chimeric mice were injected with zymosan 8 weeks after 
irradiation (circle) or 26 weeks after irradiation (square) **p<0.01 determined 
by one-way ANOVA followed by Tukey’s multiple comparisons test. Data 
shown as mean ± standard deviation. Each symbol represents an individual 







Figure 7.3 Inflammatory macrophages persist after severe peritonitis. 
(a) Representative expression of of F4/80 and Ly6c in conjunction with PKH26-
PCL dye labelling and gating strategy to identify RMacZ10, IMacZ10 3 days after 
low dose zymosan(10µg) treatment and IMacZ1000 3 days after high dose 
zymosan (1000µg) treatment. (b) Engraftment efficiency of RMacZ10 (n=6), 
IMacZ10 (n=5), and IMacZ1000 (n=6), 8 weeks after transfer into mirroring 
inflamed recipient mice.  **p<0.01, one-way ANOVA followed by Tukey’s 
multiple comparisons test. Engraftment efficiency was calculated on the basis 
of absolute numbers as described in the M&M (c) Representative expression  
of F4/80 and MHCII on indicated donor (top) and host (bottom) macrophage 
populations, 8 weeks after indicated treatment. (d) GATA6 MFI on RMacZ10, 
IMacZ10 and IMacZ1000 ,8 weeks following transfer into mirroring inflamed 
recipients (n=3,2,3 for each population respectively). **p<0.01, one-way 
ANOVA followed by Tukey’s multiple comparisons test. (e) Proportion of donor 
CD102Hi/F4/80Hi RMacZ10 (blue), IMacZ10 (orange) or IMacZ1000 (purple), 8 
weeks after transfer into mirroring inflamed recipient mice that express 
markers of interest (n=6,5,6 for each population respectively).*p<0.05 
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**p<0.01 ***p<0.001, one-way ANOVA followed by Dunnet’s multiple 
comparisons test for each marker individually, followed by Bonferroni 
adjustment. Data shown as mean ± standard deviation. Each symbol 
represents an individual animal. Data were pooled from 3 independent 





Figure 7.4 Persistent inflammatory macrophages after severe peritonitis 
are phenotypically unique. 
(a) Principal component analysis of donor RMacZ10, IMacZ10 and IMacZ1000 and 
F4/80Hi/CD102Hi host macrophages in the same mice. Principal components 
were calculated on based on the markers presented in Figure 6.3e. (b) 
Proportion of donor CD102Hi/F4/80Hi donor IMacZ1000(n=6) and 
CD102Hi/F4/80Hi host macrophages in the same cavity that express markers 
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of interest 8 weeks after adoptive transfer. (c) Proportion of CD102Hi/F4/80Hi 
donor RMacZ10 (n=6) and CD102Hi/F4/80Hi host macrophages in the same 
cavity that express markers of interest 8 weeks after adoptive transfer. *p<0.05 
**p<0.01 ***p<0.001, repeated student’s t test with Holm-Sidak correction. (d) 
Proportion of CD102Hi/F4/80Hi donor IMacZ10 (n=5) and CD102Hi/F4/80Hi host 
macrophages that express markers of interest 8 weeks after adoptive transfer. 
*p<0.05 **p<0.01, repeated student’s t test with Holm-Sidak correction. (e) 
Proportion of CD102Hi/F4/80Hi host macrophages 8 weeks after treatment with 
low dose zymosan (n=6, grey) or high dose zymosan (n=6, black) that express 
markers of interest. *p<0.05 **p<0.01 ***p<0.001, repeated student’s t test with 
Holm-Sidak correction. (f) Absolute number of CD11B+ lineage- myeloid cells, 
8 weeks after treatment with low dose zymosan (n=12) or high dose zymosan 
(n=6).  *p<0.05, student’s t test. (g) Absolute number of CD62L+/CD62L- T 
cells, 8 weeks after treatment with low dose zymosan (n=12) or high dose 
zymosan (n=6). Statistical significance determined using repeated t test with 
Holm-Sidak correction. Data shown as mean ± standard deviation. Each 









Figure 7.5 Following severe peritonitis the peritoneal microenvironment 
is altered. 
(a) Experimental outline for the adoptive transfer of donor RMac (F4/80Hi 
MHCIILo) into mice that were pre-treated with high dose zymosan 3 days prior. 
(b) Representative expression levels of of F4/80, MHCII and Tim4 by donor 
RMac (left) and host macrophages (right), 8 days following adoptive transfer. 
(c) Proportion of RMac (n=5) that express MHCII and F4/80, before transfer 
and 8 days following transfer into high dose zymosan treated recipient mice. 
Proportion of RMac that express F4/80 at the time of transfer is set to 100% 
as cells were sorted on this marker (see Figure 7.5a). ****p<0.0001, student’s 
t test. (d) Absolute number of host macrophages that express Tim4 (left) or do 
not (right), 8 days after PBS treatment (n=6) or transfer of donor RMac (n=5).  
*p<0.05, student’s t test. Data shown as mean ± standard deviation. Each 
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Figure 7.6 Severe peritonitis leads to impaired recruitment of B1 cells. 
(a) Absolute number of host macrophages that express the B1 cell 
chemoattractant CXCL13, 8 weeks following treatment with 10µg of zymosan 
(n=11) or 1000µg zymosan (n=6). **p<0.01, student’s t test. Data are derived 
from the adoptive transfer experiments presented in Figure 7.3. (b) Absolute 
number of host Lineage+ CD11B+ B1 cells, 8 weeks following treatment with 
10µg of zymosan (n=11) or 1000µg zymosan (n=6). *p<0.05, student’s t test. 
Data are derived from the adoptive transfer experiments presented in Figure 
7.3. (c) Absolute number of peritoneal Lineage+ CD11B+ B1 cells present in 
the cavity at indicated timepoints in naïve mice (black; n= 5,6,10 for each time 
point respectively), mice treated with 10µg of zymosan (n=6,11,20 for each 
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time point respectively) and mice treated with 1000µg of zymosan (n=3,3,4 for 
each time point respectively) *p<0.05, ***p<0.001, ****p<0.0001, two-way 
ANOVA and post hoc Tukey test. (d) Levels of serum anti 0127-LPS or 
phosphorylcholine specific IgM and IgG detected using enzyme linked 
immunosorbent assay. Serum was sourced from naïve mice (n=6), mice 
treated with low dose zymosan treatment 8 weeks prior (n=16) and mice 
treated with high dose zymosan 8 weeks prior (n=2). *p<0.05 ***p<0.001, one 
way ANOVA and Dunnet’s multiple comparisons test. Serum was collected by 
me but analysis was performed by Dr. Steve Jenkins and Ms. Lucia Badiola 
Gomez. Data shown as mean ± standard deviation. Each symbol represents 
an individual animal. Data for naïve and 10µg zymosan treated animals were 



















As described in the introduction the question of whether monocytes recruited 
into the inflamed peritoneal cavity persist long-term and integrate into the 
macrophage compartment has remained contentious. The same question has 
been asked in many tissues now, with numerous recent studies indicating that 
integration of monocytes into the macrophage compartment occurs following 
inflammation and that the presence of these cells can alter the long-term 
responsiveness of the tissue to further challenge. The degree to which 
inflammatory monocyte-derived cells integrate into the resident population 
appears to be, in part, dictated by the size and proliferative capacity of the 
remaining resident macrophage compartment. In the peritoneal cavity, 
seemingly contrasting results have been obtained suggesting resident 
macrophages repopulate by proliferation following zymosan induced 
peritonitis87,144, thus limiting monocyte integration. Conversely, integration of 
monocytes into the macrophage compartment has been found following more 
severe thioglycolate-induced peritonitis, but the extent to which integration 
may occur is unclear28,123,145. Hence, in this project I set out to establish 
whether monocytes recruited into the inflamed cavity integrate into the 
peritoneal macrophage compartment and if so, whether these cells become 
transcriptionally and functionally equivalent to their bona-fide resident 
counterparts. Moreover, I set out to investigate whether this integration is 
impacted by the presence of a population of competing resident macrophages 
or the severity of the initial inflammatory insult.   
 
8.2 A niche that determines peritoneal macrophage survival and 
proliferation 
In chapter 3 it was found, using tissue-protected bone marrow chimeric mice, 
that the degree of resident-macrophage loss and replacement by monocyte-
derived cells is dependent on the severity of the inflammatory insult. Following 
low-dose zymosan treatment (10µg), the macrophage compartment as a 
whole is temporarily expanded. When inflammation is resolved by day 3, as 
indicated by resolution of neutrophilia, resident and inflammatory 
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macrophages inhabit the cavity side by side. I used these well-defined 
populations for adoptive transfer studies throughout the thesis. 
 
I first used this adoptive transfer methodology to investigate the short-term fate 
of inflammatory in chapter 4. Immediately following the resolution of 
inflammation the presence of a sizeable resident macrophage population with 
significant proliferation potential42,146,147 failed to prevent survival of 
inflammatory macrophages during this period or, as shown in chapter 5, long-
term. However, the presence of resident-macrophages did inhibit the 
proliferation of inflammatory macrophages as inflammatory macrophages 
expanded considerably following transfer into macrophage-deplete recipients. 
Surprisingly, transferred resident macrophages were unable to expand to a 
similar degree following transfer into macrophage-deplete recipient mice. 
These findings are similar to work by Cain et who found that LPM transferred 
into the cavity of macrophage-deplete CEBPb-/- recipient mice did not 
expand60. In contrast, monocytes are known to have the capacity to undergo 
high levels of proliferation and reconstitute an artificially-depleted macrophage 
compartment in the liver and lung67,73. A likely explanation for this observation 
is that monocyte-derived macrophages proliferate more rapidly than their 
resident-counterparts following transfer, similar to what occurs in the lung67.  
 
 A slower rate of proliferation could be a general feature of mature resident 
macrophages. This would be consistent with earlier studies indicating that 6 
weeks after transfer into alveolar macrophage-deficient CSF2Rb-/- mice, fetal-
liver monocytes had expanded considerably more than transferred alveolar 
macrophages. By 1-year post-transfer, both populations had similar size, 
indicating that alveolar macrophages have the capacity to expand 
considerably, but do so at a slower pace than fetal-liver monocytes67. Although 
variable, the experiments where I transferred RMacZ10 or IMacZ10 info FIRE-/- 
mice, constitutively devoid of resident peritoneal macrophage106, suggested 
more rapid expansion of IMacZ10 that RMacZ10 similar as following transfer into 
clodronate pre-treated recipients. To definitely establish whether RMacZ10 
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ultimately have similar proliferative capacity to IMacZ10, the transfer RMacZ10 
or IMacZ10 into FIRE-/- mice should be repeated but expansion investigated at 
a later timepoint, similar to studies in the lung67. If both RMacZ10 and IMacZ10 
prove capable of reconstituting the macrophage compartment, albeit at a 
different rate, the functional profile of each subset can be investigated in more 
detail as a cavity inhabited exclusively by one subset can then be generated 
using this experimental system.  
 
Following adoptive transfer of IMacZ10 into naïve recipients, even in the 
presence of a completely intact macrophage compartment, IMacZ10 persisted. 
This finding was somewhat unexpected, as the naive cavity is inhabited by an 
intact macrophage compartment. Following transfer into naive recipients, 
RMacZ10 and IMacZ10 persisted equally well, suggesting that IMacZ10 have 
equivalent survival capacity as RMacZ10. However, following transfer into 
inflamed recipients, IMacZ10 persisted marginally poorer, suggesting that 
following resolution IMacZ10 have lower survival capacity as RMacZ10. As the 
period investigated corresponds with a contraction of the myeloid 
compartment, these observations support the notion that competitive pressure 
with both resident and other inflammatory macrophages limits but ultimately 
fails to prevent IMacZ10 survival, following peritoneal inflammation. These 
finding contrast with published work in the liver indicating that after partial 
depletion of Kupffer cells using Clec4f-DTR mice38 or acetaminophen 
treatment83, remaining Kupffer cells exhibit heightened proliferation to 
reconstitute the macrophage compartment thus limiting monocyte integration. 
This raises the question why the ‘proliferative burst’ exhibited by resident 
macrophages in the cavity in the first few days following zymosan treatment 
144, fails to similarly prevent inflammatory macrophage survival.  
 
The shared dependency of resident and inflammatory macrophages on CSF1 
for their survival may underlie this discrepancy. During peritoneal 
inflammation, both resident and inflammatory macrophages rely on CSF1 for 
survival87,193. Moreover, the ‘proliferative burst’ of resident-macrophages is 
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mediated by CSF1 and not Il467,, another driver of resident-macrophage 
proliferation146. During early stages of thioglycolate-induced peritoneal 
inflammation levels of CSF1 are temporary increased, with high amounts 
transiently produced by macrophages and neutrophils193. However, after 
neutrophilia is resolved levels of CSF1 rapidly drop193. During resolution of 
zymosan-induced peritonitis, the levels of CSF1 in peritoneal fluid are 
equivalent to pre-inflammation levels87. However, the overall number of 
myeloid cells, including resident and inflammatory macrophages is increased, 
suggesting increased competition for CSF1. Following zymosan treatment, 
expression of CSF1r mRNA is equivalent between resident macrophages and 
inflammatory macrophages64, which may explain why inflammatory 
macrophages are not outcompeted. In the liver both resident and inflammatory 
macrophages are also dependent on CSF173. Unpublished data from our lab 
suggest that following CCL4-induced liver injury, monocytes infiltrate the liver 
that do not persist long-term. Importantly, these monocytes give rise to 
inflammatory macrophages that express lower levels of CSF1r than bona-fide 
Kupffer cells, as determined using a transgenic CSF1r-mApple reporter mouse 
line. Similarly, after acetaminophen treatment, inflammatory macrophages do 
not persist, an effect which can be ameliorated by exogenous CSF1 
treatment83. Combined, these data would suggest that the impaired capacity 
of inflammatory macrophages to persist in the liver may be due to an inability 
to compete for CSF1 with incumbent Kupffer cells due to lower CSF1R 
expression. Conversely, the ability of inflammatory macrophages to effectively 
compete for CSF1, due to high levels of CSF1r, in the peritoneal cavity may 
underlie their capacity to persist long-term. 
 
However, the fluidic nature of the peritoneal cavity may also affect the ability 
of inflammatory macrophages to persist. In the liver, there is a clear 
anatomically defined niche for which cells compete73.In contrast, the peritoneal 
niche is largely a fluidic environment103 with intermittent interaction with 
surrounding stromal niche cells99. Possibly, the fluidic nature of the peritoneal 
niche allows expansion of the macrophage compartment, even under 
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homeostatic conditions, as expansion only marginally impacts on the levels of 
niche factors, including CSF1, in the fluid that are available to individual 
macrophages. To test if levels of CSF1R directly impact on inflammatory 
macrophage survival, the transgenic FIRE-/- mice may prove useful. Loss of a 
single FIRE enhancer domain does not alter the peritoneal macrophage 
compartment106. My preliminary findings indicated that FIRE+/- mice recruit 
inflammatory macrophages similar to FIRE+/+ mice following low-dose 
zymosan treatment. However, the level of CSF1R on both resident and 
inflammatory macrophages were noticeably lower in FIRE+/- mice than in 
FIRE+/+ mice. Hence, adoptive transfer of resident/inflammatory macrophages 
sourced from (CSF1rHi) FIRE+/+ mice into equivalently inflamed (CSF1rInt) 
FIRE+/- recipients, could ascertain whether somewhat higher levels of CSF1r 
provide a survival advantage following zymosan-induced peritonitis. 
 
 
8.3 The omentum as a short-term niche for inflammatory macrophage 
conversion 
 
In vitro, studies indicated that inflammatory macrophages, sourced 11 days 
after low-dose zymosan treatment, upregulated F4/80 and downregulated 
MHCII in response to retinoic-acid and omentum factors respectively. As 
F4/80 is directly regulated by GATA663, these data support the notion that 
GATA6 can be upregulated by inflammatory macrophages in response to 
retinoic-acid. Importantly, in this in vitro assay, inflammatory macrophages 
were co-cultured with resident macrophages. As cells were co-cultured, 
these data suggest it is unlikely that resident macrophages secrete factors to 
actively inhibit the conversion of inflammatory macrophages. Instead, the 
impaired capacity to compete for retinoic-acid and omentum factors likely 
underlies the inability of inflammatory macrophages to adopt a resident 
phenotype. Published in vitro data indicates that a sizeable set of genes 
unique to peritoneal macrophages are regulated by retinoic-acid and/or 
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omentum factors99 as co-culture with these factors was required for 
peritoneal macrophage to retain expression of these genes in vitro. 
 
Consistent with a potential role for the omentum, in vivo adoptive transfer 
studies suggested that by day 8 post transfer both RMacZ10 and IMacZ10 
migrated into the omentum of mice deplete of peritoneal and omental 
macrophages. Migration to the omentum has long been postulated to occur 
but to my knowledge this is the first evidence of peritoneal macrophage 
migration to the omentum that is not based on dye-labelling or inferred based 
on levels of chimerism in macrophage subsets in the cavity and the 
omentum63,164. Neither RMacZ10 nor IMacZ10 migrated into the omentum 
following transfer into inflamed or naïve recipient mice, both of which have an 
intact omental macrophage compartment. The importance of this migration is 
hard to asses as it is unclear if these cells persist in the omentum long-term. 
In the only long-term transfer into macrophage-deplete recipients experiments 
in which I investigated the omentum 8 weeks following transfer, neither one of 
the donor populations was detectable in the omentum, suggesting no long-
term residency in the omentum. It should be noted, peritoneal macrophages 
that are transiently and weakly interacting with the omentum would likely not 
be detected in the omentum tissue-preparation, as the omentum was collected 
after repeated peritoneal washes. Hence, these findings support the notion 
that those donor IMacZ10 and RMacZ10 recovered from the omentum after 8 
days, had either incorporated into the omental tissue or strongly adhered to 
the omentum.  
 
A potential role of the omentum as a niche for peritoneal macrophages has 
been suggested63. Omentum factors affect expression of numerous peritoneal 
macrophage identity genes and some genes are thought to be driven by direct 
interaction between macrophages and the omentum99. In addition, the 
omentum is thought to be the predominant source of retinoic- acid in the 
cavity63. However, these studies have largely been carried out in vitro and are 
inconclusive concerning the role of the omentum in vivo. To investigate the 
potential role of the omentum in vivo is challenging. Omentectomy, the surgical 
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removal of the omentum, could be utilized to investigate the role of the 
omentum as a niche. However, this procedure causes a considerable degree 
of peritoneal inflammation (personal communication from Dr. Calum Bain), 
resolution of which will likely be altered by the absence of the omentum. To 
circumvent this issue, adoptive transfer of RMacZ10 or IMacZ10 into fully 
recovered omentectomized recipient mice might be an option. If transferred 
RMacZ10 lose their identity features, but IMacZ10 maintained their inflammatory 
gene-signature, this would be indicative of a role for the omentum in 
maintaining and establishing the peritoneal macrophage identity. However, it 
will not be possible to discriminate the effects of soluble factors secreted by 
the omentum from those that require direct interaction with the omentum. A 
starting point to investigate these temporal interactions could be previous work 
by a PhD student at the CIR, Simon Watson. He developed a methodology to 
externalize the omentum prior to peritoneal lavage. His studies indicated no 
changes in the overall number of peritoneal macrophages recovered, following 
lavage of the cavity with or without the omentum. However, absolute numbers 
retrieved are variable and he identified peritoneal macrophages solely on the 
basis of F4/80. Consequently, he could have missed out on small omentum-
interacting subsets. To ascertain if temporal interactions with the omentum 
occur either under steady-state or inflamed conditions, his methodology could 
be used. In addition, the externalised omentum could be gently washed to 
collect cells loosely adhering to the omentum, although this may yield too few 
cells for analysis. In summary, the role of the omentum in shaping peritoneal 
macrophage identity remains unclear but should be investigated in more detail. 
 
8.4 A niche that determines peritoneal macrophage identity. 
In chapter 5 I elaborated on the early time-point findings and investigated the 
long-term survival of inflammatory macrophages. By 8 weeks following 
adoptive transfer into macrophage-deplete recipients, transferred resident 
macrophages did not appear to have expanded relative to the 8-day time-point. 
However, clodronate pre-treatment only temporarily depletes resident 
macrophages and leads to an influx of host monocytes that reconstitute the 
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niche in parallel to transferred cells. Although definitive conclusions cannot be 
drawn on these data it did appear that IMacZ10 seemingly did not proliferate 
between the 8 day and 8-week timepoints. If, RMacZ10 have lower proliferation 
capacity, the available niche space may be more rapidly colonized by host 
monocytes thus limiting expansion of RMacZ10. Hence, these data suggest that 
mature RMacZ10 fail to undergo sufficient proliferation to prevent integration of 
monocytes into the macrophage compartment. Moreover, once monocytes 
have colonized the peritoneal cavity, mature resident-macrophages appear to 
be unable to recover occupied niche space. Studies by Rosas et al found that 
peritoneal macrophages devoid of GATA6 have heightened levels of baseline 
proliferation64. Hence, high expression of GATA6 by RMacZ10 relative to 
IMacZ10 at the time of transfer could underlie the impaired ability of the former 
to expand, following transfer into macrophage-deplete recipients.  
 
Moreover, the short-term timepoint studies in chapter 4 indicated that, 
following transfer into similarly inflamed or naïve recipient mice, IMacZ10 failed 
to completely adopt a resident F4/80Hi MHCIILo GATA6Hi phenotype. This 
failure was still apparent even after 8 weeks, as shown in chapter 5. In contrast, 
following transfer into recipients deplete of macrophages, by 8 weeks IMacZ10 
had completely adopted an F4/80Hi MHCIILo GATA6Hi phenotype. Combined 
with the in vitro data presented in chapter 4 indicating that inflammatory 
macrophages are retinoic acid responsive, these data suggest that the 
GATA6Int phenotype of IMacZ10 is likely to exist, in part, due to competition with 
resident macrophages for retinoic-acid. Indeed, more complete acquisition of 
a GATA6hi phenotype occurred following transfer of IMacZ10 into macrophage-
deplete recipients, and by IMacZ1000 following transfer into severely inflamed 
recipients in which resident macrophages were absent, as presented in 
chapter 7. 
 
Moreover, in chapter 5 it became apparent that the inability of transferred 
IMacZ10 to adopt a GATA6Hi MHCIILo resident phenotype was indicative of an 
inability to undergo transcriptional conversion, as the mRNA profile of IMacZ10 
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differed considerably from RMacZ10 8 weeks after transfer into inflamed 
recipient mice. A sizeable proportion of these gene differences are regulated 
by GATA6, of which, IMacZ10 failed to acquire equivalent levels as RMacZ10. 
However, following transfer into macrophage-deplete recipients, IMacZ10 
adopted a more complete resident macrophage mRNA profile and, 
importantly, equivalent levels of GATA6 and most GATA6-regulated genes. A 
number of genes that were differentially expressed between RMacZ10 and 
IMacZ10 are regulated by RXRa and/or RXRb98. Signalling through these 
nuclear-receptors is mediated by retinoic-acid and regulates expression of 
GATA6 and numerous GATA6-regulated genes98. However, RXR-signalling 
also mediates expression of numerous GATA6-independent genes98. Indeed, 
the gene-profile of IMacZ10 was enriched for genes downregulated on RXRAB-
/- LPM.  
 
Combined, these data indicate that the inability of inflammatory macrophages 
to effectively acquire retinoic-acid, hampers their conversion potential. These 
findings are consistent with published work, suggesting thioglycolate-induced 
inflammatory macrophages fail to adopt a resident F4/80Hi phenotype following 
transfer into mice deficient in vitamin-A and its active metabolite, retinoic 
acid145. 
 
However, over half of the genes that differentiated IMacZ10 from RMacZ10 are 
not regulated by retinoic-acid. The majority of these genes are environment-
responsive as expression was altered following transfer into macrophage-
deplete recipients. Some of these genes, including those encoding for the 
MHCII machinery, are likely regulated by omentum factors, as suggested by 
the in vitro studies described in chapter 4.  However, these genes could be 
regulated by other peritoneal identity driving transcription factors, including 
CEBP/b60 and BHLHE4061,62. These transcription factors may be regulated by 
unknown environmental cues. Indeed, expression of CEBP/b and BHLHE40 is 
lost by cultured peritoneal macrophages9, suggesting that their expression 
relies on continual signals from the cavity micro-environment. Retinoic-acid 
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has been proposed to drive BHLHE40 in peritoneal macrophages in vitro9 but 
this has been contrasted by other in vitro studies99. Loss of CEBP/b leads to 
almost complete loss of peritoneal macrophages60. However, the degree to 
which CEBP/b-deficiency alters the transcriptional profile of the few remaining 
peritoneal macrophage is unknown. In addition, little is known concerning the 
steady-state niche signals that could be driving expression of CEBP/b.  
However, CEBP/b has been studied extensively in the context of inflammation. 
LPS stimulation of macrophages induces expression of CEBP/b in vitro and in 
vivo194-196. Chromatin immunoprecipitation studies indicated that CEBP/b is 
constitutively present at the Serpinb2 promoter and drives constitutive, low 
expression of Serpinb2, and upregulates levels of Serpinb2 in response to 
LPS197. This CEBP/b- Serpinb2 interaction occurs in both resident-peritoneal 
macrophages and thioglycolate-elicited inflammatory macrophages197. This 
finding is likely to be of importance, since macrophage-specific loss of 
Serpinb2 alters migratory capacity and transcriptional identity of peritoneal 
macrophages156. My Nanostring analysis suggested levels of CEBP/b were 
equivalent between RMacZ10 and IMacZ10 at week 8 and Serpinb2-regulated 
genes were not enriched in my dataset as assessed by GSEA analysis, unlike 
GATA6-regulated genes. As microbial products are thought to be present in 
the steady-state peritoneal cavity and affect development and identity of 
SPM104 and potentially LPM198, it is possible that low level of microbial LPS is 
required for constitutive expression of CEBP/b by peritoneal macrophages. 
However, the CEBP/b promoter  also contains two CREB binding sites, loss of 
which abrogates LPS-mediated activation199. Prostaglandin E2 has been 
shown to activate CREB which proceed to bind CREB binding-sites in the 
CEBP/b promoter in bone-marrow derived macrophages200. Notably, 
prostaglandin E2 is produced in low-levels by steady-state by peritoneal 
macrophages120, and it’s production by peritoneal macrophages is highly 
responsive to IFNg which, under steady-state conditions, is present in the 
peritoneal fluid in detectable levels120. Hence, CEBP/b signalling may be 
driven by autocrine signalling via peritoneal macrophage produced 
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prostaglandin E2, production of which is driven by peritoneal fluid IFNg. 
Moreover, the bronchoalveolar fluid to which alveolar macrophages, that are 
also CEBP/b dependent, are exposed also contains quantifiable levels of 
prostaglandin that increase with age201. Loss of prostaglandin receptor E2 led 
to an increase in the number of alveolar macrophages and heightened 
proliferation201, indicating that prostaglandin signalling is not required for 
alveolar macrophage survival, as would be expected if CEBP/b signalling 
relied solely on prostaglandin E2.  
 
Hence, the environmental cues that drive the peritoneal macrophage identity, 
and how these may be altered following inflammation, remain unclear. 
However: IFNg, Prostaglandin E2 and microbial products are possible signals 
that could be mediating CEBP/b-mediated gene expression, driving part of the 
peritoneal macrophage identity.  
 
8.4.1 The influence of time and origin on peritoneal macrophage identity 
and functionality 
 
As described in chapter 5, after 8 weeks of residence, a small set of genes 
remained differentially expressed between RMacZ10 and IMacZ10, irrespective 
of whether cells were transferred into inflamed or artificially-depleted 
recipients, thus supporting the idea that origin, in part, dictates macrophage 
identity. These features included proteins highly expressed by resident 
macrophages that are not acquired by IMacZ10 (Tim4, VSIG4,CD209b), but 
gradually acquired with time. Other environment-independent features, are 
those more highly expressed by IMacZ10 (CD62L), that are features of 
monocyte-derived cells that are retained, but gradually lost with time. By 22 
weeks post-transfer, the engraftment efficiency of both RMacZ10 and IMacZ10 
had dropped considerably, relative to earlier 8 week datasets, indicative of 
gradual loss of both populations. Hence, it remains unclear whether the 
lifespan of IMacZ10 is sufficient to undergo complete conversion. This 
observation highlights the importance of the finding that the transcriptional 
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identity of IMacZ10 overlaps with that of a small population of monocyte-derived 
resident macrophages (Mo-LPM), present under steady-state conditions. 
Similar to IMacZ10, the identity of Mo-LPM is, in part, an effect of lower GATA6 
expression, supporting the notion that Mo-LPM are similarly less-able to 
compete for retinoic-acid with bona-fide resident macrophages. Hence, the 
developmental path that IMacZ10 traverse, following an inflammatory event, 
does not appear to differ from that of monocytes giving rise to resident 
macrophages under steady-state conditions. Consequently, the loss of IMacZ10 
observed by week 22 is likely to result in replacement by ‘new’ monocyte-
derived macrophages that similarly require a long time to acquire a resident-
macrophage identity. Alternatively, these cells may, similar to IMacZ10, not live 
long enough to undergo full conversion.  
 
A key question that still remained was the functional implication of long-term 
inflammatory macrophage integration. Inflammatory macrophages failed to 
acquire expression of CD209b even after 22 weeks. Expression of CD209b by 
peritoneal macrophages is required for effective clearance of S.Pneunomiae 
in vivo97. Hence, the increases susceptibility mice that have received zymosan 
21 days120 or 8 weeks111, prior to S.Pneunomiae infection may be due to loss 
of CD209b-expressing resident macrophages and presence of CD209b-
deficient inflammatory macrophages. In addition, inflammatory macrophages 
failed to acquire expression of VSIG4 after 8 weeks but eventually acquired 
expression by 22 weeks. In the liver, VSIG4 has been identified as pattern 
recognition receptor required for Kupffer cells to clear circulating S.aureus and 
limit systemic dissemination202. Specifically, VSIG4 recognises lipoteichoic 
acid, which constitutes part of the cell wall of gram positive bacteria like S. 
aureus202 but also S. Pneunomiae203. Hence, it is likely that CD209b/VSIG4-
deficient inflammatory macrophages that inhabit the cavity following zymosan-




Combined, these data indicate that inflammatory macrophages persist long-
term following zymosan-induced peritoneal inflammation, but that their inability 
to compete for niche factors inhibits conversion into bona-fide resident 
macrophages which has potentially functional implications. Part of their 
transcriptome is not responsive to environmental cues, and is cell-intrinsically 
regulated. Irrespective, with time inflammatory macrophages adopt a more 
resident-like phenotype by altering expression of both environment- and 
intrinsically-regulated features.  
 
8.5 The functional effects of historic peritoneal inflammation  
 
In chapter 6 I then set out to expand on the potential functional impact of 
inflammatory macrophage integration following peritoneal inflammation. 
Indeed, integration of monocytes into the peritoneal macrophage compartment 
after mild-peritonitis resulted in the presence of a sizeable population of 
functionally divergent cells. Using a combination of two markers Tim4 and 
Sema4a, I was able to identify persistent monocyte-derived inflammatory 
macrophages, and the corresponding population of monocyte-derived 
macrophages present under homeostatic conditions. Monocyte-derived 
macrophages exhibited higher baseline levels of proliferation than their 
resident counterparts, irrespective of whether they had differentiated under 
homeostatic or inflammatory conditions. Moreover, monocyte-derived LPM 
had lower granularity than their resident counterparts which correlated with 
impaired capacity to phagocytose Phrodo labelled E.coli particles, compared 
to RM-LPM. Following LPS stimulation both Mo-LPM populations had 
divergent cytokine/chemokine production from their resident counterparts. 
Whilst, Mo-LPM produced more Il1b the overall pattern of cytokine production 
of both MoZ10-LPM and Mo-LPM appeared to be less-inflammatory as 
indicated by lower production of TNFa and heightened secretion of Il10, than 
their resident counterparts. Consistent with these findings, a smaller proportion 
of MoZ10-LPM produced TNFa in response to LPS stimulation in vivo. 
Moreover, the transcriptional profile of MoZ10-LPM differed from that of RMZ10-
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LPM stimulated in vivo with LPS. The differential gene expression following in 
vivo LPS stimulation seemingly resulted from an inability of MoZ10-LPM to 
upregulate LPS-driven genes, to the same degree as RMZ10 -LPM.  
 
Based on the data presented in this thesis a definitive conclusion regarding 
the in vivo effects of monocyte integration on subsequent inflammatory insults 
cannot be drawn. However, my findings support a model whereby having 
undergone a historic inflammatory event dampens the overall immune 
response and ability to limit dissemination of bacteria due to the presence of 
an enlarged population of less phagocytic and anti-inflammatory, monocyte-
derived LPM.  
 
However, zymosan-induced monocyte integration may have beneficial effects 
in other contexts. For example, peritoneal macrophages are key players in the 
development of ovarian cancer metastasis. Notably, Tim4+ embryonically-
seeded peritoneal macrophages that infiltrated the tumour enhanced growth 
whereas Tim4- monocyte-derived macrophages did not204. Moreover, using 
the clodronate-depletion methodology described in this thesis, the laboratory 
of Dr. Erin Greaves found that depletion of Tim4+ peritoneal macrophages and 
consequent replacement by monocyte-derived Tim4- macrophages inhibited 
development of endometriosis. Hence, alterations to the macrophage 
compartment following peritoneal inflammation are likely a double-edged 




8.6 A severity-dependent state of altered homeostasis following 
peritoneal inflammation  
 
In chapters 5 and 7 I had observed that one of the key features that was not 
acquired by transferred inflammatory macrophages, irrespective of the 
degree of inflammation was the B1 cell chemokine, CXCL13118. Peritoneal 
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B1 cells account for a sizeable proportion of the peritoneal exudate cells and 
are known to produce natural antibodies118,192,205. In addition, these cells 
have been shown to take over key phagocytic functions upon loss of resident 
peritoneal macrophages and have even been postulated to give rise to 
resident-macrophages158,206. Unpublished data from the lab indicate that 
during normal aging the number of B1 cells in the cavity increases. This 
expansion is thought to be due to homing of B1 cells from the blood into the 
cavity, a process mediated by CXCL13 produced by peritoneal cells118. The 
predominant source of CXCL13 in the peritoneal cavity are the resident 
macrophages118 and omental stromal cells136. Importantly, CXCL13 is 
required for homing of B1 cells into the cavity but not for the survival of B1 
cells that are already sequestered in the cavity118. Consistent with this, I 
found that loss of CXCL13-expressing macrophages, following zymosan 
induced peritonitis, did not result in a loss of B1 cells but rather an impaired 
ability to sequester B1-cells in the cavity with time.  
 
Indeed, in chapter 8 it became apparent that, following high dose zymosan-
treatment and the complete loss of CXCL13-expressing macrophages, the 
number of B1 cells remained stable rather than increasing with time, 
suggesting a failure to recruit further cells into the cavity. This failure to 
sequester B1 cells corresponded with increased levels of circulating natural 
antibodies against phosphorylcholine. A possible explanation for this result is 
that B1 cells in the peritoneal cavity produce very low levels of natural 
antibodies118,192. In contrast, B1 cells in the bone marrow and the spleen 
secrete higher levels of natural antibodies118,192. Hence, a failure to sequester 
B1 cells in the cavity may result in their accumulation in the spleen and bone 
marrow where they consequently produce higher antibody titters. This 
hypothesis is supported by the work of Broker et al, indicating that a failure to 
sequester B1 cells in the cavity, likely as a result of impaired CXCL13 
production by peritoneal macrophages, led to accumulation of antibody 
producing B1 cells in the spleen207.  
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Hence, these findings support the notion that local peritoneal inflammation can 
affect systemic immunity long-term. At present we don’t have the tools to 
definitively attribute the failure to sequester B1 cells in the cavity to the failure 
of monocyte-derived-macrophages to produce CXCL13. A recent conference 
abstract by Wenxin Ma, describes a transgenic flox-STOP-flox-CXCL13 
transgene mouse. A rescue experiment using this line crossed to a monocyte-
specific CRE-driver line (e.g MS4a3Cre)123, driving CXCL13 on monocyte-
derived macrophages, followed by high-dose zymosan treatment, could 
attribute the inability to sequester B1-cells in the cavity, to the inability of 
monocyte-derived macrophages to produce CXCL13.  
 
Following high dose zymosan treatment, IMacZ1000 retained high levels of 
MHCII until 8 weeks following the inflammatory event. Donor RMac 
upregulated MHCII, 8 days following transfer into high-dose zymosan treated 
recipient mice, suggesting the micro-environment is reprogrammed to drive 
MCHII expression. This effect could be regulated by cavity levels of IFNg, a 
well-known regulator of MHCII expression208 that has been found to increase 
following peritoneal inflammation120. Peritoneal NK cells have been proposed 
as a source of IFNg120, following zymosan treatment. However, in these studies 
the number of NK cells in the cavity dropped by 21 days following the 
inflammatory insult120. In my studies I found no indication of long-term 
alterations to the number of CD11BLo CD62L+ NK-cells in the cavity following 
high-dose zymosan treatment, compared to low-dose zymosan treatment. 
Another potential source of IFNg could be activated T-cells108,120. The number 
of T-cells present in the cavity following high-dose zymosan treatment was 
decreased compared to mice treated with low-dose zymosan. This loss of T-
cells was largely due to loss of CD62L+ naïve T cells98 whilst the population of 
activated CD62L- T-cells98 cells was unaltered. Unfortunately, our panel lacked 
the markers required identify T-cell subsets. Unpublished findings from our 
laboratory indicate that approximately 60% of Foxp3+ regulatory T-cells in the 
peritoneal cavity express CD62L. As I observed almost complete loss of 
CD62L+ T cells, it is likely some regulatory T-cells are lost. This may be 
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important as absence of regulatory T-cells has been found to directly impact 
the transcriptional identity of LPM. Using an adoptive transfer methodology, it 
was revealed that WT-LPM transferred into regulatory T-cell deficient FOXP3-
KO mice altered their transcriptome and MHCII expression. Conversely LPM 
sourced from FOXP3-KO mice rapidly downregulated MHCII following transfer 
into WT recipient mice209. Hence, changes to the peritoneal macrophage 
compartment following severe peritoneal inflammation may be, in part, knock-
on effects of changes to other cell populations, such as T-cells and NK cells, 
that can alter the peritoneal-micro-environment.  
 
8.7 Evidence for a peritoneal immune-cell niche.  
 
These findings raise the question whether in addition to a fluidic biochemical 
niche and a surrounding stromal-cell niche, interactions between peritoneal 
macrophages and other peritoneal exudate cells play an important role in the 
programming of resident macrophages. The absence of regulatory T-cells 
seemingly alters the peritoneal micro-environment and as such these cells 
could be considered part of the peritoneal niche as this change in-turn affects 
peritoneal macrophage identity209. Peritoneal B1 cells, a population that is 
gravely affected by peritoneal inflammation due to their reliance on peritoneal 
macrophage derived CXCL13, may in-turn provide signals to peritoneal 
macrophages. Indeed, B1 cells have been shown to produce Il10 and 
modulate peritoneal macrophage polarization and phagocytic capacity in vivo 
and in vitro210,211. Moreover, residency in the peritoneal cavity uniquely 
protects resident B1 cells from CD20 antibody-mediated depletion but this 
effect is abrogated following thioglycolate induced-peritonitis and the 
corresponding loss of resident macrophages212. Finally, peritoneal B1 cells are 
largely absent in the peritoneal cavity of vitamin-A deficient mice. The active 
metabolite of vitamin-A, retinoic-acid drives expression of nuclear factor of 
activated T cells c1, a transcription factor required for B1 cell development and 
survival213. Hence, peritoneal macrophages and B1 cells both depend on 
retinoic-acid to drive key transcription factors. Taken together, these data are 
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suggesting a symbiotic relationship between peritoneal macrophages and 
peritoneal B1 cells that co-inhabit the fluidic peritoneal cavity.  
One of the differentially expressed genes between RMacZ10 and IMacZ10 
following transfer into mild inflamed recipients was CCL24, commonly known 
as Eotaxin 2. Under steady-state conditions both resident-LPM and SPM 
produce CCL24214 and steady-state peritoneal lavage fluid contains a 
quantifiable amount of CCL24215. Under steady-state conditions eosinophil 
recruitment into the peritoneal cavity is uniquely dependent on G protein-
coupled receptors, as pertussin toxin pre-treatment of eosinophils completely 
abrogated recruitment into the peritoneal cavity but not into the spleen and 
lung216. Moreover, recruitment of eosinophils into the peritoneal cavity occurs 
normally in RAG-/- mice but is partially reduced following clodronate treatment 
216, indicating a potential role for peritoneal macrophages in eosinophil 
recruitment. Following Ascaris suum infection, a helminth infection model, 
peritoneal macrophages produce high levels of CCL24, driving expansion of 
peritoneal eosinophils. Conversely, eosinophils produce high levels of Il4 
expanding resident macrophages. This effect required peritoneal 
macrophages and eosinophils to cluster closely together in a CCL24-
dependent manner215. Similar interactions may be occurring under steady-
state conditions and potentially more frequently following zymosan-induced 
peritonitis due to an influx of CCL24-expressing IMacZ10. Moreover, IMacZ10 
exhibited heightened expression of numerous features associated with the M2 
phenotype, driven by Il4, including Retnla (encoding for Relma)  and Mrc1 
(encoding for CD206)217. Although just speculation at this stage these findings 
could be indicative of increased exposure of IMacZ10 to eosinophil derived Il4 
as a result of increased CCL24-mediated proximity between the two cell-types. 
Hence, future studies into the effects of inflammation on the peritoneal cavity 
should take full advantage of techniques such as single-cell RNA sequencing 
to investigate effects on all immune cells inhabiting the cavity. Indeed, using 
single-cell RNA sequencing Wang et al found that loss of Beclin1 in peritoneal 
macrophages led to increased turnover of the peritoneal macrophage 
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compartment, but also affected various other immune cells in the cavity, 
including B1-cells and T-cells108.  
Combined, these data highlight that in a fluidic environment, such as the 
peritoneal cavity, different immune-cells are uniquely inhabiting the same 
fluidic niche. Consequently, the micro-environment is shaped by factors 
secreted by all cells inhabiting the fluidic niche. Hence, these various immune-
cells are likely to affect the survival and identity of one-another. Consequently, 
changes to one cell population, for example through an inflammatory event, 
can lead to a domino effect which affects other cavity-resident cells that in-turn 
alters the micro-environment further. 
8.8 The type of inflammatory stimuli likely dictates monocyte integration 
 
Both the zymosan model of peritonitis and thioglycolate model of peritonitis 
are characterized by loss of resident-macrophages123. However, other models 
of peritoneal inflammation, most notably LPS injection, have generated 
contrasting results. Initial studies indicated a loss of resident-macrophages 
and a concurrent increase monocyte following LPS treatment95. In contrast, 
recent studies utilizing a novel transgenic monocyte fate-mapping mouse 
indicated no loss of resident-macrophages and no concurrent monocyte 
infiltration following LPS injection123. In the studies I carried out with LPS 
injection, no apparent loss of resident macrophages was detectable 8 hours 
following injection, but this this is likely because of the early time-point 
investigated, as disappearance in response to LPS is thought to occur later132. 
It is challenging to extrapolate between studies that have utilized LPS as model 
of peritoneal inflammation due to the use of different doses and, more 
importantly, different serotypes used. Recently published work from our lab 
indicated that following abdominal surgery, monocytes integrate into the 
macrophage compartment and concurrent with this, the number of B1 cells 
sequestered in the cavity following surgery is reduced97. Hence, my findings 
regarding the determinants of long-term integration of inflammatory 
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macrophages may not occur after LPS-induced peritonitis, but are likely to hold 
true following abdominal surgery. 
 
8.9 Inflammation-driven integration of monocytes into the macrophage 
compartment likely occurs in humans 
 
The human peritoneal cavity contains very similar populations of immune cells 
as the murine cavity218. Under steady-state conditions 2 populations of 
peritoneal macrophages that express CD14 and CD16 can be identified in the 
human cavity, both of which express GATA6219. Similarly, studies by Irvine et 
al. identified two subsets of peritoneal macrophages in the ascites fluid of liver 
cirrhosis patients. One populations had high capacity to phagocytose E.coli in 
vitro  and expressed high levels of VSIG4 and Tim4. A second population that 
less effectively phagocytosed E.coli in vitro was characterized by low 
expression of VSIG4 and expressed Sema4a and CCR2173. GSEA analysis 
indicated that the gene signature of VSIG4+ macrophages was enriched for 
genes regulated by GATA6, in murine peritoneal macrophage studies. In 
contrast, the transcriptional signature of Vsig4- human peritoneal 
macrophages overlaid with that of murine acute-stage thioglycolate-elicited 
inflammatory macrophages, suggesting these cells are likely inflammatory 
macrophages of monocyte origin. Ex vivo exposure of VSIG4+ and VSIG- 
human macrophages to retinoic-acid induced upregulation of GATA6 and 
retinoic-acid receptor b by VSIG4- macrophages173, suggesting that retinoic-
acid is potentially driving GATA6 which could in turn drive human peritoneal 
macrophage identity. Finally, a macrophage disappearance reaction has been 
shown to occur in patients during spontaneous bacterial peritonitis, as 
indicated by a loss of resident CD206+LPM172. Hence, key features of 
peritoneal inflammation such as loss of resident macrophages, an influx of 
macrophages likely of monocyte origin and a role for environmental retinoic-
acid as a driver of GATA6 seemingly overlap between human and murine 
studies. Hence, it is likely that in humans inflammatory macrophages persist 
following resolution of inflammation. If so, it is likely that their phenotype is 
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dictated by a combination of environmental signals and cell-intrinsically 
regulated features, similar to what I have found to occur following murine 
peritonitis. 
 
Figure 8.1 Long-term effects of zymosan-induced peritonitis 
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Overview of inflammatory macrophage dynamics following mild (i) or severe 
(ii) zymosan-induced peritonitis presented in this thesis. The x-axis denotes 
time following resolution of zymosan-induced peritonitis. The y-axis denotes 
the degree to which cells have the resident-LPM identity. During resolution of 
mild zymosan-induced peritonitis(i) phenotypically distinct resident-LPM and 
inflammatory macrophages inhabit the cavity. As time progresses 
inflammatory macrophages slowly adopt a more resident-like identity (black 
arrow) but this process is directly inhibited by competing resident-LPM and, in 
the absence of the resident-LPM, can occur more rapidly (dotted grey arrow). 
By 8 weeks the cavity contains a phenotypically distinct populations of 
persistent inflammatory macrophages that are less phagocytic and more 
immunoregulatory. Following severe zymosan-induced peritonitis (ii) resident-
LPM are completely lost and the cavity is completely reconstituted by 
monocyte-derived inflammatory macrophages. Shortly following severe 
zymosan-induced peritonitis the cavity environment limits conversion of 
inflammatory macrophages to a resident-like identity but this is temporary 
phenomenon and by 8 weeks persistent inflammatory macrophages adopt a 
unique identity that is more resident-like than those inflammatory 
macrophages that persist following mild zymosan-induced peritonitis. 
Following severe zymosan-induced peritonitis an altered state of homeostasis 
is established during which the cavity is inhabited by phenotypically unique 
persistent inflammatory macrophages as well as lower numbers of B1 cells 
and CD62L+T cells in the cavity, the former likely as a result of the ompaired 




My PhD project has highlighted how different degrees of peritoneal 
inflammation alter the peritoneal macrophage compartment long-term. 
Monocytes that infiltrate the cavity during the early stages of inflammation 
persist long-term and competition for niche signals, time-of-residency and 
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alterations to the stromal and immune-cell niche underlie the ability of these 
monocytes to adopt a bona-fide resident LPM identity and, likely, functionality. 
These findings highlight the plasticity and environment-responsiveness of 
monocytes and macrophages in the peritoneal cavity and highlight how historic 
inflammation may alter progression of subsequent abdominal pathologies in 
which peritoneal macrophages are involved including endometriosis114,115, 
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